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 Steroid hormones, such as cortisol and aldosterone, are synthesized from cholesterol 
through a series of enzymatic reactions in steroidogenic-competent tissues. In the human adrenal 
cortex, cortisol biosynthesis is controlled by adrenocorticotropin (ACTH) via the activation of a 
cAMP-dependent signaling pathway. ACTH signaling induces the transcription of all the genes 
required for steroid hormone production. The nuclear receptor steroidogenic factor 1 (SF-1) is the 
primary transcriptional regulator of most steroidogenic genes. Our laboratory has uncovered a 
link between ACTH signaling and sphingolipid metabolism by demonstrating that ACTH rapidly 
activates sphingolipid turnover concomitant with sphingosine-1-phosphate (S1P) secretion from 
H295R human adrenocortical cells, and identifying sphingosine (SPH) as an antagonist for SF-1. 
Sphingolipids are bioactive molecules that modulate multiple cellular functions. We also 
demonstrated that SPH-dependent repression of SF-1 function is dependent on the expression of 
acid ceramidase (ASAH1), an enzyme that forms SPH by hydrolyzing ceramide (Cer). Based on 
these data, I hypothesized that ACTH/cAMP signaling regulates ASAH1 function at both 
transcriptional and post-transcriptional levels. In addition, because SF-1 is predominantly a 
nuclear protein, I postulated that ASAH1 modulates SF-1 function and, therefore, steroidogenic 
gene expression by controlling the nuclear concentrations of SPH. To test these hypotheses, I 
first examined the effect of chronic ACTH/cAMP signaling on the transcription of the ASAH1 
gene. Next, the functional significance of ASAH1 expression in adrenocortical cells was probed 
by generating an ASAH1-knockdown cell line. I subsequently characterized the role of ASAH1 as 
a transcriptional nuclear receptor coregulator. Finally, I defined the role of S1P, a bi-product of 
ASAH1 activity, in the acute phase of cortisol biosynthesis. Using a variety of experimental 
approaches, I identified cAMP response element binding protein (CREB) as an essential 
transcriptional activator of the ASAH1 gene. Analysis of adrenocortical cells lacking ASAH1 
revealed that ASAH1 is a global regulator of steroidogenic capacity. Furthermore, I identified 
ASAH1 as a nuclear protein and defined the molecular determinants of the interaction between 
ASAH1 and SF-1. Collectively, this body of work establishes the integral role of ASAH1 in the 





1.1.  Steroid hormone biosynthesis in the human adrenal cortex 
 Adrenal steroid hormones, such as cortisol and aldosterone, are important 
endocrine messengers that are involved in a vast array of physiological processes 
including glucose metabolism, inflammation, and electrolyte and fluid balance (1-4). The 
vital role that these molecules play in human physiology dictates the need for a complex 
network of regulatory mechanisms that act concertedly to maintain optimal circulating 
plasma hormone concentrations. All steroid hormones are derived from cholesterol 
through a series of enzymatic reactions, which is defined as steroidogenesis (i.e. the 
production of steroids). Cholesterol-metabolizing enzymes and other accessory proteins 
are selectively expressed in different steroidogenic tissues to assure the production of 
steroid hormones in a tissue-specific manner. 
The adrenal gland is comprised of a neuroendocrine medulla and a steroidogenic 
cortex. The adrenal cortex, which makes up most of the adrenal gland, can be sub-
divided into 3 distinct zones, each with a characteristic steroidogenic profile: (1) the zona 
glomerulosa is the outer cortical zone where the mineralcorticoid aldosterone is 
produced, (2) The middle zone, zona fasciculata, makes glucocorticoids (e.g. cortisol), 
and (3) the inner zone, zona reticularis, is the site of androgen (DHEA and its sulfate 
DHEA-S, and androstenedione) biosynthesis. Each of the three cortical zones expresses 
a unique profile of steroidogenic enzymes, thereby allowing for zone-specific cholesterol 
metabolism (5-6) (Figure 1.1) 
 In the zona fasciculata and reticularis, activation of the steroid hormone 
biosynthetic pathway is initiated when the peptide trophic hormone ACTH binds to the 
melanocortin 2 receptor (Mc2R), a cell surface G-protein coupled receptor (GPCR). 
Hormone binding activates two temporally distinct responses: a rapid phase and a 




transported to the inner mitochondrial membrane, the site of the first enzymatic step of 
cholesterol metabolism. Hormone sensitive lipase (HSL) (7) catalyzes the de-
esterification of newly imported and stored cholesterol esters, a pre-requisite for its 
utilization in steroid hormone production. Several transport proteins then facilitate the 
transport of free cholesterol into mitochondria, the rate-limiting step in steroid hormone 
production (Figure 1.2). One key protein is steroidogenic acute regulatory protein (StAR) 
(8-11), the founding member of the START (StAR-related lipid transport) family of 
transport proteins. StAR is rapidly transcribed, translated, and localized to mitochondria 
Figure 1.1. Steroid hormone biosynthetic pathway and steroidogenic genes of the three 
zones of the adrenal cortex. Genes that encode P450 or hydroxysteroid dehydrogenase 
enzymes responsible for each catalytic step in cholesterol metabolism are depicted in 
italics. The three steroidogenic zones are distinguished by different colors: zona 




upon hormonal stimulation (12-14). In addition to StAR, 18-kDa translocator protein 
(TSPO) (15), PKA regulatory subunit-Iα (PKA-RIα)- associated protein, and voltage-
dependent anion channel (VDAC) (12,16-17) form a macromolecular complex that 
facilitated cholesterol mobilization into the inner mitochondrial membrane. 
 In the chronic phase of steroidogenesis, all the genes responsible for cholesterol 
metabolism are transcriptionally activated (Figure 1.2). The activation of ACTH signaling 
culminates in the interaction of various transcription factors, including GATA4 and 
GATA6 (18-20), CREB (21-22), specificity protein (Sp) family members (18,23), nerve 
growth factor 1B (NGF-1B, NR4A1) (24-25), and SF-1 (26-27), with promoters of target 
steroidogenic genes. A detailed description of SF-1 function is presented in Section 1.3 
of this Introduction. At this point, it is sufficient to note that because SF-1 plays a major 
role in integrating extracellular signals (i.e. ACTH) and gene expression, elucidating the 
mechanisms that controls receptor activity is central for the complete understanding of 
ACTH actions in steroidogenic cells. As it will be discussed throughout subsequent 
introductory Sections, the present work defines the role of ASAH1, the enzyme that 
generates the SF-1 ligand SPH, as a regulator of receptor function and cortisol 
production in adrenocortical cells.   
 
1.2.  The Cortisol Biosynthetic Pathway 
Cortisol is the primary human glucocorticoid and regulates inflammation (1), 
carbohydrate and lipid metabolism, and the stress response (28). In target tissues, 
cortisol mediates its effects via activation of the glucocorticoid receptor (GR) and, in 
some tissues, the mineralcorticoid receptor, both of which regulate the transcription of 
several genes (29-30). As stated previously, the biosynthesis of this steroid hormone is 
primarily regulated by ACTH via the activation of a cAMP/PKA-dependent signaling 




metabolism: the cytochrome P450 heme-containing proteins (CYPs) and hydroxysteroid 
dehydrogenase (HSD) enzymes (27,31). P450 side chain cleavage (P450scc) (encoded 
by CYP11A1) is an inner mitochondria membrane-bound enzyme that catalyzes the first 
enzymatic reaction in the synthesis of all steroid hormones: cleavage of free cholesterol 
into pregnenolone (Figure 1.1). P450c17α (17α-hydroxylase/17,20-lyase) is an 
endoplasmic reticulum (ER)-localized enzyme encoded by the CYP17A1 gene. 
P450c17α catalyzes the hydroxylation of progesterone and pregnenolone at the carbon-
17 as well as the conversion of pregnenolone to DHEA in the zona reticularis and the 
conversion of progesterone into androstenedione in the zona fasciculata. The 
microsomal 3β-hydroxysteroid dehydrogenase type II (3β-HSDII) catalyzes the 
conversion of pregnenolone, 17α-hydroxypregnenolone, and DHEA into progesterone, 
17α-hydroxyprogesterone, and androstenedione, respectively. P450c21 hydroxylase, 
encoded by CYP21A2, is also microsomal and catalyzes the conversion of progesterone 
and 17α-hydroxyprogesterone into 11-deoxycorticosterone and 11-deoxycortisol, 
respectively. P45011-β-hydroxylase (CYP11B1) is localized in the inner mitochondrial 
membrane and converts 11-deoxycorticosterone or 11-deoxycortisol into corticosterone 
or cortisol in the zona fasciculata. In the zona glomerulosa, aldosterone synthase 
(CYP11B2) is expressed in the inner mitochondrial membrane and catalyzes the 
conversion of 11-deoxycorticosterone into aldosterone (Figure 1.1).  
The zone-specific expression of CYP11B1, CYP17A1 (31), and cytochrome b5, 
an electron transfer protein that potentiates P450c17α activity (32-36), allow for 
glucocorticoid production in the zona fasciculata and androgen synthesis in the zona 
reticularis of the adrenal cortex. Increased 17,20-lyase activity of P450c17α drives 
androgen synthesis in the zona reticularis. Conversely, the absence of CYP17A1 and 




Temporal expression of these enzymes is also important for proper steroid hormone 











1.3.   Sphingolipids and the sphingolipid metabolic pathway 
 Sphingolipids are a large family of glycolipids and phospholipids that share a 
common sphingoid base backbone (Figure 1.3), which is often derivatized with an 
amide-linked fatty acid to make Cer (N-acylsphingosine) and other head groups and/or 
substituents to form more structurally complex sphingolipid molecules. These lipids are 
not only important structural components of cell membranes but also act as second 
messengers in various signaling transduction pathways (37-51). Aberrant sphingolipid 
metabolism is linked to various disease states including insulin resistance (52-54), 
cancer (39,55-56), and neurodegeneration (57-59), thus illustrating their importance in 
the maintenance of proper cellular functions. The structural diversity of this family of 
lipids is vast and many intermediate metabolites are highly bioactive. Therefore, 
Figure 1.2. ACTH activates two temporally distinct responses in target cells. 
Adrenocorticotropin (ACTH) binds to the melanocortin 2 receptor (Mc2R) at the 
cell surface of target cells and activates a cAMP/protein kinase A (PKA)-
dependent pathway. Activation of this pathway rapidly (acute response) 
upregulates the activity of hormone sensitive lipase (HSL), which cleaves 
cholesterol esters into free cholesterol, and steroidogenic acute regulatory protein 
(StAR), which facilitates cholesterol transport into the inner mitochondrial 
membrane. Chronically, ACTH/cAMP signaling induces the transcription of all the 




sphingolipid metabolism is tightly regulated by a series of metabolizing enzymes that 
work concomitantly to regulate sphingolipid homeostasis and signaling (Figure 1.4).  
 De novo sphingolipid biosynthesis begins with the condensation of L-serine and 
palmitoyl-CoA by serine palmitoyltransferase (SPT) to form 3-ketodihydrosphingosine. 
This intermediate is rapidly metabolized to dihydrosphingosine (sphinganine) and 
dihydroceramide by the catalytic activities of 3-ketosphinganine reductase and Cer 
synthase (CerS), respectively (Figure 1.4). Six mammalian CerS isoforms have been 
described, each utilizing fatty acyl-coAs with varying chain lengths and thus producing 
Cer subspecies with different fatty acyl-chain compositions (60). Recent lipidomic 
analysis revealed that Cer with varying fatty acyl-chain length have distinct cellular 
functions (61-62), which exemplifies the importance of multiple CerS isoforms. 
Desaturation of dihydroceramide forms Cer, which constitutes the basic structure of 
higher order sphingolipids (Figure 1.3). Distinct complex sphingolipid species is formed 
by the combination of different head groups to Cer {e.g. O-linked phosphocholine and 
carbohydrates to form sphingomyelin (SM) or glycosphingolipids [e.g. hexosylceramide 
(HexCer) and lactosylceramide (LacCer)], respectively}. Additional sphingolipid moieties 
with varying backbone and fatty-acyl chain length, number and position of double bonds, 
and hydroxyl and methyl group substituents have also been described (63). 
Ceramidases catalyze the breakdown of Cer to form SPH, which can be phosphorylated 
by sphingosine kinases (SPHK1 and SPHK2) to generate S1P. Alternatively, Cer can be 
phosphorylated by ceramide kinase (CERK) to form ceramide-1-phosphate (C1P). S1P 
can be irreversibly metabolized into hexadecenal and phosphoethanolamine by S1P 
lyase (SPL) or recycled back to SPH by S1P phosphatases (SGPP1 and SGPP2) 
(Figure 1.4).  
 Recently, it was shown that SPT is able to utilize L-alanine (64), L-glycine (64), 




atypical metabolites and expanding the list of possible physiologically important 
sphingolipid species. There are a multitude of physiological and cellular roles for 
individual sphingolipid species, including SM, Cer, C1P, SPH, and S1P (38,40,43-44,46-
47,54,67-80). SM is the most abundant sphingolipid in mammalian cells and, in addition 
to being an important membrane component, is the primary intracellular source of Cer 
(Figure 1.4). As will be discussed later, many extracellular factors induce intracellular 
Cer accumulation by activating sphingomyelinase (SMase), the enzyme responsible for 
the degradation of SM into Cer (Figure 1.3). Cer participates as a second messenger in 
numerous cellular events including apoptosis, senescence, and cell cycle arrest (81-83) 
Figure 1.3. Chemical structure of selected sphingolipid species and their metabolism. Numbers 
‘4’ and ‘5’ on the structure of sphingosine designates the position of the double bond. Diffferent 
chemical groups are highlighted by different colors: Sphingoid backbone (pink), phosphate 
group (blue), phosphorylcholine (purple), N-acyl-chain (yellow). Abbreviations: 
phosphatidylcholine (PC), phosphorylcholine (PPC), diacylglycerol (DAG), sphingomyelin (SM), 




while its phosphorylated form, C1P, promotes cell differentiation and survival (68,84-85). 
Similar to Cer and C1P, SPH and S1P have opposing roles in cellular processes: the 
former acts as a pro-apoptotic agent (67,86-87) while the later mediates cell migration, 
proliferation, and survival (40,42,49,88). Regulatory roles for SPH and S1P in 
adrenocortical steroidogenesis will be discussed in subsequent Sections of this 
Introduction. Defining their roles in the regulation of steroidogenic gene expression is 
one of the aims of this dissertation.  
 Because different sphingolipids have specific cellular functions, the intracellular 
concentrations of different sphingolipid species are tightly controlled by sphingolipid 
metabolizing enzymes. Most of these enzymes are localized to specific subcellular 
compartments, where they act to maintain sphingolipid homeostasis in distinct 
microenvironments (89). Enzymes linked to de novo sphingolipid synthesis (e.g. SPT, 
CerS, dihydroceramide desaturase, Figure 1.4) are primarily localized in the ER lumen 
whereas enzymes associated with the production of more complex sphingolipids (e.g. 
SM synthase and glucosylceramide synthase, Figure 1.4) reside in the Golgi apparatus. 
The mechanism by which sphingolipids are transported between two cellular 
compartments (e.g ER-Golgi, different Golgi stacks, and cytosolic side-lumen side of an 
organelle) during de novo biosynthesis is an important issue. To date, two sphingolipid-
transfer proteins have been identified: CERT (Cer transfer protein) and FAPP2 (four-
phosphate adaptor protein 2). CERT mediates ER-to-Golgi non-vesicular transport of 
Cer for SM synthesis (90-91). FAPP2, on the other hand, transfer glucosylceramide to 
appropriate Golgi sites for the synthesis of complex glycosphingolipids (92). Enzymes 
responsible for sphingolipid catabolism, such as different isoforms of ceramidase and 
SMase, are expressed in the plasma membrane, lysosomes, and mitochondria (93). 
Because sphingolipids are mainly hydrophobic, the subcellular location where these 




intracellular localization of ASAH1 in adrenocortical cells is one of the questions 
addressed in the present work. 
 
1.4.  Acid Ceramidase: a key regulator of ceramide metabolism 
 Ceramidases (N-acylsphingosine amidohydrolase) are lipid hydrolases that 
catalyze the degradation of Cer into SPH and a free fatty acid (Figure 1.3). In vertebrate 
cells, five human ceramidase genes have been cloned and their encoded enzymes are 
categorized by the pH at which they exhibit optimal in vitro activity as acid (ASAH1), 
neutral (ASAH2), and three isoforms of alkaline (ACER1-3) (37). Each isoform has a 
different subcellular localization (94-99) and substrate specificity (96,100-103), which 
suggest that these enzymes have unique biological functions. Furthermore, the tissue 
distribution and expression levels of each isoform differ. ASAH1 and ACER3 are 
ubiquitously expressed and have high mRNA abundance whereas ACER1 expression is 
high in skin (37) (Table 1.1). ASAH2 and ACER2 are also ubiquitously expressed but 
have a low mRNA abundance (37), suggesting that post-trascriptional mechanisms are 
involved in their regulation (Table 1.1). Because Cer degradation is the only source of 
cellular SPH (104), these enzymes are not only essential for limiting Cer-mediated 
signaling but also for controlling the cellular functions of SPH and its phosphorylated 
form, S1P (83,105-106). 
ASAH1 is a glycoprotein processed from a 55 kDa precursor into a 14 kDa α and 
a 40 kDa β subunits via autoproteolytic cleavage (107-108). This enzyme has been 
reported to localize to lysosomes (99) and to be secreted extracellularly from murine 
endothelial cells, macrophages, and human fibroblasts (98). ASAH1 not only function to 
regulate sphingolipid metabolism but also participate in signal transduction pathways to 
regulate various physiological and pathological processes. In mouse, ASAH1 is 




resulting in embryonic lethality (109). Moreover, ASAH1 overexpression has been 
reported in various human cancers (110-113) and a genetic deficiency in ASAH1 
catalytic activity causes the lysosomal sphingolipid storage disorder, Farber’s disease 
(114). Therefore, although the precise role of ASAH1 in the etiology of these conditions 
is unclear, it is likely that the function of this enzyme as a regulator of the intracellular 
levels of Cer, SPH, and S1P is crucial for cellular homeostasis.  
As stated previously, our laboratory has demonstrated that ACTH signaling 
promotes rapid changes in sphingolipid concentrations, including SM and Cer turnover 
Figure 1.4. The sphingolipid metabolic pathway. Abbreviations: serine palmitoyltransferase (SPT), 
ceramide (Cer), sphingosine-1-phosphate (S1P), sphingomyelin (SM), sphingomyelinase 




and the secretion of S1P from H295R cells (75).  S1P was characterized as an activator 
of CYP17A1 transcription (115) while its unphosphorylated counterpart, SPH, was 
identified as an antagonist for SF-1 (47). The intricate details of these findings are 
discussed in later Sections of this Introduction. At this point, what can be appreciated is 
the potential role of ASAH1 in maintaining the capacity of the human adrenal gland to 
regulate cortisol secretion, and thus the inflammatory response and gluconeogenesis. 
As a SPH-generating enzyme, ASAH1 plays a pivotal role in regulating the intracellular 
concentrations of SPH and S1P. Therefore, defining the significance of ASAH1 
expression in ACTH-stimulated adrenocortical steroidogenesis and elucidating the 
functional roles of this ceramidase in the regulation of SF-1 transcriptional activity are 
two of the central goals of this dissertation.   
 
Table1.1. Summary of the current knowledge about protein sequences, tissue distributions, 
substrate specificity, and cellular localizations of the different ceramidase isoforms. Abbreviations: 
acid (ASAH1), neutral (ASAH2), and alkaline (ACER) ceramidase, plasma membrane (PM), golgi 
apparatus (GA). Under ‘substrate specificity’, N-acyl chain length and number of double bonds 





pH optimum Substrate 
specificity 
mRNA abundance 
ASAH1 lysosome 4.5 C6- to C16-Cer ubiquitous (high) 
ASAH2 PM 7.0 ≥ C14-Cer ubiquitous (low) 
ACER1 ER 8.5 ≥ C24:1-Cer High in skin 
ACER2 GA 9.0 ≥ C14-Cer ubiquitous (low) 




1.5.  Steroidogenic Factor 1 (SF-1): a key transcription factor in adrenal 
 steroidogenesis 
 
 The nuclear receptor SF-1 (Ad4BP/NR5A1) plays an essential role in the 
development and function of steroidogenic tissues by controlling the expression of most 
steroidogenic genes. In the human adrenal cortex, SF-1 is recruited to the promoter of 
target genes in response to ACTH/cAMP signaling. Because of the central role of this 




molecular underpinnings of receptor function is essential for understanding ACTH action. 
SF-1 has a unique tissue distribution within steroidogenic tissues, being expressed in all 
three zones of the adrenal cortex, Sertoli and Leydig cells in the testis, granulosa, theca, 
and corpus luteum cells in the ovary, as well as in the placenta, and adipose tissue 
(116). SF-1 is a member of the nuclear receptor superfamily of transcription factors (117) 
and has a modular domain structure: an amino-terminal conserved DNA binding domain 
(DBD) consisting of two zinc-binding modules, an intervening hinge region containing a 
ligand-independent activation domain (AF1), and a carboxy-terminal ligand-binding 
domain (LBD) containing a conserved AF-2 hexamer domain (LLIEML) that forms a 
helical structure (denoted as ‘helix 12’) and is critical for receptor activation (118) (Figure 
1.5). The zinc-finger module has a central role in recognizing the canonical AGGTCA 
DNA sequence recognized by all nuclear receptors. The hinge region and LBD 
participate in transcriptional repression or ligand-dependent activation. These domains 
serve as the interface for interactions between SF-1 and numerous coregulatory 
proteins, including steroid receptor coactivator 1 (SRC-1, NC0A1) (119-120), SRC-2 
(GRIP1, NC0A2) (121), nuclear receptor corepressor 1 (NCoR1) (122), NCoR2/SMRT 
(silencing mediator for retinoid and thyroid hormone receptors) (121), and GCN5 
(general control nonderepressed 5, KAT2A) (123).   
 In adrenocortical cells, SF-1 is an integral regulator of StAR (22,124), Mc2R 
(125), CYP17A1 (126-127), CYP11B1 (128), CYP21A2 (129), 3β-HSDII (130), and 
CYP11A1 (131-132) gene transcription. SF-1 is also essential for gonadal and adrenal 
development (133-134) as evidenced by the phenotype of targeted disruption of the 
receptor in mice (135-136). Strong evidence for a developmental role of SF-1 originates 
from studies of forced SF-1 expression in various SF-1-negative cell lines. Studies of 
embryonic stem cells and mesenchymal cells from mice and human bone marrow 




and promotes steroid hormone synthesis (137-139). Similarly, a recent study has 
highlighted a novel role for SF-1 in stem cell differentiation into gonadal steroid-
producing cells (140). The central role of this receptor in steroidogenesis is also evident 
in humans where mutations in the receptor result in various clinical pathologies including 
gonadal dysgenesis, adrenal failure, sex reversal, and underandrogenization (141). 
Furthermore, mice studies using tissue-specific conditional knockouts of SF-1 revealed 
novel roles for this receptor in modulating neural function (142-144). Similarly, SF-1 has 
been implicated in the regulation of energy homeostasis (145-146). 
  
 Most nuclear receptors are cytoplasmic and translocate into the nucleus in 
response to ligand binding and dimerization. Differently, SF-1 is a predominantly nuclear 
protein that binds as a monomer (147) to target gene promoters that contain at least one 
element of C/TCAAGGTCA (121). Its transcriptional function is regulated by various 
post-translational modifications including phosphorylation (148-151), sumoylation (152-
153), acetylation (154-156), as well as by protein-protein interactions (126,157-162). 
More recently, ligand binding has been implicated in the regulation of SF-1 activity 
(155,163-167).  Crystallographic studies using bacterially expressed SF-1 demonstrated 
that phospholipids are present in the receptor’s ligand binding pocket (163,165,167). As 
stated previously, our laboratory has identified SPH and the phospholipid phosphatidic 
Figure 1.5. Schematic overview of SF-1. SF-1 contains the major structures of 
all nuclear receptors: the DNA-binding domain (DBD), the hinge region, and the 
ligand-binding domain (LBD). The DBD contains two zinc-fingers (Zn I, Zn II) 
and the nuclear localization signal (NLS) while the hinge has a proline-rich 
region (Pro-rich). Abbreviations: Activation function domains 1 (AF1) and 2 




acid (PA) as endogenous ligands for SF-1 (164,166). SPH acts as an antagonist for SF-
1 whereas PA enhances receptor activity. SPH binds to SF-1 under basal conditions and 
cAMP promotes its displacement from the receptor ligand-binding pocket (Figure 1.6). 
Furthermore, our group has found that diacylglycerol kinase θ (DGKθ), the enzyme that 
produces PA, interacts with SF-1 in the nucleus of H295R cells. We postulated that an 
interaction between these two proteins facilitate ligand delivery to the ligand-binding 
pocket of SF-1 (Figure 1.6). Based on these findings, I hypothesized that a similar 
interaction occurs between ASAH1 and SF-1. Because SPH has low water solubility, 
direct binding of ASAH1 to the receptor would facilitate ligand exchange. Multiple 
experimental approaches will be used to address this question. 
 
1.5.1.  SF-1 coregulators 
 Transcriptional activation by nuclear receptors requires dynamic protein-protein 
interactions between the receptor, coregulator proteins, and the RNA polymerase II 
transcription machinery at target gene promoters. Coregulators are not only sufficient to 
promote nuclear receptor activity but also required for optimal receptor activation. These 
regulatory factors either have intrinsic catalytic properties or recruit enzymatic protein 
complexes to mediate chromatin modifications that influence gene transcription. 
Coregulators act to activate (i.e. coactivators) or repress (i.e. corepressors) transcription. 
Coactivators generally enhance transactivation of agonist-bound nuclear receptor by 
interacting with the receptor through at least one LXXLL motif (also called NR boxes), 
where X is any amino acid and L is a leucine (168). Importantly, modified NR boxes 
where the leucine residues are substituted with isoleucine (I), phenylalanine (F), or 
methionine (M) have also been described (169-170). On the receptor side, formation of a 




Figure 1.6. Model for the role of ligands in controlling steroidogenic factor 1 (SF-1) 
transactivation potential. Under basal conditions, sphingosine (SPH) is bound to SF-1 
and corepressors. ACTH signaling activates protein kinase A (PKA), which promotes 
the release of SPH from the receptor’s ligand binding pocket. Concomitantly, 
activation of the ACTH/cAMP pathway increases nuclear diacylglycerol kinase θ 
(DGKθ) activity, leading to increased phosphatidic acid (PA) biosynthesis. PA binding 
to SF-1 activates the receptor and facilitates its recruitment to target gene promoters 
and association with coactivator proteins. Abbreviations: silencing mediator for 
retinoid and thyroid hormone receptors (SMRT), steroid receptor coactivator 1 
(SRC1), general control nonderepressed 5 (GCN5), histone deacetylase (HDAC), 




required for interaction with coactivators (171). The p160 family of coactivators, which 
include SRC-1, SRC-2, and SRC-3 (ACTR/RAC-3, NC0A3), are among the most studied 
coregulators (172).  
 Corepressors, on the other hand, are characterized by selectively repressing 
nuclear receptor activity by interacting with unliganded or antagonist-bound receptor. 
Usually, these proteins have repression domains that serve as docking platforms for the 
recruitment of enzymes associated with transcriptional suppression, including histone 
deacetylases (HDAC). NCoR1 and SMRT were the first corepressors to be identified. 
They were found to interact with nuclear receptors through helical motifs denoted 
CoRNR (corepressor nuclear receptor) box with consensus sequence (L/I)-XX-(I/V)-I or 
L-XXX-(I/L)-XXX-(I/L) (168). Subsequently, additional corepressors that were able to 
interact with agonist-bound nuclear receptors, such as RIP140 (receptor interacting 
protein 140, NRIP1) and LCoR (ligand-dependent nuclear receptor corepressor), were 
identified. Most of these corepressors have LXXLL motifs (similar to coactivators) that 
mediate binding to the AF-2 domain of nuclear receptors (173). However, opposite to 
coactivators, these LXXLL-containing corepressors recruit corepressor protein 
complexes to suppress gene transcription. The ability of either class of coregulators to 
bind to nuclear receptors is determined by the ligand-dependent positioning of helix 12 
(AF-2) relative to the LBD. Ligand binding triggers the movement of helix 12 towards the 
LBD, increasing steric accessibility of the binding surface, thus facilitating coactivator 
binding (174). Conversely, in the absence of ligand, helix 12 adopts an extended 
conformation that removes steric restrains and allows corepressor binding (173).      
 As stated above, SF-1 has been shown to interact with many coregulators 
including SRC-1 (119-120), SRC-2 (121), NCoR1 (122), SMRT ((121), and GCN5 (123). 
Using temporal chromatin immunoprecipitation (ChIP) in synchronized H295R cells, our 




the CYP17A1 promoter during cAMP-stimulated transcriptional activation (158). Early in 
the transcriptional cycle, cAMP promotes the formation of a complex containing SF-1, 
SRC-1, and GCN5 on the CYP17A1 promoter. Dissociation of this complex is followed 
by the recruitment of HDAC1, RIP140, and the corepressor Sin3A. Subsequently, 
another cycle of transcription is enabled by the re-association of SF-1 and RNA 
polymerase II on the promoter (158). Building upon these findings, some of the 
experiments described in this dissertation will explore the function of ASAH1 in 
controlling SF-1 activity and the role of coregulators as potential mediators and/or 
disruptors of this process. 
Figure 1.7. Model pathway of 
the crosstalk between 
ACTH/PKA signaling and 
sphingolipid metabolism in the 
human adrenal cortex.  ACTH 
binding to melanocortin 2 
receptor (Mc2R) activates 
cAMP production and protein 
kinase A (PKA) activation, 
which stimulates sphingolipid 
metabolism, activates hormone 
sensitive lipase (HSL) and 
steroidogenic acute regulatory 
protein (StAR) as well as SF-1. 
SF-1 then induces the 
transcription of all 
steroidogenic genes required 
for cortisol production. 
Sphingosine (SPH) produced 
in the cytosol and nucleus 
antagonizes SF-1 function 
while sphingosine-1-phosphate 
(S1P) enhances CYP17A1 
transcription via a receptor-
mediated activation of steroid 
regulatory element binding 
protein (SREBP). 
Abbreviations: Ceramidase 
(ASAH), acid ceramidase 
(ASAH1), sphingomyelinase 





1.6.  Sphingolipid signaling in steroidogenesis 
 A growing body of literature has established the integral role that distinct 
sphingolipid species play in steroid hormone production. One of the mechanisms by 
which extracellular signals (e.g. ACTH) control steroidogenesis is by modulating the 
intracellular concentrations of sphingolipids. For example, as previously stated, ACTH 
rapidly activates sphingolipid metabolism in H295R cells by decreasing the intracellular 
amounts of SM, Cer, and SPH, while concomitantly increasing S1P secretion via SPHK 
activation (75). S1P, in turn, acts as a paracrine/autocrine activator of CYP17A1 
transcription (115) (Figure 1.7). Therefore, there is mounting evidence to support the 
interconnection between sphingolipid metabolism and gene-specific regulation of SF-1 
targets. Generally, sphingolipids act at different levels of the steroidogenic signaling 
pathway, including (I) functioning as paracrine/autocrine regulators, (II) participating in 
regulatory signaling cascades as second messengers, and (III) serving as ligands for 
nuclear receptors.  
  
1.6.1.  Sphingolipids as paracrine/autocrine regulators 
 As mentioned previously, S1P is formed by the phosphorylation of SPH (Figure 
1.4). This bioactive lipid acts intracellularly as a second messenger or extracellularly by 
binding and activating signaling through cell surface S1P receptors (S1PRs) in a 
paracrine and/or autocrine manner. In steroidogenesis, the regulatory functions of S1P 
are primarily mediated through S1PRs. Our laboratory has demonstrated that S1P is 
secreted from cAMP-stimulated H295R cells and induces CYP17A1 transcription via a 
paracrine mechanism that requires S1PR activation and nuclear translocation of sterol 
regulatory element binding protein 1 (SREBP1) (115) (Figure 1.7). Similarly, in the zona 
fasciculata of bovine adrenal cells, S1P stimulates cortisol biosynthesis by activating 




sensitive receptor-mediated mechanism (175). Furthermore, S1P has been implicated in 
the production of aldosterone in the zona glomerulosa of bovine adrenal cells through an 
S1PR1/3-mediated mechanism involving the activation of phosphatidylinositol 3-kinase 
(PI3K)/Akt and extracellular signal regulated kinase (ERK) pathways (176). These 
findings provide compelling evidence for the integral role of S1P in controlling steroid 
hormone biosynthesis. 
 S1P is generated intracellularly by the actions of SPHK1 and SPHK2 (Figure 
1.4), with both having similar endogenous substrate specificities, i.e. SPH and 
dihydroSPH (177-179), although SPHK2 is also able to phosphorylate the 
immunosupressant synthetic sphingoid base analog FTY720 (fingolimod) (180). In 
mammals, these isoenzymes have a wide and overlapping tissue distribution, with 
SPHK1 being highly expressed in spleen and lung, and SPHK2 being predominantly 
expressed in brain, liver, and heart (181-182). Homozygous single knockout mice of 
either SPHK1 or SPHK2 are viable and display no obvious phenotypes (183-184). 
However, the apparent functional redundancy between these isoforms may not always 
apply, specially under a variety of pathophysiological states (185). SPHK2 
overexpression leads to growth arrest and cell death (186-187) whereas SPHK1 has 
been demonstrated by numerous functional studies to play a role in protecting cells from 
apoptosis and promoting cell growth and differentiation (188-189). The disparity of 
physiological effects between these isoenzymes may be partially due to their opposing 
effects on Cer levels. SPHK2 expression enhances the metabolism of S1P back to Cer  
(Figure 1.4) and, therefore, leads to Cer accumulation (190). Conversely, SPHK1 
expression decreases Cer levels, partially due to inhibition of CerS (191). Additionally, in 
vitro assays have demonstrated that SPHK1 and SPHK2 are differentially regulated 
(182). From a comparison standpoint, much more is known about the physiological roles 




synthesis and it is regulated at all stages of expression (i.e. transcriptional and post-
translational regulatory mechanisms).    
 The movement of intracellular S1P to the extracellular millieu is thought to occur 
through specific transporters of the ATP-binding cassette (ABC) family of transporters, 
including ABCC1, ABCA1, and ABCG1 (192-195). However, explicit physiologic and 
genetic evidence of the precise mechanisms by which these transporters export S1P are 
yet to be defined. Extracellularly, S1P is bound to high-density lipoproteins and other 
plasma membranes (e.g. albumin), which facilitate S1P delivery to S1PRs on the surface 
of target cells (196).  
 There are 5 S1PRs, four of which (S1PR1-3 and S1PR5) are expressed in H295R 
cells (115). Each receptor couples to multiple heterotrimeric G proteins (197-199) 
Figure 1.8. S1P receptors (S1PR) and their G protein coupling and downstream signaling 
pathways.  Abbreviations: extracellular signal regulated kinase (ERK), adenylyl cyclase 





(Figure 1.8) and significant work has been done to characterize the downstream 
signaling cascades associated with the activation of the different S1PRs. S1PR1 couples 
to Gi and activates the phospholipase C (PLC), PI3K, and ERK pathways. S1PR 2 and 
S1PR3 couple to Gi, G12/13, and Gq and active multiple downstream cascades including 
PLC, PI3K, ERK, c-Jun NH2-terminal kinase (JNK), and Rho GTPase. S1PR4 activates 
PLC and ERK whereas S1PR5 inhibits adenylyl cyclase and ERK while activates JNK 
(reviewed in (197,200)) (Figure 1.8). As previously stated, work from our group 
established S1P as an inducer of CYP17A1 gene expression in H295R cells (Figure 
1.7). Given the multitude of possible signaling pathways activated by S1PRs (Figure 1.8) 
and the role of ceramidases in controlling S1P synthesis (Figure 1.4), some of the 
experiments described in this thesis are aimed at determining the role of S1P signaling 
during the acute phase of steroidogenesis (Section 1.1). 
 
1.6.2.  Sphingolipids as second messengers in steroidogenic regulatory 
 pathways 
 
 Arguably, the most extensively characterized regulator of steroidogenesis is Cer, 
which accumulates in steroidogenic cells in response to various extracellular regulatory 
signals, including cytokines and growth factors (201-207). In most cases, Cer 
accumulates as a result of activation of SM hydrolysis (203,208-209). Ultimately, 
increased Cer levels alter cellular steroidogenic output. Given that Cer comprises the 
structural backbone for all sphingolipids (Figure 1.3), Cer can modulate steroid hormone 
production both directly and indirectly through metabolism into other bioactive 
sphingolipids (Figure 1.4). Importantly, because Cer is the substrate for ceramidases, 
ASAH1 plays a pivotal role in controlling the signaling properties of Cer.   
 Cer has been shown to regulate progesterone and testosterone production. In 




progesterone production in a Cer-dependent manner (207). In Leydig cells, SM 
hydrolysis and Cer accumulation have been implicated in reduced progesterone (202) 
and testosterone (210) secretion through suppression of StAR protein expression. 
Notably, Cer accumulation observed in these reports was triggered by tumor necrosis 
factor α (TNF-α) signaling, which, similar to IL-1β, activates SMase activity (211). 
Similarly, TNF-α signaling represses the activity of P450 aromatase (CYP19A1), the 
enzyme that converts testosterone into estradiol, in granulosa cells through a 
mechanism involving Cer production (206). Furthermore, Cer suppresses human 
chorionic gonadotropin (hCG)-stimulated testosterone and progesterone production in a 
dose-dependent manner (205,212). Finally, Cer was shown to modulate the mRNA 
expression of 11β-hydroxysteroid dehydrogenase type I (11β-HSDI), the glucocorticoid 
reactivation enzyme, in pre-adipocytes (201). Cell-permeable C2-Cer (N-acetoyl-D-
erythro-sphingosine) induces the expression and recruitment of CCAAT/enhancer 
binding protein β (C/EBPβ) to the 11β-HSDI gene. In addition, Cer treatment upregulates 
11β-HSDI activity in these cells (201), thus suggesting a role for Cer in regulating the 
reactivation of circulating steroid hormones in addition to their de novo synthesis. 
 Although most studies have demonstrated a role for Cer as an inhibitor of 
steroidogenesis, other reports present opposing findings. Soboloff et al. (213) reported 
that different acyl-chain length Cer have opposite effects on luteinizing hormone (LH)-
induced progesterone production in hen granulosa cells. C6-Cer (N-hexanoyl-D-erythro-
sphingosine) and C8-Cer (N-octanoyl-D-eythro-sphingosine) increase intracellular [Ca2+] 
and progesterone secretion whereas C2-Cer has no effect on intracellular Ca2+ and 
suppresses steroid hormone production. Further, Kwun et al. (214) demonstrated that 
C2-Cer increases basal and hCG-stimulated progesterone production in MA-10 testicular 




important in dictating the cellular functions of Cer (213,215-220), discrepancies among 
different published studies are likely due to the use of Cer with different acyl-chain 
lengths.  
 Most of the reported mechanisms by which extracellular factors regulate 
sphingolipid concentrations are post-transcriptional, i.e. regulation of enzyme activity. 
However, extracellular signals can also trigger changes in sphingolipid content by 
inducing the transcription of genes encoding sphingolipid-metabolizing enzymes. For 
example, neural growth factor (NGF) was shown to induce transcription of the SPHK1 
gene via binding of Sp1 to a specific 5’ region of the promoter (221). Similarly, the 
nuclear factor - κB (NF-κB) upregulate SGPP2 gene transcription in response to 
inflammatory stimuli (222) and all-trans retinoic acid (RA) inhibits expression of the 
CERK gene in neuroblastoma cells (223). Nonetheless, the regulatory mechanisms 
controlling the expression of most steroidogenic genes, including ASAH1, remains to be 
determined. In order to determine if ACTH/cAMP signaling regulates ASAH1 at the 
transcriptional level, some of the experiments described in this dissertation are centered 
at the functional characterization of the ASAH1 promoter in ACTH/cAMP-stimulated 
H295R cells.       
 
1.6.3.  Sphingolipids as ligands for nuclear receptors 
 As discussed previously, our laboratory has contributed to expanding the role of 
sphingolipids in steroidogenesis by demonstrating that SPH is an antagonist for SF-1 
(47). SPH is bound to the receptor under basal conditions and exchanged for PA, an SF-
1-agonist (164), upon cAMP stimulation (Figure 1.6). SPH antagonizes cAMP-stimulated 
CYP17A1 reporter gene activity and antagonizes coactivator recruitment. Importantly, 
silencing ASAH1 expression mimics cAMP-induced CYP17A1 transcription, further 




we have also found that lysosphingomyelin (sphingosylphosphorylcholine) is able to bind 
to SF-1 under basal conditions and that cAMP treatment promotes its dissociation from 
the receptor (47). The implications of this binding have not been defined but it suggests 
that multiple sphingolipids can potentially regulate receptor activity.  
 Ligand binding adds yet another level of regulation to SF-1 function. To have a 
comprehensive understanding of the molecular mechanisms governing SF-1-dependent 
gene expression, the interplay between dynamic post-translational modifications 
(Section 1.5) and ligand binding needs to be explored. Moreover, the precise molecular 
mechanism by which SF-1 ligand availability is controlled is unknown. In the present 
work, various experimental approaches are used to address the role of ASAH1 in 
controlling the intracellular concentrations of SPH. Based on our previous findings 
indicating that SPH-dependent suppression of CYP17A1 transcription is dependent on 
ASAH1 expression (47),  I hypothesized that ASAH1 controls SPH availability, and 
therefore, modulates SF-1 function in the human adrenal cortex.  
  
1.7.  Nuclear localization of ASAH1 as a pre-requisite for its proposed regulatory 
 function in adrenocortical cells  
 
 As mentioned earlier, SF-1 differs from the majority of nuclear receptors in that 
its activation neither involves cytoplasm to nucleus translocation nor dimerization. 
Rather, SF-1 is a predominant nuclear protein that binds as a monomer to the promoter 
of target genes in response to hormone stimulation (Section 1.5). As a result, the nuclear 
localization of ASAH1 may be a pre-requisite for its hypothetic function as a regulator of 
SF-1 activity. Given the hydrophobic nature of most sphingolipids, the localized (i.e. 
nuclear) production of SPH, may be essential for its ability to act as an SF-1 antagonist. 
Therefore, I postulated that ASAH1 regulates SF-1 function by interacting with the 





1.7.1. Nucleus organization and endonuclear domains  
 The nucleus is a well-organized sub-structure with a dynamic framework (224). It 
is composed of a well-defined nuclear envelope (NE) that encapsulates several 
endonuclear domains, including the nuclear matrix, chromatin, and nucleolus (Figure 
1.9). The NE is a bilayer whose outer and inner leaflets display unique lipid 
compositions. Although a detailed comparison of the relative distribution of lipid species 
between the two leaflets of the nuclear membrane has not been reported, cholesterol 
has been shown to reside in the outer but not the inner membrane (225) whereas the 
gangliosides GM1 and GD1a were detected in both (226). The outer membrane is 
continuous with the ER and thus shares certain lipidomic properties. Conversely, the 
inner membrane is closely associated with the nuclear lamina and has distinct lipid 
characteristics (224) (Figure 1.9). 
 Like plasma membranes, nuclear membranes express many types of receptors, 
including inositol 1,4,5-triphosphate (IP3) and RA receptors (227). Some agonists 
activate signaling exclusively through nuclear membrane-localized receptors. RA, for 
example, has been shown to activate phospholipase A2 (PLA2), PLC, and PLD only in 
the nucleus (228). Additionally, compelling new evidence suggest that nuclear 
membrane-associated enzymes have different physicochemical properties than their 
plasma membrane and/or cytosolic counterparts. For example, the kinetic parameters of 
nuclear PLC differ from PLC associated with the plasma membrane or cytoplasm (229). 
 The nuclear matrix is often viewed as the basic organizing structure of the 
nucleus (Figure 1.9) that is responsible for maintaining nuclear shape and where many 
processes, including DNA replication, gene transcription, and protein phosphorylation, 
take place (230-232). For example, many enzymes linked to phosphatidyl inositol 




matrix is actively involved in nuclear lipid signaling cascades. Chromatin is closely 
associated with the nuclear matrix and exhibits a dynamic structure that is actively 
modified by multiple interconnected mechanisms, including DNA methylation and 
histone modification (234-235). Heterochromatin regions, which are transcriptionally 
inactive but contain many specific nuclear proteins that regulate gene transcription (224), 
are similarly organized by the nuclear matrix (Figure 1.9).    
 
1.7.2.  Nuclear Sphingolipid Metabolism 
 Recent studies have uncovered the extensive metabolism of lipids that occurs in 
the nuclei of various cell types (236-237). These studies have pointed towards important 
signaling and regulatory roles for lipids in numerous nuclear processes, including DNA 
replication, RNA processing, chromatin structure, and Ca2+ homeostasis (reviewed in 
Figure 1.9. Representation of the nucleus and subnuclear domains highlighting the 
localization of different sphingolipid species. The outer membrane is continuous with the 
endoplasmic reticulum while the inner membrane is associated with the nuclear lamina. 
Nuclear pore allows passive flow of small molecules between cytosol and nucleoplasm. 
Abbreviations: Sphingomyelin (SM), monosialotetrahexosylganglioside (GM1), 




(236-239)). Most lipids are localized to the NE, where in addition to providing structural 
support, they participate in multiple signaling cascades. Bioactive lipids are also 
localized in other nuclear compartments including chromatin (240-242) and the nuclear 
matrix (243) (Figure 1.9). The concentration of nuclear lipids can be dynamically altered 
by metabolic flux in response to signaling cascades that can often uncouple from 
cytosolic processes (236-239). PIPs are the most extensively characterized nuclear 
lipids and have pivotal roles in chromatin remodeling, gene transcription, and mRNA 
export (163,244-245). However, the nucleus is emerging as a hub for sphingolipid 
metabolism as well.  
 Biochemical, analytical, and microscopic techniques have been utilized to identify 
sphingolipid-metabolizing enzymes in nuclei and to quantify the concentrations of 
sphingolipid species (246). To date, multiple sphingolipid enzymes have been detected 
in the nuclei of various cell types. SMase was reported in the nuclear matrix (243,247-
248), NE (249), and chromatin (247) whereas SM synthase, the enzyme that catalyzes 
the formation of SM from Cer (Figure 1.3), was detected in chromatin and NE (250). In 
addition, nuclear ceramidase and SPHK activities were demonstrated in rat hepatocytes 
and Swiss 3T3 cells, respectively (251-253). SPHK2 is the predominantly nuclear 
isoform of SPHK in many cells (254). This SPHK isoform was recently shown to 
modulate gene expression by regulating histone acetylation (255). Due to the 
hydrophobic nature of most sphingolipids, the nuclear expression of sphingolipid 
enzymes suggest that there is a dynamic and localized production of bioactive lipids, 
which may have unique roles in nuclear processes that are independent from their 
cytoplasmic functions. 
 SM is the most prominent sphingolipid in the nuclei, with its concentration in 
nuclear matrix being three times higher than in chromatin (256). SM is a major 




chromatin architecture (249,257-258). Similarly, glycosphingolipids have been shown to 
promote cytoprotection through regulation of nuclear Ca2+(259). The ganglioside GM1 
forms a complex with a Na+/Ca2+ exchanger in the NE and facilitates the transfer of Ca2+ 
from the nucleoplasm to the ER lumen (260). Nuclear Cer has been shown to participate 
in Fas-induced apoptosis in Jurkat T cells as a result of caspase-3-dependent activation 
of SMase (261). Recently, Hait et al. (255) linked nuclear SPHK2/S1P to epigenetic 
regulation of gene expression by demonstrating that SPHK2 is associated with HDAC1/2 
in repressor complexes. S1P inhibits HDAC1/2 activity and induces p21CIP1/WAF1 and C-
FOS gene transcription by enhancing histone H3 acetylation (255). Collectively, studies 
of nuclear sphingolipids not only illustrate the multifaceted regulatory capabilities of 
these lipid mediators, which, in most cases, differ from their cytoplasmic functions, but 
also highlight the importance of location (e.g. chromatin versus NE versus nuclear 
matrix) in determining their nuclear functions. 
 As stated earlier, SPH not only serves as the precursor of S1P but also plays an 
important regulatory role in the nucleus of steroidogenic cells by acting as an antagonist 
for SF-1 (47) (Figure 1.6). In this manner, SPH regulates gene expression and steroid 
hormone secretion (47) (Figure 1.7). SF-1 is a nuclear protein and, as discussed above, 
nuclear expression of sphingolipid enzymes allow for localized and dynamic sphingolipid 
metabolism within various endonuclear compartments. Therefore, the nuclear 
localization of ASAH1 is likely to be imperative for my hypothesis of ASAH1 controlling 
SF-1 function to hold true. This is a central question that will be addressed in this 
dissertation. Furthermore, building upon this question, the physical interaction between 
these proteins will be investigated and the role of various SF-1 coregulators (Section 
1.5.1) in bridging ASAH1 function to SF-1 activity will be addressed. Collectively, these 




is that ASAH1 modulates SF-1 function and steroidogenic gene expression by 








Sphingosine-1-phosphate rapidly increases cortisol biosynthesis and the expression of 
genes involved in cholesterol uptake and transport in H295R adrenocortical cells  
 
2.1.  Introduction 
 In the zona fasciculata of the human adrenal cortex, cortisol is synthesized from 
cholesterol via the concerted action of P450 heme-containing monooxygenases and 3β-
HSD enzymes (262-264). Additionally, StAR, TSPO, HSL, low-density lipoprotein 
receptor (LDLR), and scavenger receptor class B type I (SR-BI) are equally important in 
assuring adequate amounts of substrate for steroid hormone production. Cortisol 
biosynthesis is primarily regulated by the peptide hormone ACTH, which upon binding to 
Mc2R, activates a cAMP/PKA-dependent pathway. Acutely, ACTH promotes cholesterol 
uptake and mobilization from intracellular stores to the inner mitochondrial membrane, 
where the first enzymatic step in steroid hormone production occurs. In the chronic 
phase of steroidogenesis, ACTH coordinately activates the transcription of all genes in 
the steroid hormone biosynthetic pathway, thus maintaining optimal steroidogenic 
capacity (265-267). 
 Import of free cholesterol into the inner mitochondrial membrane is facilitated by 
the formation of a macromolecular protein complex at the outer mitochondrial membrane 
containing TSPO, StAR, the TSPO-associated protein PAP7, and the regulatory subunit 
RIα of PKA (268-269). StAR is essential for cholesterol trafficking (270) and is rapidly 
synthesized in response to activation of the ACTH signaling pathway (271). The 
regulation of StAR transcription has been extensively studied (reviewed in (272)), and 
SF-1 is required for StAR gene expression (273) via its binding to a cAMP-responsive 
region located within the first 350 base pairs upstream of the transcription initiation site 
(274-276). Alternatively, Ca2+ influx through L-type Ca2+ channels abrogates StAR 




sensitive sex reversal, adrenal hypoplasia critical region, on chromosome X, gene 1), a 
repressor of the StAR gene (277). ACTH/cAMP rapidly increases StAR mRNA and 
protein levels (278-280) as well as its enzymatic activity through PKA-mediated 
phosphorylation events at conserved serine residues (281). Further, the PKC signaling 
pathway also plays an integral role in StAR regulation by potentiating cAMP-stimulated 
StAR expression and phosphorylation (282). Of note, Manna et al. (283) have recently 
shown that different PKC isoforms, including PKCα, PKCδ, PKCε and PKD, exhibit 
diverse effects on phorbol 12-myristate 13-acetate (PMA)-mediated StAR transcription 
and steroidogenesis. Finally, A-kinase anchoring protein 121 (AKAP121) enhances the 
post-transcriptional regulation of StAR by recruiting type II PKA regulatory subunit α and 
StAR mRNA transcripts to the outer mitochondria membrane, thus promoting spatially 
localized protein synthesis and increasing steroidogenic efficiency (284). Similarly, HSL, 
which is responsible for the neutral cholesteryl ester hydrolase activity in steroidogenic 
tissues (285), plays a vital role in steroid hormone production by increasing the 
availability of free cholesterol. HSL interacts with StAR and this partnering between the 
two proteins facilitates the transport of cholesterol from lipid droplets to mitochondria 
(286).  
 Several studies have reported various roles for sphingolipids in adrenal and 
gonadal steroidogenesis (287-298). As a bioactive lipid mediator, S1P regulates a broad 
array of physiological functions, including cell proliferation and survival (299-301), 
chemotaxis (302-304), and protection against Cer-mediated apoptosis (305). S1P has 
also been shown to stimulate cortisol production in zona fasciculata bovine adrenal cells 
in a PKC- and Ca2+-dependent manner (306), and promote aldosterone secretion in 
bovine glomerulosa cells via the PI3K/Akt and MAPK/ERK pathways (290,307). S1P 
also mediates cAMP-dependent cortisol secretion in H295R cells by promoting the 




 S1P not only functions as an intracellular messenger (309-310) but also exerts 
many of its effects through cell surface GPCRs (311). The mechanism of S1P export 
from cells is not completely understood, however, studies have provided evidence for 
the involvement of the ABC family of transporters in this process (312-315). Five S1PRs 
(S1PR1-5) have been identified (316-317), four of which (S1PR1, S1PR2, S1PR3, S1PR5) 
are expressed in H295R steroidogenic cells (308). Differences in signaling through these 
receptors are primarily due to differential coupling to G-proteins. S1PR1 signals through 
Gαi (318-319) whereas S1PR2 and S1PR3 couple to Gαi, Gαq, and Gα13 (319). S1PR4 
associates with Gαi and Gα12/13 (320-322) and S1PR5 couples to Gαi/o and Gα12 (323). 
 Our laboratory has shown that ACTH rapidly stimulates sphingolipid metabolism 
in H295R cells (295). ACTH and the cAMP analog dibutyryl-cAMP (Bt2cAMP) decrease 
cellular amounts of SM, Cer, and SPH, while simultaneously increasing the secretion of 
S1P (295). The S1P produced stimulates cortisol secretion from H295R cells by 
promoting the maturation and binding of SREBP1 to the CYP17A1 promoter, thereby 
inducing gene transcription (308). These findings implicate S1P as a paracrine mediator 
of ACTH-dependent CYP17A1 transcription. Therefore, the aim of the present study was 
to characterize the role of S1P in mediating the acute phase of steroidogenesis in 
H295R cells. I show that S1P rapidly increases cortisol biosynthesis and the mRNA 
expression of multiple genes involved in the acute phase of steroid hormone production 
including StAR, TSPO, SR-BI, and LDLR. In addition, I demonstrate that S1P acutely 
increases the phosphorylation of HSL at Ser563 and show that S1P-stimulated StAR 





2.2.  Materials and Methods 
2.2.1.  Cell culture and Treatment   
 H295R adrenocortical cells (324-326) were generously donated by Dr. William E. 
Rainey (Medical College of Georgia, Augusta, GA) and cultured in Dulbecco's modified 
Eagle's/F12 medium (DMEM/F12) (Mediatech, Manassas, VA) supplemented with 10% 
Nu-Serum I (BD Biosciences, Palo Alto, CA), 1% ITS Plus (BD Biosciences, Palo Alto, 
CA), antibiotics, and antimycotics.  H295R cells were sub-cultured in 12-well plates and 
pretreated for 18 h with 10 µM VPC23019 (S1PR1 and S1PR3 inhibitor), 5 pg/ml PTX 
(pertussis toxin), 10 µM U73122 (PLC inhibitor), 10 µM U73343 (inactive PLC analog), 
10 µM KN-93 (CamKII inhibitor), or 10 µM U0126 (MEK1 inhibitor) followed by treatment 
with 1 µM S1P, 50 nM ACTH, or 0.4 mM Bt2cAMP for 2 h.  
 
2.2.2.  Cortisol and DHEA Assay 
 Cells were cultured in 12-well plates and treated with 0.4 mM Bt2cAMP or 1 µM 
S1P for 3 to 48 h. Cortisol and DHEA released into the media were determined in 
triplicate against standards made up in DMEM/F12 medium using a 96-well plate 
enzyme-linked immunosorbent assays (ELISA; Enzo Life Sciences Inc., Plymouth 
Meeting, PA). Results are expressed as nanomoles per milligram of cellular protein in 
each sample. 
 
2.2.3.  RNA isolation and real time RT-PCR (qRT-PCR) 
 Total RNA was extracted using Isol-RNA Lysis Reagent (5 Prime, Inc., 
Gaithersburg, MD) and amplified using a One-Step SYBR Green RT-PCR Kit (Thermo 
Scientific Inc., Waltham, MA) and the following primer sets: β-actin (forward 5’-ACG GCT 
CCG GCA TGT GCA AG-3’ and reverse 5’-TGA CGA TGC CGT GCT GCA TG-3’), 




TCT TCC-3’), TSPO (forward 5’-GCA GAT TCC GTG ATT ACA GTG-3’ and reverse 5’- 
TCC TCC TCG TCG TCA TCG-3’), HSL (forward 5’-CAC TAC AAA CGC AAC GAG AC-
3’ and reverse 5’-CCA GAG ACG ATA GCA CTT CC-3’), SR-BI (forward 5’-CCA TCC 
TCA CTT CCT CAA-3’ and reverse 5’-CCA CAG GCT CAA TCT TCC-3’, LDLR (forward 
5’-ACG GTG GAG ATA GTG ACA ATG-3’ and reverse 5’-AGA CGA GGA GCA CGA 
TGG-3’).  mRNA expression of StAR, TSPO, HSL, SR-BI, and LDLR was normalized to 
the transcript levels of β-actin and calculated using the delta-delta cycle threshold 
(∆∆CT) method.  
  
2.2.4.  Measurement of Inositol 1, 4, 5-Trisphosphate (IP3)  
Cells were treated with 1 µM S1P or 0.4 mM Bt2cAMP for 5 to 60 min. Cells were 
harvested into PBS and centrifuged 5 min at 4,000 rpm. Supernatant was removed and 
the cells resuspended in 20% (w/v) perchloric acid on ice for 30 min. Cells were 
centrifuged and the supernatants neutralized with HEPES-KOH solution. Amounts of 
inositol 1, 4, 5-trisphosphate in each sample were measured by a radioreceptor assay 
with the D-myo-inositol 1, 4, 5-triphosphate [3H] assay kit (TRK 1000, Amersham 
Biosciences, Piscataway, NJ). 
 
 
2.2.5.  Intracellular Ca2+quantification 
 H295R cells were sub-cultured onto coverslips for 24 h and intracellular calcium 
was labeled with Fluo 3/AM (327-329). Fluo 3/AM (5 mM) was loaded into the cells in 
serum-free medium for 1 hour at 37 °C.  0.02% pluronic acid (Sigma, St. Louis, MO) was 
added to the medium to disperse Fluo 3/AM (EMD Biosciences). After the incubation, 
cells were washed three times with medium. Then cells were placed in a chamber with 




UltraVIEW Vox Spinning Disk Confocal Microscope (Perkin Elmer Inc., Waltham, MA). 
Intensity ratio of Fluo 3/AM was quantified using the Volocity software (Perkin Elmer 
Inc.). 
 
2.2.6.  Western Blotting  
 For analysis of StAR protein expression, cells were treated with 1 µM S1P (0 – 
18 h).  Phospho-ERK1/2 (pERK1/2) and total ERK2 expression was assessed in lysates 
purified from cells that were serum-starved for 30 h, pretreated with 10 µM KN-93, or 5 
pg/ml PTX for 1 h followed by treatment with 1 µM S1P. Phospho-CamKII (pCamKII) and 
total CamKII expression was assessed in lysates purified from cells that were pretreated 
with 10 µM VPC23019, 10 µM U0126, or 5 pg/ml PTX for 1 h followed by treatment with 
1 µM S1P for 30 min. To assess the phosphorylation status of HSL, cells were treated 
for 15, 30, or 60 min with 1 µM S1P. Cells were harvested into RIPA buffer (1X PBS, 1% 
Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS) containing 1X Protease Inhibitor 
Cocktail Set I (EMD Biosciences) and lysed by sonication (one 2 sec burst) followed by 
incubation on ice for 30 min. Lysates were centrifuged at 12,000 rpm for 15 min at 4° C 
and the supernatant collected for analysis by SDS-PAGE. Aliquots of each sample (30 
µg of protein) were run on 8% SDS-PAGE gels and transferred to Immobilon FL 
polyvinylidene difluoride (PVDF) membranes (Millipore). Blots were probed with anti-
phospho-ERK1/2 (sc-7383, Santa Cruz), ERK2 (sc-154, Santa Cruz), StAR (sc-25806, 
Santa Cruz), phospho-Ser563-HSL (4139, Cell Signaling), HSL (sc-25843, Santa Cruz), 
phospho- Thr286-CamKII (06-881, Millipore), CamKII (04-1079, Millipore), or GAPDH (sc-
25778, Santa Cruz). Expression was detected using an ECF western blotting kit (GE 
Healthcare, Piscataway, NJ) and visualized by scanning the blots on a VersaDoc 4000 
imager (Bio-Rad). Protein concentrations were determined by the bicinchoninic acid 




2.2.7.  Statistical Analysis 
 One-way ANOVA and Tukey-Kramer multiple comparison test were performed 
using GraphPad InStat software (GraphPad Software Inc., San Diego, CA). Significant 
differences from compared value were defined as p < 0.05 and denoted by asterisks (*) 




2.3.  Results 
2.3.1.  S1P stimulates cortisol biosynthesis 
 As previously discussed, our laboratory has demonstrated that ACTH and 
Bt2cAMP rapidly stimulate sphingolipid metabolism (295) and S1P secretion from H295R 
cells (308). Additionally, S1P induces CYP17A1 transcription (308). Therefore, in order 
to investigate the role of S1P in the acute phase of steroid hormone biosynthesis, I 
determined the effect of S1P on cortisol biosynthesis in H295R cells. Cells were treated 
for time points ranging from 3 to 48 h and the concentrations of steroid hormone 
secreted into the media were quantified as described in Section 2.2. As shown in Figure 
2.1A, S1P maximally increased cortisol production by 2.5-fold at the 12-h time point. 
While S1P resulted in a significant increase in cortisol production at the 48 h time point 
(Figure 2.1A), this bioactive sphingolipid was unable to evoke a sustained increase in 
DHEA secretion over the same time period (Figure 2.1B). Bt2cAMP treatment robustly 
stimulated the secretion of both cortisol and DHEA at all time points assayed, with a 7-
Figure 2.1. S1P increases cortisol secretion.  H295R cells were treated for time periods 
ranging from 3 to 48 h with Bt2cAMP (0.4 mM) or S1P (1 µM) as described in Section 2.2. 
Cortisol (A) or DHEA (B) released into the media was quantified by ELISA. Values represent 
the mean ± SEM of 3 experiments, each performed in triplicate and normalized to the total 
cellular protein content. Asterisks (*) denote p < 0.05 for agonist-stimulated hormone 





fold increase in cortisol production and a 6-fold increase in DHEA biosynthesis at the 24 
h time point. 
 
2.3.2.  S1P induces the mRNA expression of various acute phase steroidogenic 
 genes 
  
 To characterize the mechanism by which S1P acutely increases cortisol 
secretion, the effect of S1P on the mRNA expression of multiple genes involved in the 
acute steroidogenic response was assessed. StAR is essential for the delivery of free 
cholesterol into the inner mitochondrial membrane (269-270), the rate-limiting step in 
steroid hormone biosynthesis. To determine the effect of S1P on the mRNA expression 
of StAR, H295R cells were treated for 0.5, 1, or 2 h with 0.4 mM Bt2cAMP or 1 µM S1P 
and total RNA was isolated for quantification by qRT-PCR. As shown in Figure 2.2A, 
Figure 2.2. S1P acutely increases steroidogenic gene expression. A. H295R cells were 
treated with 0.4 mM Bt2cAMP or 1 µM S1P for 30 min to 2 h. StAR mRNA levels were 
quantified by qRT-PCR and normalized to the mRNA expression of β-actin. B. H295R cells 
were treated with 0.4 mM Bt2cAMP or 1 µM S1P for 2 h and mRNA expression of SR-BI, 
HSL, LDLR, and TSPO was quantified by qRT-PCR and normalized to the mRNA levels of 
β-actin. Data graphed are expressed as percent of control group mean and represent the 
mean ± SEM of 3 experiments, each performed in triplicate. Asterisk (*) denotes p < 0.05 for 





S1P and Bt2cAMP induced StAR mRNA expression by 2.0- and 1.8-fold after 1 h 
treatment, respectively. S1P further increased StAR expression at the 2-h time point by 
5.0-fold, as compared to the 14-fold induction in StAR mRNA expression elicited by 
Bt2cAMP (Figure 2.2A). 
 In addition to examining StAR transcription, the mRNA expression of four 
additional genes that are involved in the biosynthesis of cortisol was quantified: TSPO, 
SR-BI, LDLR and HSL. TSPO forms a macromolecular complex with StAR to facilitate 
the import of cholesterol into the inner mitochondrial membrane (330). SR-BI mediates 
the selective uptake of cholesteryl esters from high-density lipoprotein (HDL) particles in 
rodents and humans (331-333) and HSL has neutral cholesteryl ester hydrolase activity 
and is critical for hydrolyzing internalized cholesteryl esters (334). Importantly, cAMP has 
been shown to regulate both HSL enzymatic activity and SR-BI mRNA expression (335). 
LDLR enables receptor-mediated endocytic delivery of cholesteryl esters from low 
density lipoprotein (LDL) particles (336). In humans, LDLR provides most of the 
cholesterol necessary for steroid hormone production (337). I examined the mRNA 
expression of these genes in H295R cells that were treated with 1 µM S1P or 0.4 mM 
Bt2cAMP for 2 h. As shown in Figure 2.2B, S1P induced the mRNA expression of SR-BI, 
LDLR, and TSPO by 2.5-, 4.7-, and 4.5-fold, respectively. The mRNA expression of HSL 
was not affected by S1P, but Bt2cAMP significantly increased the expression of all four 
genes. 
  
2.3.3.  S1P-mediated induction of StAR gene expression is pertussis toxin 
 sensitive 
 
 As discussed earlier, many of the effects elicited by S1P are mediated through 
S1PR1-5 that activate multiple downstream signaling cascades (311,317,338). In order to 




effect of the Gαi inhibitor PTX on S1P-dependent StAR gene expression was 
determined. H295R cells were pretreated with 5 pg/ml PTX, followed by stimulation with 
1 µM S1P for 2 h. As shown in Figure 2.3A, PTX prevented S1P-induced expression of 
StAR. Because multiple S1PR isoforms have been reported to couple to Gαi pathways 
(309,318,321,338), I next sought to identify the specific S1PR that mediates S1P-
induced StAR transcription by pre-treating H295R cells with the S1PR1/S1PR3 
antagonist VPC23019 followed by S1P stimulation. VPC23019 abolished S1P-mediated 
StAR gene expression (Figure 2.3A). Taken together, these data suggest that S1P 
Figure 2.3. S1P-stimulated StAR gene expression 
occurs through receptor-mediated Gαi signaling. A. 
H295R cells were treated for 2 h with 1 µM S1P in the 
presence or absence of 10 µM VPC23019 or 5 pg/ml 
PTX. Total mRNA was isolated and StAR mRNA 
expression was quantified by qRT-PCR and normalized 
to the mRNA levels of β-actin. B. H295R cells were 
pre-treated with 10 µM VPC23019 or 5 pg/ml PTX for 
18 h and then stimulated for 2 h with 50 nM ACTH or 
0.4 mM Bt2cAMP. Total mRNA was isolated and StAR 
mRNA expression was quantified by qRT-PCR and 
normalized to the mRNA levels of β-actin. C H295R 
cells were treated for 2 h 1 µM S1P in the presence or 
absence of 0.4 mM Bt2cAMP or 50 nM ACTH. Total 
mRNA was isolated and StAR mRNA expression was 
quantified by qRT-PCR and normalized to the mRNA 
levels of β-actin. Data graphed represent the mean ± 
SEM of 3 experiments, each performed in triplicate. 
Asterisk (*) and carat (^) denote statistically different (p 






acutely activates StAR transcription through activation of Gαi-protein coupled receptors 
S1PR1 and/or S1PR3. Because our laboratory has previously found that ACTH/cAMP 
signaling promotes the secretion of S1P from H295R cells (295,308), I assessed the 
effect of PTX and VPC23019 on ACTH/cAMP-stimulated StAR mRNA expression and 
found that neither inhibitor affected the ability of Bt2cAMP to induce StAR expression 
(Figure 2.3B). However, VPC23019 significantly reduced ACTH-dependent StAR mRNA 
levels by 34% (Figure 2.3B). The ability of the S1PR1/3 antagonist to partially repress 
ACTH-stimulated StAR expression is consistent with a second messenger role for S1P 
in ACTH-dependent steroidogenesis. To further define the relationship between S1P-
dependent StAR transcription and ACTH signaling, the effect of S1P on ACTH- and 
Bt2cAMP-induced on StAR mRNA expression was examined. Neither Bt2cAMP nor 
ACTH had an additive effect on the S1P response (Figure 2.3C). Unexpectedly, ACTH-
stimulated StAR transcription was suppressed in the presence of S1P (Figure 2.3C).   
 
2.3.4.  S1P-dependent StAR transcription requires PLC activation 
 Signaling through Gαi affects multiple downstream effectors including adenylyl 
cyclase, the small G protein Rac, Src, PI3K/Akt, MAPK, and PLC. The inhibitory effect of 
PTX and VPC23019 on S1P-mediated StAR mRNA expression suggested that the 
stimulatory effect of S1P on gene expression occur through the interaction of S1P with 
S1PR1/3. Therefore, in order to identify effectors in the signaling pathway downstream of 
Gαi, the effect of PLC inhibition on S1P-stimulated StAR transcription was determined. 
H295R cells were pre-treated with 10 µM U73122 followed by treatment with 1 µM S1P 
for 2 h. PLC inhibition completely abolished S1P-induced StAR mRNA expression, 
whereas the inactive PLC analog U73343 had no significant effect on the ability of S1P 






Figure 2.4. S1P-mediated StAR transcription is dependent on PLC activation. A. H295R 
cells were pretreated with U73122 or U73343 (10 µM) for 1 h and then stimulated for 2 h 
with 1 µM S1P. Total RNA was isolated and StAR mRNA expression assessed by qRT-
PCR and normalized to the mRNA levels of β-actin. Data are graphed as percent of 
control group mean and represent the mean ± SEM of 3 experiments, each performed 
in triplicate. Asterisks (*) denote statistically different from the control group (p < 0.05). 
B. H295R cells were treated with 1 µM S1P or 0.4 mM Bt2cAMP for time periods 
ranging from 5 to 60 min. IP3 content was determined by radioreceptor assay as 
described in Section 2.2. Data graphed are expressed as pmol of IP3 per milligram of 
protein and represent the mean ± SEM of 2 experiments, each performed in triplicate. 
Asterisks (*) denote p < 0.05 of S1P-treated cells versus vehicle-treated controls. C. 
Representative immunofluorescence live cell images of cytosolic Ca2+ in H295R cells 
treated for 0 to 15 min with S1P (top panel) or Bt2cAMP (bottom panel). Cytosolic Ca2+ 
was visualized using Fluo 3/AM (green). D. Quantification of cytosolic Ca2+ in H295R 
cells treated for 5 to 15 min with Bt2cAMP or S1P using the Volocity software. Data are 
graphed as mean intensity over area and represent the mean ± SEM of 4 experiments, 




2.3.5.  S1P stimulates IP3 release and increases cytoplasmic Ca2+ 
 Based on the findings described above demonstrating that S1P-stimulated StAR 
gene transcription is dependent on PLC activity, the amount of IP3 release in response to 
S1P was quantified. H295R cells were treated with 1 µM S1P for 5 to 60 min and IP3 
intracellular levels were determined as described in Section 2.2. As shown in Figure 
2.4B, S1P significantly increased intracellular IP3 by 2.5- and 4.8-fold after 5 and 15 min, 
respectively, compared to untreated controls. IP3 levels in S1P-treated cells gradually 
decreased after 15 min of stimulation, although they remained significantly higher than 
untreated controls. Notably, Bt2cAMP had no significant effect on IP3 release (Figure 
2.4B), suggesting that the mechanism by which S1P induces StAR expression exhibits 
distinct elements when compared to Bt2cAMP. The increase in IP3 was concomitant with 
a 2.9- and 5.8-fold increase in cytosolic Ca2+ after 5 and 15 min of S1P stimulation, 
respectively (Figure 2.4D). Bt2cAMP also stimulated an increase in cytosolic Ca2+, 
however, the magnitude of the response was lower than the increase elicited by S1P. 
 
2.3.6.  Induction of StAR mRNA expression requires CamKII and ERK1/2 
 activation 
 
 The increases in IP3 and Ca2+ led me to postulate that S1P-stimulated StAR 
expression requires CamKII. To test this hypothesis, H295R cells were treated for 2 h 
with 1 µM S1P in the presence or absence of the CamKII inhibitor KN-93 (10 µM) and 
StAR mRNA transcript levels were quantified by qRT-PCR. As shown in Figure 2.5A, 
inhibiting CamKII activity attenuated S1P-induced StAR mRNA expression. Consistent 
with this finding, S1P stimulation activated CamKII after 30 min, and pre-treatment with 




Figure 2.5.  S1P-stimulated StAR transcription requires CamKII and ERK1/2 activation. A. 
H295R cells were pretreated with 10 µM KN-93 and then stimulated with 1 µM S1P for 2 h. 
Cells were harvested and total RNA isolated for analysis of StAR mRNA expression by qRT-
PCR and normalized to the mRNA levels of β-actin. Data graphed are expressed as percent of 
control group mean and represent the mean ± SEM of 3 experiments, each performed in 
triplicate. Asterisk (*) denotes p < 0.05 for S1P-stimulated mRNA expression versus vehicle-
treated control. B. H295R cells were pre-treated with 10 µM VPC23019 or 5 ng/mL PTX and 
then treated with 1 µM S1P for 30 min. Cell lysates were harvested and separated by SDS-
PAGE. CamKII activity was assessed in cell lysates by western blotting using an antibody 
against phospho-Thr286-CamKII (top panel) or CamKII (bottom panel). C. H295R cells were 
serum-starved for 30 h, treated for 15 or 30 min with 1 µM S1P, and cell lysates were 
harvested and separated by SDS-PAGE followed by western blotting using anti-phospho-
ERK1/2 (top panel) and ERK2 (bottom panel) antibodies. D. H295R cells were serum-starved 
for 30 h, pre-treated with 10 µM KN-93 and then treated for 15 or 30 min with 1 µM S1P. 
Some cells were treated with 25 ng/ml EGF for 10 min. ERK activity was assessed in cell 
lysates by western blotting using an antibody against phospho-ERK1/2 (top panel) or ERK2 
(bottom panel). E. H295R cells were treated for 2 h with 1 µM S1P in the presence or absence 
of 10 µM U0126. Total RNA was isolated and StAR mRNA expression was quantified by qRT-
PCR and normalized to the mRNA levels of β-actin. Data graphed represent the mean ± SEM 
of 3 separate experiments, each performed in triplicate. Asterisk (*) denotes statistically 
significant difference (p < 0.05) compared to vehicle-treated control. F. H295R cells were 
serum-starved for 30 h, pre-treated with 5 pg/ml PTX and then treated for 15 or 30 min with 1 
µM S1P. Some cells were treated with 25 ng/ml EGF for 10 min (positive control). Cell lysates 
were harvested and separated by SDS-PAGE followed by western blotting using antibodies 





Because CamKs can crosstalk with many intracellular pathways, including MAPK 
signaling (339-342), the effect of S1P on the activation of ERK1/2 was investigated.  
As shown in Figure 2.5C, S1P activates ERK1/2 after 30 min of stimulation. To 
determine if ERK1/2 activation is upstream of CamKII, the phosphorylation status of 
ERK1/2 was quantified by western blotting from H295R cells pre-treated with 10 µM KN-
93 and stimulated with 1 µM S1P for 15 or 30 min. As shown in Figure 2.5D, pre-
treatment with KN-93 prevented ERK1/2 phosphorylation in S1P-treated cells. 
Additionally, pre-treatment of H295R cells with the MEK1 inhibitor U0126 completely 
ablated S1P-induced StAR gene expression (Figure 2.5E). Taken together, my results 
indicate that S1P-dependent StAR transcription requires the sequential activities of 
CamKII and ERK1/2.  
 
2.3.7.  S1P-mediated ERK1/2 activation is dependent on Gα i signaling  
 My data show that ERK1/2 activation is required for S1P-dependent StAR gene 
transcription and that CamKII is upstream of ERK1/2. Moreover, Gαi and PLC are also 
required for the S1P response. Therefore, in order to determine if ERK1/2 
phosphorylation occurs through activation of Gαi signaling, western blotting analysis of 
H295R cells pre-treated with 5 pg/ml PTX and stimulated with 1 µM S1P for 15 or 30 min 
was carried out. As shown in Figure 2.5F, suppression of Gi signaling by PTX prevents 
S1P-induced ERK1/2 phosphorylation. 
 
2.3.8.  S1P acutely increases StAR protein expression and HSL phosphorylation  
 To determine if the increase in StAR transcription resulted in an increase in 
protein expression, StAR protein levels in S1P-treated H295R cells were quantified by 




protein expression by 1.9- and 2.5-fold after 3 and 6 h of stimulation, respectively. 
Significantly, although S1P had no effect on HSL mRNA (Figure 2.2B) or protein 
expression (data not shown), densitometric analysis of western blots revealed that S1P 
stimulated the phosphorylation of HSL at Ser563, a PKA target site that stimulates HSL 
activity (343-346), by 2.4- and 2.8- fold after 15 and 30 min, respectively (Figure 2.6C 
and 2.6D).    
 
  
Figure 2.6. S1P increases StAR protein expression and HSL phosphorylation. A. H295R 
cells were treated with 1 µM S1P for 0 to 18 h and cell lysates were harvested and 
separated by SDS-PAGE followed by western blotting analysis using anti-StAR and anti-
GAPDH antibodies. B. Densitometric analysis of western blots of StAR protein 
expression, normalized to GAPDH protein content in cells treated for 0 to 18 h with 1 µM 
S1P. Data graphed represent the mean ± SEM of 2 separate experiments, each done in 
triplicate. Asterisks (*) denote statistically significant difference (p < 0.05) versus untreated 
controls. C. H295R cells were treated with 1 µM S1P for 15 to 60 min and cell lysates 
were harvested and separated by SDS-PAGE followed by western blot analysis using 
antibodies against phospho-Ser563-HSL (top panel) and anti-HSL (bottom panel). D. 
Densitometric analysis of western blots of phospho-HSL protein expression, normalized to 
HSL protein content in cells treated for 0 to 18 h with 1 µM S1P. Data graphed represent 
the mean ± SEM of 2 separate experiments, each done in triplicate. Asterisks (*) denote 




2.4.  Discussion 
 ACTH promotes glucocorticoid production by coordinating a series of spatially 
and temporally distinct cellular processes. In what is classically known as the acute 
phase of steroidogenesis, ACTH-stimulated PKA activation leads to an increase in the 
hydrolysis of cholesterol esters and the subsequent trafficking of this substrate to the 
inner mitochondrial membrane, the site of the first enzymatic reaction in the steroid 
hormone biosynthetic pathway. During the acute phase, ACTH signaling rapidly induces 
the expression of StAR (278,347) and the activation of HSL (348). Based on previous 
studies from our laboratory showing ACTH-stimulated sphingolipid metabolism and S1P 
secretion (308), I sought to define the role of S1P in the acute phase of steroidogenesis. 
This Chapter describes that S1P induces the transcription of multiple acute 
steroidogenic genes, stimulates the phosphorylation of HSL at Ser563, and increases 
cortisol production. Further, I show that S1P-stimulated StAR gene expression occurs 
through an S1PR1/SIPR3-mediated Gαi signaling pathway that involves PLC, CamKII, 
and ERK1/2 activation.  
 Although ACTH is the main regulator of cortisol biosynthesis, multiple additional 
signaling molecules can modulate steroidogenic gene transcription, including growth 
factors, prostaglandins, and phospholipids (349-352). S1P regulates aldosterone 
secretion in zona glomerulosa adrenocortical cells (290,307) and stimulates cortisol 
secretion in zona fasciculata bovine adrenal cells (306). I show that S1P is a novel 
modulator of acute cortisol biosynthesis in human adrenocortical cells. Although the 
effect of S1P and Bt2cAMP were similar at earlier time points, the magnitude of the 
response elicited by Bt2cAMP was significantly greater at later time points (Figure 2.1A). 
Notably, S1P only increased DHEA secretion transiently at the 6 and 12 h time points 
(Figure 2.1B). Because the biosynthesis of cortisol requires the movement of 




previously shown that ACTH/cAMP-mediated mitochondrial movement plays a pivotal 
role in glucocorticoid biosynthesis (353), it is tempting to speculate that S1P is 
stimulating cortisol production by facilitating substrate delivery to mitochondria. Indeed, 
our laboratory has found that S1P increases the rate of mitochondrial trafficking (354). 
  
  
 During the acute phase of steroidogenesis, ACTH-dependent cholesterol 
mobilization is mirrored by an increase in the transcription of genes essential for its 
uptake, transport, and de-esterification, including StAR and TSPO (355). My data show 
that S1P rapidly increases the transcription of TSPO, SR-BI, LDLR, and StAR (Figure 
2.2). Significantly, although S1P had no effect on HSL mRNA expression (Figure 2.2B), 
phosphorylation of HSL at Ser563 was acutely stimulated S1P (Figure 2.6C). As 
discussed earlier, the activity of HSL is regulated by phosphorylation at multiple residues 
Figure 2.7.  Proposed model for S1P-
mediated cortisol biosynthesis in H295R 
cells. S1P binds to S1PR1 and/or S1PR3 
and activates Gαi. Gαi couples to PLC, 
thereby increasing intracellular IP3 and 
subsequently cytosolic Ca2+. Intracellular 
Ca2+ accumulation activates CamKII, 
which in turn mediates the 
phosphorylation of ERK1/2. Acute 
activation of the S1P signaling pathway 
culminates in an induction of StAR gene 
expression and an increase in cortisol 
secretion. S1P also stimulates PKA-
mediated phosphorylation of HSL at 
Ser563, which increases cholesterol ester 






(356-359). However, the phosphorylation of HSL at Ser563 by PKA (356) triggers HSL 
translocation to the surface of lipids droplets where it hydrolyzes cholesteryl esters (360-
361). Moreover, HSL has been found to interact with StAR (362). Therefore, my data 
identify multiple roles for S1P in facilitating increased substrate availability and delivery 
for cortisol biosynthesis (Figure 2.7).  
 Most of the physiological effects elicited by S1P are the result of binding to 
tissue-specific S1P receptors (311,363). In this manner, S1P has been shown to activate 
PLC, PI3K/Akt, and MAPK signaling as well as Ca2+ mobilization (290,300,307,320-
321,364-365). My results demonstrate that S1P-dependent StAR gene expression 
occurs through a PTX-sensitive Gαi-coupled receptor (Figure 2.3A). Moreover, because 
the S1PR1/SIPR3 antagonist VPC23019 prevented S1P-induced gene expression, it is 
likely that S1P signals through one or both of these receptor isoforms. Notably, both 
isoforms are expressed in the H295R cell line (308) and can couple to Gαi (307,318-
319,366). Furthermore, S1P and Bt2cAMP did not have an additive effect on StAR 
mRNA expression (Figure 2.3C), suggesting that these stimuli activate a common 
downstream effector. Conversely, S1P abrogated ACTH-stimulated StAR transcription 
(Figure 2.3C). Because my data suggests that S1P signals through Gαi to induce StAR 
mRNA expression (Figure 2.3A) and ACTH activates a Gαs-cAMP-PKA signaling 
pathway (367), it is possible that S1P-mediated Gαi activation downregulates ACTH-
dependent Gαs signaling by inhibiting adenylyl cyclase (368). Gαi-mediated 
downregulation of cAMP production by S1P has been previously reported (369-372).  
Many reports support the activation of Ca2+ mobilization by S1P through GPCR-
mediated PLC activation (364,373-375). Consistent with these findings, I show that the 
transcriptional response evoked by S1P requires PLC activation and results in the 




been shown to increase cytosolic Ca2+ by stimulating release from intracellular stores 
and by activating Ca2+ influx (376-378). Although my studies do not distinguish between 
these two sources, the increase in IP3 levels elicited by S1P (Figure 2.4B) suggest that 
elevated cytosolic Ca2+ in response to S1P stimulation stems, at least in part, from 
intracellular stores. Notably, even though Bt2cAMP also elevated cytosolic Ca2+ levels 
(Figure 2.4D), it did so independently of cellular IP3 levels (Figure 2.4B), which supports 
the notion that the molecular mechanism of S1P-mediated glucocorticoid production 
displays unique components when compared to ACTH/cAMP signaling.    
 In order to further characterize the signaling molecules involved in the S1P 
transcriptional response, I show that downstream of PLC, CamKII and ERK1/2 activation 
are required events for S1P-dependent StAR gene transcription (Figure 2.5). CamKII is 
a well-established Ca2+-activated kinase, thus its activation by increased cytoplasmic 
Ca2+ is plausible. In addition, S1P has been shown to activate this enzyme in vascular 
smooth muscle cells (377). Consistent with previous reports on the crosstalk between 
CamK and the MAPK/ERK pathway (339,341-342,379) and the activation of MAPK 
signaling by S1P (307,380-381), I show that S1P rapidly activated ERK1/2 (Figure 2.5B) 
in a CamKII-dependent manner (Figure 2.5C). Further, ERK1/2 activation was required 
for S1P-dependent StAR mRNA expression (Figure 2.5D). Importantly, MAPK/ERK 
activation in response to S1PR1 and S1PR3 coupling to Gαi has been reported 
(307,318,366,382-383), further supporting my findings. 
 ERK1/2-mediated StAR gene expression is well established (384-386) and both 
PKA and PKC signaling can activate ERK1/2 (386) and StAR transcription (281,386-
388). My data identify S1P as a novel regulator of StAR gene expression via the 
activation of the MAPK/ERK pathway. Regulation of StAR gene transcription involves 
multiple transcription factors including the bZIP family of transcription factors 




conserved 5’-CRE half-sites (389-390). In addition, increased Ca2+ and subsequent 
activation of CamK leads to CREB phosphorylation in a MAPK-dependent manner (391).  
Further, S1P was shown to partially activate CREB in this manner (392). Thus, it is 
tempting to speculate that S1P-induced StAR transcription is mediated, at least in part, 
through ERK1/2-dependent CREB phosphorylation. Moreover, because ERK1/2 
regulate StAR function by phosphorylation at Ser232 (393), it is possible that S1P 
stimulation triggers StAR phosphorylation in addition to inducing its gene expression. 
Future studies are needed to test these hypotheses as well as uncover other regulatory 
proteins involved in S1P-dependent acute steroidogenic gene expression. 
Our laboratory (308) and others (290,306-307) have reported that S1P mediates steroid 
hormone biosynthesis by activating various intracellular cascades. Rabano et al. (175) 
demonstrated that S1P-mediated cortisol secretion in bovine adrenocortical cells is 
dependent on PKC and intracellular Ca2+ in a PTX-sensitive manner. My results support 
a similar mechanism of action for S1P in human H295R cells, although I demonstrate 
that PLC activation is also required. Importantly, S1P induces the phosphorylation of 
HSL at Ser563, providing evidence that S1P regulates steroidogenesis by acting via 
multiple pathways. Given that ACTH/cAMP promotes the secretion of S1P from H295R 
cells (308), it is plausible that adrenocortical cells might utilize an ACTH/S1P feed-
forward mechanism to facilitate rapid steroidogenic output and fine-tune sustained 
hormone production. In summary, I demonstrate that S1P acts at multiple levels to 





The cAMP responsive element binding protein (CREB) regulates the expression of acid 
ceramidase in H295R human adrenocortical cells 
  
3.1.  Introduction 
Bioactive sphingolipids such as Cer, SPH, and S1P have been implicated in 
steroidogenesis. Cer suppresses progesterone secretion in ovarian granulosa cells (207) 
and rat luteal cells (212), decreases testosterone production in rat gonadal Leydig cells 
(205,210), modulates P450c17α enzymatic activity in rat Leydig cells (205), and inhibits 
hCG-induced P450 aromatase (CYP19A1) activity and estradiol production in ovarian 
granulosa cells (206,394). Our laboratory has shown that in H295R cells, suppression of 
ASAH1 expression leads to increased transcription of the CYP17A1 gene, indicating a 
role for this ceramidase in adrenocortical steroidogenesis (166). Furthermore, we have 
also demonstrated that SPH inhibits CYP17A1 transcription and cortisol biosynthesis by 
acting as an antagonistic ligand for SF-1 (26-27). SPH can be rapidly phosphorylated by 
SPHKs to form S1P, which mediates Bt2cAMP-stimulated CYP17A1 transcription in 
H295R cells (395), increases cortisol secretion in bovine fasciculata cells (175), and 
stimulates aldosterone secretion in bovine glomerulosa cells (176,396). In addition to 
studies demonstrating that sphingolipids regulate steroidogenesis, trophic factors that 
activate steroid hormone biosynthesis (e.g. ACTH) have been found to modulate 
sphingolipid metabolism. In H295R cells, ACTH stimulates sphingolipid metabolism by 
rapidly promoting the catabolism of SM and Cer. ACTH acutely activates SPHK activity, 
thus increasing S1P concentrations (166,395,397). Collectively, these data highlight the 
intimate, reciprocal relationship between sphingolipid metabolism and steroid hormone 
biosynthesis. 
CREB proteins are leucine zipper-containing transcription factors that regulate 




399).  In response to cAMP signaling, PKA phosphorylates CREB at Ser133, a post-
translational modification that is essential for its transcriptional activity (398,400-401). 
CREB binds to the promoter of target genes and facilitates the recruitment of 
coactivators, including CREB binding protein (CBP/p300) (402-404) and transducer of 
regulated CREB-binding proteins (TORCs) (405-406) by a mechanism that is either 
dependent (e.g. CBP/p300) or independent (e.g. TORCs) of Ser133 phosphorylation. In 
addition to activating target gene transcription, CREB can also mediate transcriptional 
repression by partnering to repressor proteins. For instance, Kibler and Jeang (407) 
reported that a CREB/ATF-dependent cyclin A repression occurs through a protein-
protein interaction with the human T cell leukemia virus type 1 Tax protein. Furthermore, 
the transcription factor YY1 represses C-FOS transcription by forming a complex with 
CREB/ATF on the DNA (408). 
Based on previous data from our laboratory identifying SPH as an antagonist for 
SF-1 and the effect of ACTH-stimulated sphingolipid metabolism on steroidogenic gene 
transcription and hormone output, I sought to determine the role of ACTH/cAMP 
signaling in regulating the expression of the ASAH1 gene in H295R cells. I identify 
ASAH1 as a CREB-responsive gene and show that CREB is essential for Bt2cAMP-
stimulated ASAH1 transcription. Moreover, CREB enrichment at multiple sites on the 
ASAH1 promoter facilitates the recruitment of CBP and p300 as well as histone H3 
lysine 4 (H3K4) trimethylation. Finally, I demonstrate that Bt2cAMP-mediated ASAH1 
transcription lead to a significant increase in protein expression and enzymatic activity, 





3.2.  Materials and Methods 
 
3.2.1.   Cell culture 
 
H295R adrenocortical cells were cultured as described in Chapter Two.  
3.2.2.  Real time RT-PCR (qRT-PCR) 
Cells were sub-cultured into 12-well plates and 48 h later treated with 0.4 mM 
Bt2cAMP for 1-24 h. Total RNA was extracted using TRIzol (Invitrogen, Carlsbad, CA) 
and amplified using a One-Step SYBR Green RT-PCR Kit (Thermo Fisher Scientific Inc, 
Waltham, MA) and the primers listed in Table 3.1. ASAH expression was normalized to 
β-actin content and calculated using the delta-delta cycle threshold (∆∆CT) method. 
 
3.2.3.   Cloning of the human ASAH1 promoter and site-directed mutagenesis 
 The human ASAH1 promoter was cloned using LA Taq DNA polymerase 
(Takara, Madison, WI), 500 ng of human genomic DNA (Promega, Madison, WI) and 
300 nM of the primers listed in Table 3.1. PCR fragments were then cloned into the 
pGL3 (Promega) reporter gene plasmid at the Mlu I (5’) and Bgl II (3’) sites. The pGL3-
ASAH1 constructs were confirmed by sequencing prior to use in transient transfection 
experiments. In silico analysis using the MatInspector software (Genomatix Software, 
Ann Arbor, MI) was used to identify putative consensus binding sites for CREB on the 
ASAH1 promoter.  
 
3.2.4.  Transient transfection and reporter gene analysis 
 H295R cells were sub-cultured into 24-well plates and transfected with 150 ng of 
pGL3-ASAH1, 1.5 ng pRL-TK (Promega), and/or 5 ng of pCMV-CREB (BD Biosciences, 
Franklin Lakes, NJ) or 5 ng of pCMV-K-CREB (BD Biosciences) using GeneJuice 




0.4 mM Bt2cAMP for 16 h and the transcriptional activity of the ASAH1 reporter gene 
determined using a dual luciferase assay kit (Promega). Firefly (pLG3-ASAH1) luciferase 
activity was normalized to Renilla luciferase activity (pRL-TK) and expressed as fold 
change over the mean of the untreated control group. 
 
3.2.5.  Electrophoresis mobility shift assay (EMSA) 
 Nuclear extracts were isolated from H295R cells that were incubated with 0.4 
mM Bt2cAMP for 1 h using the NE-PER kit (Pierce, Rockford, IL). Double-stranded 
oligonucleotides (Table 3.1) were labeled with [α-32P] dCTP (MP Biomedicals, Solon, 
OH) using DNA polymerase I, Klenow fragment (Stratagene, La Jolla, CA). For EMSA 
reactions, 5 µg of nuclear protein, 0.5 µg poly(dI•dC), 50 µg BSA, and 10,000 CPM of 
32P-labeled probe were mixed in 25 µL binding buffer [20 mM HEPES (pH 7.9), 80 mM 
KCl, 5 mM MgCl2, 2% Ficoll, 5% glycerol, 0.1 mM EDTA, and 0.2 mM dithiothreitol] at 
room temperature. For supershift assays, 1 µg of anti-CREB antibody (sc-240X, Santa 
Cruz) was incubated with nuclear extracts, BSA, and poly(dI•dC) for 20 min at room 
temperature. Labeled probe was added and the reactions were incubated for an 
additional 15 min at room temperature. In some reactions, 500 ng of recombinant CREB 
protein (Biomol International, Plymouth Meeting, PA) was used instead of nuclear 
extracts. DNA-protein complexes were resolved on 5% polyacrylamide/0.5% Ficoll/0.5X 
TBE gels and the dried gels exposed to a phosphoimager screen. Complexes were 
visualized by prosphoimager scanning (Phospho/Fluorimager, Fuji Film, Japan).   
 
3.2.6.  Chromatin immunoprecipitation (ChIP) 
 ChIP assays were performed as described in Dammer et al. (158). Briefly, 
H295R cells were sub-cultured into 150-mm dishes and treated with 0.4 mM Bt2cAMP 




of anti-phospho-Ser133-CREB, anti-CBP, anti-p300, and anti-trimethyl H3K4. Real-time 
PCR was carried out using the primer sets indicated in Table 3.1 and output 
(immunoprecipitated promoter region) normalized to input DNA. Some reactions were 
also subjected to agarose (4%) gel electrophoresis.   
 
3.2.7.  RNA interference (RNAi) and real time RT-PCR (qRT-PCR) 
 Cells were sub-cultured into 12-well plates and 24 h later transfected with 75 nM 
of nonspecific small interfering RNA (siRNA) oligonucleotides or siRNA oligonucleotides 
directed against CREB (SI00299894, Qiagen, Valencia, CA) using HiPerfect 
Transfection Reagent (Qiagen). After 48 h, cells were treated with 0.4 Bt2cAMP for 24 h.  
Total RNA was extracted using TRIzol (Invitrogen) and ASAH1 mRNA expression was 
quantified using a One-Step SYBR Green RT-PCR Kit (Thermo Scientific) and 
normalized to β-actin. Western Blotting was performed to confirm reduction of CREB 
protein expression. 
 
3.2.8.  Western blotting  
 H295R cells were treated with 0.4 mM Bt2cAMP for 24, 48, or 72 h and harvested 
into RIPA buffer. Cells were then lysed by sonication (one 5 sec burst) followed by 
incubation on ice for 30 min. Lysates were centrifuged for 10 min at 4°C and the 
supernatant collected for analysis by SDS-PAGE. Aliquots of each sample (30 µg of 
protein) were run on 10% SDS-PAGE gels and transferred to PVDF membranes 
(Thermo Scientific, Rockford, IL). Blots were probed with an anti-ASAH1 (HPA005468, 
Sigma, St. Louis, MO) and anti-GAPDH (Santa Cruz) antibodies and expression was 
detected using an ECF western blotting kit (GE Healthcare, Piscataway, NJ) and 
visualized by scanning blots on a Typhoon Trio Scanner (GE Healthcare). Protein 




3.2.9.  In vitro acid ceramidase activity assay 
 Activity assays were performed as described in Nikolova-Karakashian and Merrill 
(409). H295R cells were sub-cultured into 100-mm dishes as treated for 24, 48, or 72 h 
with 0.4 mM Bt2cAMP. After treatment, cells were harvested into lysis buffer (0.2% Triton 
X-100, 10 mM Tris-Cl, pH 7.4, 1 mM 2-mercaptoethanol, 1 mM EDTA, 15 mM NaCl) with 
protease inhibitors (EMD Chemicals, Gibbstown, NJ) and sonicated 5 times for 2 sec 
burst. Protein concentrations were determined using the BCA Protein Assay (Pierce). 
Acid ceramidase activity was assayed by incubating 100 µL of cell lysate (at least 15 
µg/µL of proteins) with 2 µL of a 1 mM NBD-12-cer stock in 0.5 M acetate buffer (pH 4.5) 
for 2 h at 37°C. Reactions were terminated by the addition of 10 µL oleic acid (10 
mg/mL), 1mL chloroform:methanol (2:1, v/v), and 1 mL Dole’s solution 
(isopropanol:heptane:2 N H2SO4, 40:10:1, v/v/v) followed by vortexing and a 10 min 
incubation at room temperature. Four hundred µL heptane and 600 µL distilled H2O was 
added, the mixtures were vortexed for 2 min, and then centrifuged for 10 min at 4,000 
rpm. The lower organic phase was dried under a stream of nitrogen and spotted on 
Silica Gel 60 thin-layer chromatogray (TLC) plates (EMD Chemicals). Plates were 
developed in chloroform:methanol:25% NH4OH (90:20:0.5, v/v/v) and visualized by 
fluorescence scanning on a Typhoon Trio Scanner (GE Healthcare). NBD-dodecanoic 
acid formation was quantified by densitometry and normalized to the protein content of 
each sample. 
  
3.2.10. Statistical analysis 
 One-way ANOVA, Tukey-Kramer multiple comparison, and unpaired student t-




Diego, CA).  Significant differences from a compared value were defined as p < 0.05 and 
denoted by asterisks (*) or carats (^).  
 
Table 3.1. Primer and oligonucleotide sequences used for ChIP, RT-PCR, EMSA, and cloning. 
Method Region Forward primer     Reverse primer 




















































 -1430 TCACCGAGAACATACGCCTCAG  CTTAGATCGCAGATCTGGCGGCAG
CCAGGAGGAC 
 -906 CTTTGAAATCCAACCCGGTCCC CTTAGATCGCAGATCTGGCGGCAG
CCAGGAGGAC 
 -496 CGCTTTTCTCAGAGGGCAAAG CTTAGATCGCAGATCTGGCGGCAG
CCAGGAGGAC 





3.3.      Results 
 
3.3.1.  Bt2cAMP regulates ASAH1 mRNA expression 
 As discussed earlier, steroidogenesis in adrenocortical cells is activated by a 
cAMP-dependent pathway. There are 5 genes that encode ceramidase enzymes 
(ASAH1, ASAH2, ACER1-3). Therefore, the effect of increased intracellular cAMP on 
ASAH gene expression in H295R cells was determined by treating with 0.4 mM Bt2cAMP 
for 24 h. ASAH1 mRNA expression was increased by 2.8-fold after 24 h treatment with 
Bt2cAMP (Figure 3.1A). Conversely, no increase in expression in response to Bt2cAMP 
was observed for both ASAH2 and ACER3 (Figure 3.1A), indicating that the cAMP 
signaling pathway differentially regulates the expression of these genes. Of note, similar 
results were obtained for mouse Y1 adrenocortical cells (data not shown). Next, I 
assessed the kinetics of the ASAH1 response to Bt2cAMP by treating H295R cells for 1 
Figure 3.1. Bt2cAMP increases ASAH1 mRNA expression. A. H295R cells were cultured into 
12-well plates and treated for 24 h with 0.4 mM Bt2cAMP. Total RNA was isolated for analysis 
of ASAH1, ASAH2, or ACER3, and β-actin mRNA expression by qRT-PCR. Data is graphed 
as fold change in ASAH mRNA expression and normalized to the mRNA expression of β-
actin. Data graphed represent the mean ± SEM of 3 separate experiments, each performed in 
triplicate. *; Statistically different from untreated control group, p < 0.05. B.  H285R cells were 
treated for 1 to 24 h with 0.4 mM Bt2cAMP and ASAH1 and β-actin mRNA expression 
quantified by qRT-PCR. Data is graphed as fold change in ASAH1 mRNA content and is 
normalized to the mRNA expression of β-actin. Data graphed represent the mean ± SEM of 3 
separate experiments each performed in triplicate*; Statistically different from untreated 




to 24 h. These temporal experiments revealed that Bt2cAMP evoked a rapid and 
transient decrease in ASAH1 mRNA expression within 1 h, followed by a chronic 
increase in mRNA expression (Figure 3.1B). A maximal 4-fold increase in ASAH1 mRNA 
expression was observed at the 18 h time point.  
 
3.3.2.  CREB increases ASAH1 reporter gene activity 
To further define the mechanism by which Bt2cAMP modulates ASAH1 mRNA 
expression, 2.7 Kb of the human ASAH1 promoter was cloned and the amplified product 
ligated into the pGL3 vector. H295R cells were transfected with this reporter construct 
for 24 h followed by exposure to 0.4 mM Bt2cAMP for 16 h. As shown in Figure 3.2, 
Bt2cAMP treatment significantly increased the transcriptional activity of the 2.7 Kb 
reporter gene by 1.5-fold. Because I observed a significant increase in ASAH1 
transcription in response to Bt2cAMP treatment, I performed in silico analysis of the 2.7 
Figure 3.2.  Localization of the cAMP- and CREB-responsive region(s) of the ASAH1 promoter.  
H295R cells were transfected with reporter gene plasmids (pGL3-ASAH1) containing varying 
regions of the ASAH1 promoter and a CREB expression plasmid using GeneJuice as described in 
Section 3.2. Twenty-four hours after transfection, cells were treated with 0.4 mM Bt2cAMP for 16 h 
and luciferase activity in the cell lysates quantified by luminometry. Statistical difference from 
untreated control within each transfection group or between control and Bt2cAMP-treated cells 





Kb ASAH1 promoter and found 6 putative CREs (Figure 3.2). Overexpression of CREB 
increased luciferase activity of the 2.7 Kb construct by 2.3 fold when compared to cells 
transfected with only pGL3-ASAH1(-2740). Bt2cAMP stimulation resulted in a further 30 
% increase in reporter gene activity over the CREB-mediated activation in luciferase 
expression.   
To define the cAMP-responsive region(s) of the ASAH1 promoter, deletion 
constructs were generated and assayed in transfection assays. While deletion of region -
2740 to -906 had no significant effect on the ability of Bt2cAMP to stimulate reporter 
gene activity, removal of 410 base pairs (-496 construct) completely attenuated the 
Bt2cAMP response (Figure 3.2). Deletion of the region encompassing -2740 to -1430 
decreased the stimulatory effect of CREB overexpression by approximately 33 % in both 
control and Bt2cAMP-treated cells and deletion of the region encompassing -1430 to -
906 completed ablated the CREB response. The integral role of CREB was confirmed in 
reporter gene studies using a dominant-negative CREB (pCMV-K-CREB) (410) which 
Figure 3.3.  Dominant-negative mutant 
CREB abrogates ASAH1 reporter gene 
activity. H295R cells were transfected 
with pGL3-ASAH1(-2740), wild type 
(pCMV-CREB) or dominant negative 
mutant (pCMV-K-CREB) CREB 
expression plasmids, and pRL-TK.  
Luciferase activity in lysates isolated 
from control and Bt2cAMP-treated cells 
was quantified by luminometry. Data 
are expressed as the fold change in 
pGL3-ASAH1(-2740) reporter gene 
activity over the untreated control 
group mean and represent the mean ± 
SEM of three separate experiments, 
each performed in triplicate.  Asterisks 
(*) and carats (^) denote a statistically 
significant difference (p < 0.05) from 
the untreated control group and the 






completely attenuated the stimulatory effects of both CREB and Bt2cAMP (Figure 3.3).  
Notably, dominant negative CREB also reduced basal luciferase activity by 50 %, 
suggesting that CREB may play a role in regulating the constitutive expression of 
ASAH1. 
 
3.3.3.  CREB is required for Bt2cAMP-stimulated ASAH1 mRNA expression 
 In order to investigate if CREB was required for ASAH1 transcription, RNAi was 
used to suppress CREB translation (Figure 3.4A) and the effect of reduced CREB 
expression on Bt2cAMP-stimulated ASAH1 transcription was assessed. As shown in 
Figure 3.4B, H295R cells transfected with CREB siRNA oligonucleotides lose the ability 
to respond to Bt2cAMP.  
 
3.3.4.  CREB binds to the ASAH1 promoter in vitro and Bt2cAMP strengthens this 
 binding 
 
  My reporter gene assay with ASAH1 deletion constructs indicated that CREs 
located between -2750 and -906 confer CREB responsiveness (Figure 3.2). Therefore, 
Figure 3.4. Silencing CREB decreases 
Bt2cAMP-stimulated ASAH1 
transcription. A. H295R cells were 
transfected with 75 nM CREB or 
scrambled siRNA oligonucleotides for 72 
h and total cell lysates were isolated for 
SDS-PAGE and western blotting. Blots 
were hybridized to an anti-CREB 
antibody. B. RNA isolated from untreated 
or Bt2cAMP-stimulated cells that were 
transfected with CREB siRNA were 
subjected to qRT-PCR. Data is graphed 
as fold change in ASAH1 mRNA 
expression and is normalized to the 
mRNA expression of β-actin and 
represent the mean ± SEM of three 
separate experiments, each performed in 
triplicate.  -, Control; +, Bt2cAMP.  (*) 
indicates a statistically significant 
difference compared to untreated 






EMSA was carried out to determine which of the putative CREs interacted with CREB.  
Radiolabeled double-stranded oligonucleotides corresponding to the 6 regions depicted 
in Figure 3.5A (sequences in Table 3.1) were incubated with either recombinant CREB 
or nuclear extracts isolated from control or Bt2cAMP-treated cells. As shown in Figure 
3.5B, specific DNA-protein complexes were found with 4 of the 6 probes tested (-1861/-
1841, -1776/-1756, -969/-949, -281/-261). The putative CREs at -1861/-1841 (panel 1, 
lane 1) and -1776/-1756 (panel 2, lane 1) exhibited weak interaction with recombinant 
CREB when compared to the -969/-949 (panel 3, lane 1) probe.  
 A weak upper and more intense lower band were revealed in reactions 
containing recombinant CREB and-1861/-1841 or -1776/-1756 (lane 1 in panels 1 and 
Figure 3.5. CREB binds to the ASAH1 promoter in vitro. A. Depiction of the regions of the 
ASAH1 promoter corresponding to each oligonucleotide probe. Ovals indicate putative 
CREB binding sites. B. Nuclear extracts isolated from cells treated with 0.4 mM Bt2cAMP for 
1 h or recombinant CREB (0.5 mg) were incubated with 32P radiolabeled oligonucleotides 
(10,000 cpm) corresponding to the following regions of the ASAH1 promoter: -1861/-1841, -
1776/-1756, -969/-949, and -281/-261.  Lanes in panels 1 – 3: 1) recombinant CREB, 2) 
control nuclear extracts, 3) Bt2cAMP-treated nuclear extracts, 4) recombinant CREB + anti-
CREB antibody, 5) control nuclear extracts + anti-CREB antibody, 6) Bt2cAMP-treated 
nuclear extracts + anti-CREB antibody.  Panel 4: untreated nuclear extracts (lane 1), 
Bt2cAMP-treated nuclear extracts (lane 2), untreated nuclear extracts + anti-CREB antibody 
(lane 3), Bt2cAMP-treated nuclear extracts + anti-CREB antibody (lane 4).  Solid arrows 





2), suggesting the interaction of monomeric (lower band) and dimeric (upper band) 
CREB with these regions of the ASAH1 promoter. In contrast, the -969/-949 probe 
exhibited one major DNA-protein complex when incubated with recombinant CREB 
(panel 3, lane 1). A supershift was observed when anti-CREB antibody was added to the 
reaction containing recombinant CREB and the -969/-949 probe (panel 3, lane 4). 
Further, when nuclear extracts were incubated with the -969/-949 probe in the presence 
of anti-CREB antibody, a significant reduction in DNA-protein complex formation was 
observed (panel 3, lanes 5 and 6). Notably, the mobility of DNA-protein complexes 
formed when the -969/-949 region was incubated with nuclear proteins (panel 3, lanes 3 
and 4) was significantly retarded when compared to reactions containing recombinant 
CREB (panel 3, lane 1). This difference in mobility suggests that CREB may be a 
component of a multi-protein complex.  
 A weak supershift was also found when the antibody was added to reactions 
containing the -1861/-1841 probe and nuclear extracts isolated from Bt2cAMP-treated 
cells (panel 1, lane 6). Bt2cAMP treatment increased the affinity of nuclear proteins for 
the -281/-261 region (compare lanes 1 and 2 in panel 4) and the CREB antibody 
decreased cAMP-stimulated complex formation (compare lanes 2 and 4 in panel 4). No 
significant binding to -1565/-1545 and -1110/-1086 oligonucleotides was observed (data 
not shown). Additionally, no changes in the formation of DNA-protein complexes were 
observed when reactions contained antibodies against ATF-1 or ATF-2 (data not 
shown).   
 
3.3.5.  Bt2cAMP promotes the recruitment of CREB and other coregulatory 
 proteins to the ASAH1 promoter 
 
I next examined the effect of Bt2cAMP stimulation on the recruitment of CREB 




performing chromatin immunoprecipitation (ChIP) assays using chromatin isolated from 
H295R cells that were treated with 0.4 mM Bt2cAMP for 30 or 60 min. CREB was 
enriched by 2.6-fold at region A (-1779/-1596) and 15-fold at region D (-325/-214) in cells 
treated with Bt2cAMP for 30 min (Figure 3.6B). One h exposure to Bt2cAMP increased 
CREB recruitment to region A by 4.9-fold. Region A is also shown in the agarose gel in 
the panel B inset. Bt2cAMP had no significant effect on CREB binding in the other three 
regions (B, C, and E) of the ASAH1 promoter that were examined.   
 
I also assessed the effect of cAMP signaling on coactivator association with the 
regions (A and D) of the ASAH1 promoter that exhibited enriched CREB binding. Both 
CBP and p300 were recruited to region A in cells exposed to Bt2cAMP for 60 min (Figure 
3.6C). Finally, because activated gene transcription is associated with the increased 
Figure 3.6. CREB, CBP, and p300 bind to the ASAH1 promoter in vivo. A. Diagram of the 
promoter regions amplified by each primer set used for ChIP assay. B. H295R cells were 
treated for 30 or 60 min with 0.4 mM Bt2cAMP, cross-linked with 1% formaldehyde, and the 
sheared chromatin immunoprecipitated with antibodies against anti-phospho-Ser133-CREB. 
C. Chromatin isolated from cells treated for 60 min with 0.4 mM Bt2cAMP was 
immunoprecipitated with antibodies against anti-CBP or anti-p300 and recruitment to region 
A or D of the ASAH1 promoter assessed by qPCR. D. H295R cells were treated for 30 min 
with 0.4 mM Bt2cAMP and the isolated chromatin immunoprecipitated with an antibody 
against trimethyl-H3K4. In panels B, C, and D, DNA purified was quantified by real time 
PCR and normalized to the ΔCt values of input DNA. Data is expressed as fold change over 
untreated control. Representative agarose gels of the PCR products obtained for region A 
are shown as insets to panel B (control, 30, and 60 min Bt2cAMP treatment) and panel D 





presence of specific histone modifications, I determined the effect of Bt2cAMP on the 
amount of trimethylated H3K4, a modification associated with active transcription (411), 
in regions A and D of the ASAH1 promoter. As shown in Figure 3.6D (region A shown in 
agarose gel inset), Bt2cAMP evoked an increase in the trimethylation of H3K4, indicating 
that Bt2cAMP-stimulated CREB binding occurs concomitantly with histone H3 
modification. 
 
3.3.6.  Bt2cAMP increases ASAH1 protein expression and enzymatic activity 
 Because Bt2cAMP increased ASAH1 mRNA levels, I sought to investigate if this 
effect translates into an increase in protein expression. Western blotting analysis in 
H295R cells treated for 24, 48, or 72 h with Bt2cAMP was carried out. As shown in 
Figure 3.7. Bt2cAMP increases ASAH1 protein expression and enzymatic activity. A. 
Representative western blot of H295R cells treated for 24, 48, or 72 h with 0.4 mM 
Bt2cAMP. Cell lysates were harvested and separated by SDS-PAGE followed by western 
blotting using anti-ASAH1 or anti-GAPDH antibodies. B. Graphical representation of the 
normalized band intensities shown in A. C. H295R cells were treated for 24, 48, or 72 h 
with 0.4 mM Bt2cAMP and cell lysates were isolated and incubated (100µL of lysate per 
reaction) with 2µL of 1 mM NBD-12-Cer in acetate buffer (pH 4.5) for 2 h at 37°C. Lipids 
were extracted and spotted on TLC plates. Plates were developed in 
chloroform:methanol:25% NH4OH (90:20:0.5, v/v/v) and visualized. NBD-dodecanoic acid 
formation was quantified and normalized to the protein content of each sample. Data 
shown is representative of 2 separate experiments each done in duplicate. (*) indicates a 





Figure 3.7A and B, Bt2cAMP significantly increased ASAH1 protein levels by 1.81- and 
1.96-fold after 48 and 72 h treatment, respectively. In addition, to determine if the 
increase in protein expression was functionally significant, ASAH1 activity in Bt2cAMP-
treated H295R cells was quantified. As shown in figure 3.7C, Bt2cAMP significantly 





3.4.  Discussion 
 ACTH/cAMP signaling regulates cortisol biosynthesis in the human adrenal 
cortex by chronically stimulating the transcription of multiple genes required for 
cholesterol metabolism and transport (27). In addition, ACTH acutely increases 
sphingolipid metabolism in H295R cells, resulting in changes in the cellular 
concentrations of bioactive sphingolipids that regulate steroidogenic gene transcription 
(75). In this Chapter, I show that ACTH/cAMP induces ASAH1 gene transcription by 
promoting the binding of CREB to multiple regions on the ASAH1 promoter. 
  Bt2cAMP differentially regulates ASAH genes (Figure 3.1A) and the transcription 
of the ASAH1 gene is modulated by Bt2cAMP in a time-dependent manner with maximal 
induction of the gene at the 18 h time point (Figure 3.1B). Interestingly, Bt2cAMP acutely 
reduces ASAH1 mRNA expression within 1 h. These data indicate that ACTH/cAMP 
signaling evokes a biphasic pattern of ASAH1 mRNA expression, with an initial decrease 
followed by transcriptional induction. The rapid decrease in the mRNA expression of 
ASAH1 suggests that cAMP may regulate the stability of ASAH1 transcripts and possibly 
promote the acute degradation of ASAH1 mRNAs. Regulation of RNA stability is a 
fundamental mechanism of gene regulation.  
 MicroRNAs (miRNA) and 3’UTR AU-rich elements (AURE) are two types of 
regulatory molecules capable of destabilizing transcripts (412-414). miRNAs are single-
stranded RNA molecules that downregulate gene expression by binding to 
complementary regions of mRNA molecules and either targeting them for degradation or 
blocking the assembly of the translational machinery (414). AUREs contain clustered or 
distributed AUUUA pentameric motifs or an U-rich sequence where interacting proteins 
bind to either stabilize (e.g. HuR) or destabilize (e.g. TTP, KSRP) the transcript by signal 
transduction pathways (415-416). Of note, these regulatory elements have been shown 




and StAR (418).  Multiple miRNA target sites and 3’UTR AU-rich regions are present on 
the ASAH1 mRNA (Lucki and Sewer, unpublished observation). Thus, it is possible that 
these regulatory mechanisms are involved in the observed acute ASAH1 mRNA 
decrease induced by Bt2cAMP. Interestingly, a similar acute decrease in mRNA 
expression was also observed for ASAH2 and ACER3 in response to ACTH and 
Bt2cAMP, suggesting that a similar regulatory mechanism may be involved (Lucki and 
Sewer, unpublished observation). 
 Luciferase assays using deletion constructs of the ASAH1 promoter identified a 
role for CREB in increased reporter gene activity that was localized to the region 
encompassing -2740 and -906 base pairs upstream of the transcription start site (Figure 
3.2).  ChIP (Figure 3.6) and EMSA (Figure 3.5) studies support a role for cAMP in 
stimulating the association of CREB with the ASAH1 promoter. ChIP experiments 
(Figure 3.6) revealed that CREB is enriched at region -325/-214 (region D) of the ASAH1 
promoter, however no stimulatory effect of CREB overexpression on reporter gene 
activity was observed when cells were transfected with the pGL3-ASAH1(-496) plasmid 
that contains the –325/-214 region (Figure 3.2). It is possible that although Bt2cAMP 
promotes CREB recruitment to the endogenous promoter, an increase in transcription 
requires the coordinate binding of CREB to multiple regions of the ASAH1 promoter. It is 
equally likely that cAMP signaling increases the binding of additional transcription factors 
in conjunction with CREB to the promoter. Nonetheless, RNAi (Figure 3.4) and the use 
of a dominant-negative CREB expression plasmid (Figure 3.3) confirmed the integral 
role of CREB in conferring increased gene expression in response to Bt2cAMP. 
Trimethylation of H3K4 and the recruitment of CBP and p300 to both the distal (region A) 
and proximal (region D) regions of the promoter further support a role for CREB in 




Functional promoter characterization has been reported for some of the genes 
encoding sphingolipid-metabolizing enzymes, including SGPP2 (222), subunit 2 of SPT 
(SPTLC2) (419), ganglioside GM3 synthase (420), ceramide glucosyltransferase (421), 
and ASAH2 (422). However, few studies have identified the transcription factors involved 
in the regulation of these genes. Sobue et al. (221) reported a NGF-mediated induction 
of the SPHK1 gene via binding of Sp1 to a specific 5’ region of the promoter and 
Mechtcheriakova et al. (222) demonstrated that NF-κB is necessary for induction of the 
SGPP2 gene in response to inflammatory stimuli.  
Although previous studies have defined the structural units of the ASAH1 gene 
(423-424), to our knowledge there is only one report that investigates the transcriptional 
regulation of an ASAH gene. Park et al. (425) characterized a 1931 base pair region of 
the murine ASAH1 promoter and demonstrated that Kruppel like factor 6 (KLF6), Sp1, 
and activator protein 2 (AP2) can bind the promoter in vitro. The findings in this Chapter 
provide functional characterization of the ASAH1 promoter and establish the factors that 
facilitate ACTH/cAMP-dependent ASAH1 gene expression. 
I also show that the effect of ACTH/cAMP signaling on ASAH1 transcription 
results in a significant increase in protein expression (Figure 3.7). Increased protein 
concentration is, in turn, concomitant with an upregulation in ceramidase enzymatic 
activity. These data, coupled with previous findings from our laboratory establishing the 
role of ACTH/cAMP signaling in acutely modulating sphingolipid metabolism (75), 
demonstrate that activation of the ACTH signaling pathway elicits two temporally distinct 
effects on sphingolipid metabolism: a rapid response and a chronic, transcriptional 
response. In addition, these data supports a role for ASAH1 as an important enzyme for 
the regulation of sphingolipid metabolism in response to ACTH/cAMP signaling that 




 Our group has previously demonstrated that ACTH promotes rapid changes in 
sphingolipid intracellular concentrations, including a decrease in Cer (47). Thus, my data 
indicating an ACTH-regulated transcription and activity of ASAH1 is in agreement with 
such previously finding and suggests that ACTH signaling is directly regulating 
intracellular SPH and S1P concentrations. Given that SPH is an antagonist ligand for 
SF-1 and S1P promotes CYP17A1 expression, it is tempting to speculate that the 
transcriptional regulation of the ASAH1 gene by ACTH/cAMP signaling is part of a 
regulatory mechanism through which ACTH modulates cortisol production. In summary, 
this Chapter presents data that supports CREB as a central regulator of ASAH1 gene 
transcription and demonstrate that activation of the cAMP signaling pathway promotes 
the coordinate interaction of CREB and the coactivators CBP and p300 to multiple 
regions of the ASAH1 promoter, concomitant with the trimethylation of H3K4. 





Acid ceramidase is a global regulator of steroidogenic capacity and adrenocortical gene 
expression 
 
4.1.  Introduction 
In the human adrenal cortex, cortisol is synthesized from cholesterol by 
cytochrome P450 monooxygenase (encoded by CYP11A1, CYP17A1, CYP11B1, and 
CYP21A2 genes) and 3β-HSDII enzymes in a process primarily regulated by the peptide 
hormone ACTH (3,27,426-427). In the zonae fasciculata and reticularis, ACTH increases 
steroid hydroxylase gene expression by activating adenylyl cyclase and consequently 
increasing intracellular cAMP (27). This second messenger activates PKA, which acutely 
promotes cholesterol mobilization to the inner mitochondrial membrane and chronically 
induces the transcription of genes required for steroid hormone production 
(264,271,278,428). The transcription of most steroidogenic genes is regulated by SF-1, 
which in response to ACTH signaling binds to target promoters and facilitates the 
recruitment of coactivator proteins (264,266,429-432). Further, additional transcription 
regulators, including β-catenin (433-434), DAX-1 (435-436), and the NR4A family of 
transcription factors (Nur77, Nurr1, and Nor-1) (25,437-439) are equally important for 
maintaining optimal transcriptional output.    
Sphingolipids have emerged as important second messengers in various 
signaling transduction pathways (56,89,200,440-444). In steroidogenesis, SPH 
modulates steroidogenic gene transcription by serving as an antagonist for SF-1 (298). 
Previous work from our group has demonstrated that SPH is bound to the receptor 
under basal conditions and that Bt2cAMP stimulation promotes SPH displacement from 
the receptor ligand-binding pocket. SPH binding to SF-1 antagonizes the ability of 
Bt2cAMP to activate CYP17A1 gene transcription and stimulate DHEA production (47). 




stimulated CYP17A1 transcription (298), which supports a role for this enzyme in 
regulating SF-1 function and steroidogenic gene transcription. In many respects, steroid 
hormone biosynthesis and sphingolipid metabolism have a reciprocal relationship (445). 
In H295R cells, ACTH stimulates sphingolipid metabolism by rapidly promoting the 
catabolism of SM, Cer, and SPH (75). ACTH/cAMP signaling acutely increases the 
enzymatic activities of SPHK (75,115) and ASAH1 (Chapter Three) in H295R cells. 
Further, as described in Chapter Three, CREB is an essential transcriptional regulator of 
the ASAH1 gene in H295R cells. 
Ceramidases are a family of hydrolases that catalyze the degradation of Cer into 
SPH and a free fatty acid. ASAH1 is a glycoprotein processed from a 55 kDa precursor 
via autoproteolytic cleavage (107) into a mature heterodimeric enzyme formed by an α 
(13 kDa) and β (40 kDa) subunits (108). Because Cer degradation is the only source of 
cellular SPH (104), these enzymes are not only essential for limiting Cer-mediated 
signaling but also for controlling the cellular functions of SPH and S1P (83,105-106). In 
mouse, ASAH1 is expressed early during embryogenesis, with targeted disruption of the 
ASAH1 gene resulting in embryonic lethality (109). Moreover, ASAH1 overexpression 
has been reported in various human cancers (110-113) and a genetic deficiency in 
ASAH1 catalytic activity causes the lysosomal sphingolipid storage disorder, Farber’s 
disease (114). 
In order to determine the functional significance of Cer metabolism in 
adrenocortical steroidogenesis, an H295R stable cell line that expresses ASAH1-shRNA 
(short hairpin RNA) in a tetracycline (tet)-regulated manner was generated. Experiments 
in this Chapter show that suppression of ASAH1 protein expression results in global 
changes in gene expression, including the induction of the steroidogenic genes 
CYP17A1, CYP11A1, CYP21A2, CYP11B, StAR, TSPO, HSL, and Mc2R. Consistent 




secrete cortisol and DHEA, both basally and in response to activation of the ACTH 
signaling pathway. Furthermore, suppression of ASAH1 alters the amount of several 
sphingolipid species, including a decrease in C16-sphingolipids and a shift in the acyl-
chain composition of Cer, SM, and glycosphingolipid subspecies. Intriguingly, ASAH1 
knockdown leads to a decrease in cell proliferation with a concomitant reduction in the 




4.2.  Materials and Methods 
4.2.1.  Cell Culture 
  H295R adrenocortical cells were cultured as described in Chapter Two. H295R 
ASAH1KD (ASAH1-knockdown) cells were cultured in the same medium as the parental 
cell line with the addition of 1 µg/mL blasticidin and 50 µg/mL zeocin. 
 
4.2.2.  Generation of the H295R ASAH1-knockdown (ASAH1KD) stable cell line 
  H295R cells expressing tetracycline (tet)-inducible ASAH1shRNA were 
generated using the BLOCK-iT Inducible H1 RNAi Entry Vector Kit (Invitrogen) following 
the manufacturer’s instructions. First, the tet repressor (TetR) expression plasmid 
(pcDNA6-TR, Invitrogen) was stably transfected into H295R cells using GeneJuice 
(EMD Biosciences). Each clone was selected using 1 µg/mL blasticidin and TetR 
expression was determined by western blotting using an anti-TetR antibody (Sigma). 
The clone that expressed the highest TetR protein (H295R-TetR cells) was transfected 
with the pENTR/H1/TO-ASAH1shRNA vector. To construct an inducible vector for 
ASAH1 shRNA, the following sequences were cloned into pENTR/H1/TO: 5’-ACC GCA 
CCA ATG CTA AAG GTT ATA GTG AAC GAA TTC ACT ATA ACC TTT AGC ATT GGT 
G-3’ and 5’-AAA ACA CCA ATG CTA AAG GTT ATA GTG AAT TCG TTC ACT ATA 
ACC TTT AGC ATT GGT GC-3’, corresponding to positions 221 to 246 of the ASAH1 
mRNA sequence (NM_004315). H295R-TetR cells were stably transfected with the 
constructed pENTR/H1/TO-ASAH1shRNA expression vector or the control vector using 
GeneJuice (EMD Biosciences), and cell clones were selected using 50 µg/mL zeocin. 
Clones were treated with 5 µg/mL tet for 96 h and suppression of ASAH1 protein levels 
in each clone was confirmed by western blotting using an anti-ASAH1 antibody 





4.2.3.  DNA Microarray 
  H295R wild type (WT) or tet-treated (5 µg/mL for 72 h) ASAH1KD cells were sub-
cultured into 100-mm dishes and treated with 0.4 mM Bt2cAMP for 18 h. Total RNA was 
isolated using the Qiagen RNeasy kit (Qiagen, Valencia, CA) and gene expression 
profiling was done by Phalanx Biotech Group, Inc. (Palo Alto, CA) using the Human 
Whole Genome OneArray Microarray (HOA_004). 
 
4.2.4.  RNA isolation and real-time RT-PCR (qRT-PCR) 
  H295R WT or ASAH1KD cells were sub-cultured into 12-well plates and shRNA 
cells treated with 5 µg/mL tet for 48 - 72 h. In some experiments, cells were stimulated 
with 0.4 mM Bt2cAMP for 18 h prior to RNA extraction. Total RNA was isolated using 
Isol-RNA Lysis Reagent (5 Prime, Inc., Gaithersburg, MD) and amplified using a One-
Step SYBR Green RT-PCR Kit (Thermo Scientific Inc., Waltham, MA) and the primer 
sets listed in Table 4.1. Gene expression was normalized to β-actin mRNA content and 
calculated using the delta-delta cycle threshold (∆∆CT) method.  
 
4.2.5.  Western Blotting  
  H295R WT or ASAH1KD (5 µg/mL tet for 0 to 120 h) cells were harvested into 
RIPA buffer containing protease inhibitors. Cells were then lysed by sonication (one 2 
sec burst) followed by incubation on ice for 30 min. Lysates were centrifuged at 12,000 
rpm for 15 min at 4°C and the supernatant collected for analysis by SDS-PAGE. Aliquots 
of each sample (30 µg of protein) were resolved on 8% SDS-PAGE gels and transferred 




Table 4.1. Primer sets used in qRT-PCR experiments. 
Gene Forward (5’- 3’) Reverse (5’- 3’) 
β-Actin ACGGCTCCGGCATGTGCAAG TGACGATGCCGTGCTGCATG 
ASAH1 GCACAAGTTATGAAGGAAGCCAAG TCCAATGATTCCTTTCTGTCTCG 
ASAH2 GCATCAACACAGGAGAGTC GGAGGCAGAGGCATAGAG 
ACER3 ATCCGCCTGGTCTTCATC CTCCTTATTGCTGGTCTTCC 
SPHK1 CTGGCAGCTTCCTTGAACCAT TGTGCAGAGACAGCAGGTTCA 
SPHK2 CCAGTGTTGGAGAGCTGAAGGT GTCCATTCATCTGCTGGTCCTC 
SPTLC1 AGTCCCTTTCTCCAGCCTTTC TTCCACCGTGACCACAACC 
SPTLC2 CAAGAAGAAATACAAGGCATAC CCATCATAACATCCACATCC 
CerS1 CCTTCTACTTCTTCTTCAATGC TCGGCTGTGTCATACTCC 
CerS2 GTCATCCTGCCCTTCTGG CACTGCTGGCATCTTCTACC 
CerS3 TCATACATCTTCCTCAACCTACAG GCCTCTTCTTCTTCCTCTTCC 
CerS5 ATGGTGGCTCCTCAATGG AGGTGGTCACATCTTCTTCC 
CerS6 GCTGACGAGGTTCTGTGAG AGTTGTGAGTGGCTGATAGG 
ELOVL1 GTCTACAACTTCTCACTGGTGGC AAGTGCCTCAGGGCTGTTGGAA 
ELOVL2 TCCACTTGGGAAGGAGGCTACA CCAGGAACTCTACTGATTTGGAG 
ELOVL4 CCGAGAACCTTTTCAGATGCGTC AATCCACACTCTGGCAAATATAG 
ELOVL5 ACGTCTACCACCATGCCTCGAT TGGAAGGGACTGACGACAAACC 
ELOVL6 CCATCCAATGGATGCAGGAAAAC CCAGAGCACTAATGGCTTCCTC 
ELOVL7 CCTACTATGGACTTTCTGCATTGG GAACTGGCTTATGTGGATGGCG 
CYP17A1 CTCTTGCTGCTTCACCTA TCAAGGAGATGACATTGGTT 
CYP11A1 CGTGGAGTCGGTTTATGTC CTCTGGTAATACTGGTGATAGG 
CYP11B ACGGCGACAACTGTATCC AGAGCGTCATCAGCAAGG 
CYP21A2 TGTGGAACTGGTGGAAGC GGTGGAGCCTGTAGATGG 
3β-HSD CCAGTAGCATAGAGGTAGCC TCAGATTCCACCCGTTAGC 
NR5A1 GGAGTTTGTCTGCCTCAAGTTCA CGTCTTTCACCAGGATGTGGTT 
NR5A2 TACCGACAAGTGGTACATGGAA CGGCTTGTGATGCTATTATGGA   
NR4A1 GGACAACGCTTCATGCCAGCAT CCTTGTTAGCCAGGCAGATGTAC 
NR4A2 AAACTGCCCAGTGGACAAGCGT GCTCTTCGGTTTCGAGGGCAAA 










TSPO GCAGATTCCGTGATTACAGTG TCCTCCTCGTCGTCATCG 
HSL CACTACAAACGCAACGAGAC CCAGAGACGATAGCACTTCC 
Mc2R GTGGTGCTTACGGTCATCTGGA AGGCACAGGATGAAGACCAGCA 
PDE4B TAGTCAGCCTCCTGTCTCCAGA GAAGCCATCTCACTGACAGACC 
SGPP2 ACTCCTCATCGTCCTCAC CAGAATCCTATGGTCACTCC 
nSMase 1 GTGCTCAACGCCTATGTG GTCTGCCTTCTTGGATGTG 
nSMase 2 ACTGCTCCTCTGACGACAAG CCACGGCTTCTCCTCACC 
SGMS2 ACTCTACCTGTGCCTGGAATG AATAAGTCAGTGTCAGCGTAACC 
aSMase 1 TTGTAGCCAGGTATGAGAAC GCCGATGTAGGTAGTTGC 
CERK ACCACTGACATCATCGTTACTG GCACCTCGCTGAACATACC 





multiple antibodies and expression was detected using an ECF western blotting reagent 
kit (GE Healthcare, Piscataway, NJ) and visualized by scanning the blots on a VersaDoc 
4000 imager (Bio-Rad, Hercules, CA). Protein amounts were determined using the 
Bicinchoninic Acid (BCA) Protein Assay (Pierce, Rockford, IL). 
 
4.2.6.  Analysis of sphingolipid amounts 
  H295R WT or ASAH1KD cells (pre-treated with 5 µg/mL tet for 96 h) were sub-
cultured into 100-mm dishes and sphingolipid amounts in whole cells were analyzed by 
liquid chromatography, electrospray ionization, tandem mass spectrometry (LC-ESI-
MS/MS) as described previously (446-447).  
 
4.2.7.  Cortisol and DHEA enzyme-linked immune assays (EIA) 
  H295R WT or ASAH1KD cells (pre-treated with 5 µg/mL tet for 72 h) were sub-
cultured into 12-well plates and treated with 0.4 mM Bt2cAMP for 48 h prior to media 
collection. Cortisol and DHEA released into the media was determined in triplicate 
against cortisol or DHEA standards made up in DMEM/F12 medium using a 96-well 
plate enzyme-linked immune DHEA or cortisol assay (Assay Designs, Inc., Ann Arbor, 
MI). Steroid hormone amounts were normalized to the total cellular protein content, as 
determined using the BCA protein assay (Pierce). 
 
4.2.8.  Quantification of intracellular cAMP 
  H295R WT or ASAH1KD cells (pre-treated with 5 µg/mL tet for 96 h) were 
cultured into 12-well plates and treated with 50 nM ACTH for 5 min. Cells were lysed in 
0.1 M HCl for 20 min at room temperature, collected by scraping, and centrifuged at 




cyclic AMP Correlate-EIA™ (Assay Designs, Inc.) following the manufacturer’s 
instructions. Data were normalized to the total protein amount of each sample and is 
expressed as picomoles per milligram of total protein.  
 
4.2.9.  Chromatin Immunoprecipitation (ChIP) 
   H295R WT or ASAH1KD (pre-treated with 5 µg/mL tet for 96 h) cells were sub-
cultured into 150-mm dishes and ChIP assays were performed as described previously 
(158). The purified chromatin solutions were pre-cleared and immunoprecipitated using 
3 µg of anti-acetyl-histone H3 (06-599, Millipore) or 3 µg rabbit anti-IgG (Santa Cruz) 
antibodies and 30 µL protein A/G Plus agarose (Santa Cruz). Quantitative PCR was 
carried out using 20% of output, 5% input (diluted 1:4), the ABsolute qPCR SYBR Green 
Fluorescein Mix (Thermo Scientific), and the primer sets listed in Table 4.2.  
 
Table 4.2. Primer sets used in ChIP studies. 
Gene Forward (5’- 3’) Reverse (5’- 3’) 
StAR GCAGTGTGAGGCAATCGCTCT TGTTTCCTGGCAAATGTGGCA 
Mc2R TTGCCCAGAAAGTTCCTGCTT TTCTCCTGCTTGTGGTTAAGG 
CYP17A1 GGCTGGGCTCCAGGAGAATCTTTCTTCCAC C   GGCAGGCAAGATAGACAGCAGTGGAGTAG 
DAX-1 TCCTGCTTTTAAAGAGCACCCGCCCCT CGGCGCCCGTAGCCCAGTTCT 
NR4A2 GATCAGCTTGGACTCCCTTGAAAGT CATTCCAGAAATTGGCATCTTTTGA 
 
4.2.10.  Cell Proliferation 
  For quantitative proliferative assays, H295R wild type (WT), H295R-TetR, and 
ASAH1KD cells were seeded in 96-well plates (5 x 103 cells/well). H295R-TetR and 
ASAH1KD cells were treated for 96 h with 5 µg/mL tet. After treatment, the cultures were 
incubated for an additional 6 h in the presence of 5-bromo-2-deoxyuridine (BrdU; 10 
µM). Cell proliferation was assayed by BrdU incorporation measurements with an ELISA 




4.2.11. Statistical Analysis 
  One-way ANOVA, Tukey-Kramer multiple comparison, and unpaired student t-
tests were performed using GraphPad InStat software (GraphPad Software Inc., San 
Diego, CA).  Significant differences from a compared value were defined as p < 0.05 and 
denoted by asterisks (*) or carats (^). Hierarchical clustering analysis of DNA microarray 
studies was done by performing observation and variable tree computation using 





4.3.  Results 
4.3.1.  Characterization of the H295R ASAH1KD stable cell line 
  To characterize the functional significance of ASAH1 expression in regulating 
the steroidogenic capacity of adrenocortical cells, H295R cells were stably transfected 
with the pENTR/H1/TO vector containing a sequence for an ASAH1 shRNA. As shown 
in Figure 4.1A, ASAH1 mRNA levels were reduced by 68% in tet-treated cells (5 µg/mL 
tet for 48 h). Importantly, ASAH2 and ACER3 mRNA expression remained unchanged. 
ASAH1 protein levels are reduced by 52% and 81% after 72 h and 96 h tet treatment, 
Figure 4.1. Characterization of the H295R ASAH1KD cell line. A. ASAH1KD cells were 
treated with 5 µg/mL tetracycline (tet) for 48 h, total RNA was harvested, and ASAH1, 
ASAH2, and ACER3 mRNA levels were quantified by qRT-PCR and was normalized to 
the mRNA expression of β-actin. Inset: representative agarose gel of qRT-PCR products 
from ASAH1 mRNA transcripts. Data is graphed as mean +/- SEM of three separate 
experiments, each done in triplicate. Asterisks (*) indicate statistically significant 
differences from untreated controls (p < 0.05). B. ASAH1KD cells were treated with 5 
µg/mL tet for 48, 72, or 96 h, cell lysates were harvested, and separated by SDS-PAGE 
followed by western blotting using antibodies against ASAH1, ASAH2, ACER3, and 
GAPDH. C. Densitometric analysis of western blots of ASAH1, ASAH2, and ACER3 
protein expression in, normalized to GAPDH protein content in ASAH1KD cells treated for 
0 to 96 h with 5 µg/mL tet. Data graphed represent the mean ± STDEV of 3 separate 
experiments, each done in duplicate. Asterisks (*) denote statistically significant difference 





respectively (Figures 4.1B and 4.1C). Similar levels of ASAH1 suppression were 
observed in another clone (data not shown). 
 
4.3.2. ASAH1 suppression alters steroidogenic gene expression 
  Because SPH is an antagonist for SF-1 and transient ASAH1 silencing induces 
CYP17A1 transcription (47), the effect of reduced ASAH1 expression on global gene 
expression was determined. ASAH1 knockdown altered the expression of multiple 
classes of genes, including cell cycle and transcriptional regulators (data not shown). In 
addition, as shown in Figure 4.2, reduction of ASAH1 expression markedly changed the 
expression of genes required for steroid hormone metabolism. Real-time RT-PCR 
revealed that ASAH1 knockdown induced CYP11B and CYP21A2 transcription by 2.1- 
and 5.6-fold, respectively, while increased the expression of CYP17A1 by 4.8-fold 
(Figure 4.2B). In addition to increasing the mRNA expression of CYP11A1 by 1.6-fold, 
ASAH1 suppression also potentiated Bt2cAMP-induced CYP11A1 mRNA expression 
(Figure 4.2B). Intriguingly, ASAH1KD cells displayed significantly increased expression of 
genes involved in the uptake, de-esterification, and transport of cholesterol. As shown in 
Figure 4.2C, StAR, TSPO, and HSL expression was induced by 2.0-fold in ASAH1KD 
cells. Moreover, mRNA expression of SR-BI, which mediates HDL cholesteryl ester 
delivery into adrenal cells (448), was also upregulated by 6.8-fold (Figure 4.2C). Notably, 
suppression of ASAH1 also enhanced Bt2cAMP-stimulated transcription of StAR, HSL, 
and SR-BI genes. Finally, mRNA expression of the Mc2R gene, which encodes the 
cognate receptor for ACTH, was induced by 10.1-fold in ASAH1KD cells (Figure 4.2C). 
Induced mRNA expression was concomitant with an increase in cellular protein levels of 







Figure 4.2. ASAH1 knockdown increases the transcription of multiple steroidogenic genes. 
A. Diagram of the adrenocortical steroid hormone biosynthetic pathway. Circles represent 
genes that encode proteins that are involved in each step. Abbreviations: 18 kDa 
translocator protein (TSPO), steroidogenic acute regulatory protein (StAR), hormone 
sensitive lipase (HSL). B and C. H295R wild type (WT) and ASAH1KD (pre-treated with 5 
µg/mL tet for 72 h) cells were treated with 0.4 mM Bt2cAMP for 18 h. Total RNA was isolated 
and the mRNA levels of various steroidogenic genes were quantified by qRT-PCR and 
normalized to the mRNA expression of β-actin. Data is graphed as mean +/- SEM of three 
separate experiments, each done in triplicate. Asterisks (*) indicate statistically significant 
differences from untreated WT cells (p < 0.05). D. H295R WT and ASAH1KD (pre-treated 
with 5 µg/mL tet for 120 h) cell lysates were separated by SDS-PAGE and the protein 
expression of P450c17 (encoded by CYP17A1), P450scc (CYP11A1), P450c11B 




4.3.3.  Suppression of ASAH1 leads to increased cortisol and DHEA secretion 
  Because I observed increased expression of most genes required for steroid 
hormone production (Figure 4.2), I postulated that ASAH1KD cells have increased 
steroidogenic capacity. To test this hypothesis, the levels of cortisol and DHEA secreted 
into the media from controls and Bt2cAMP-treated WT and ASAH1KD cells were 
quantified. As shown in Figure 4.3A, ASAH1 suppression increased basal cortisol and 
DHEA secretion by 2.4- and 1.5-fold, respectively, compared to WT cells. Furthermore, 
downregulation of ASAH1 potentiated the stimulatory effect of Bt2cAMP on steroid 
hormone secretion (Figure 4.3A). 
Figure 4.3.  ASAH1 repression increases 
steroidogenic capacity. A. H295R wild type 
(WT) and ASAH1KD cells were treated with 
0.4 mM Bt2cAMP for 48 h. Cortisol and 
DHEA secreted into the media were 
quantified by EIA and normalized to the total 
cellular protein content of each sample. 
Asterisks (*) and carats (^) indicate 
statistically significant differences (p < 0.05) 
from the untreated controls within each group 
or from WT untreated controls, respectively.  
B. H295R WT, H295R-TetR (TetR), and 
ASAH1KD cells were seeded in 96-well plates 
at 5 x 103 cells/well. H295R-TetR and 
ASAH1KD cells were then treated with 5 
µg/mL tet for 96 h. Cell proliferation was 
measured with a BrdU incorporation ELISA 
kit. Data are expressed as mean % of control 
± SEM of three separate experiments, each 
done in quintuplicate. C. ASAH1KD cells were 
treated with 5 µg/mL tet for 120 h. Total cell 
lysates were harvested and separated by 
SDS-PAGE followed by western blotting 
analysis using anti-PCNA, anti-β-catenin, 






4.3.4.  ASAH1 knockdown decreases cellular proliferation 
  To further assess the role of ASAH1 in regulating H295R cell function, the effect 
of ASAH1 knockdown on cell proliferation was determined. As shown in Figure 4.4B, 
suppression of ASAH1 expression decreased cell proliferation by 29.1% compared to 
WT cells. In addition, analysis of various proliferative protein markers revealed that 
ASAH1 depletion decreased cellular levels of β-catenin, PCNA, and cyclin B2 (Figure 
4.3C). Significantly, no change in protein expression was observed in H295R-TetR cells, 
which express the Tet repressor protein but not ASAH1 shRNA (data not shown). 
Further, no significant difference in cell viability (determined by MTT assays) was 
observed among WT, H295R-TetR, and H295R-ASAH1KD cells (data not shown). 
 
4.3.5.  ASAH1KD cells have altered sphingolipid gene expression and sphingolipid 
 content 
 
  Next, the effect of ASAH1 suppression on the transcription of sphingolipid genes 
in ASAH1KD cells was examined. As shown in Figure 4.4A, reduced ASAH1 expression 
increased the mRNA expression of acid SMase 1 (aSMase1), SPHK1, and SPHK2 by 
2.3-, 3.3-, and 2.1-fold, respectively. Conversely, the expression of the catalytic subunit 
2 of SPT (SPTLC2), the enzyme that catalyzes the rate-limiting step in de novo 
sphingolipid biosynthesis, was significantly decreased by 2.6-fold in ASAH1KD cells 
(Figure 4.4A). ASAH1KD cells expressed higher levels of CerS1, CerS2, CerS3, and 
CerS6 mRNA transcripts (Figure 4.4B). These genes encode the family of CerS 
enzymes that catalyze the N-acylation of sphinganine to form dihydroCer (449). Because 
CerS enzymes use very long-chain fatty acyl-CoAs that are made by the elongation of 







Fig. 4.4. ASAH1 suppression alters the transcription of multiple sphingolipid genes. A. 
Total RNA from H295R wild type (WT) and ASAH1KD cells (pre-treated with 5 µg/mL tet 
for 96 h) was isolated as described in Section 4.2. Messenger RNA levels for the 
indicated sphingolipid genes were determined by qRT-PCR and are displayed as a heat 
map incorporated into the sphingolipid metabolic pathway. The mean mRNA expression 
values in ASAH1KD cells range from low (red) to high (green) compared to the mean level 
of mRNA expression for each gene in H295R WT cells. Abbreviations: Serine 
palmitoyltransferase (represented by 3 SPT genes), 3-ketosphinganine (3-keto-Sa), 
sphinganine (Sa), 3-keto-Sa reductase (-KSR), sphingosine kinase (SPHK), sphinganine-
1-phosphate (Sa1P), Sa1P phosphatase (Ppap2a and Sgpp2), sphingosine-1-phosphate 
(S1P), S1P lyase (SGPL1), ethanolamine phosphate (EP), hexadecanal (C16:0/1-al), 
fatty-acyl-CoA elongases (Elovl1-7), Ceramide synthase (CerS), dihydroCeramide 
(DHCer), DHCer desaturase (DES), Ceramide (Cer), Cer kinase (CERK), Cer-1-
phosphate (C1P), sphingomyelin (SM), SM synthase (SMS1-2), sphingomyelinase 
[SMase, neutral (n) and acid (a)], Ceramidase [acid (ASAH1), neutral (ASAH2), and 
alkaline (ACER3)], sphingosine (SPH). B and C. H295R WT and ASAH1KD (pre-treated 
with 5 µg/mL tet for 72 h) cells were treated with 0.4 mM Bt2cAMP for 18 h. Total RNA 
was isolated and the mRNA levels of CerS (B) or Elovl (C) genes were quantified by 
qRT-PCR and normalized to the mRNA expression of β-actin. Data is graphed as mean 
+/- SEM of three separate experiments, each done in triplicate. Asterisks (*) indicate 
statistically significant differences from untreated WT cells (p < 0.05). D. H295R WT and 
ASAH1KD (pre-treated with 5 µg/mL tet for 120 h) cell lysates were separated by SDS-
PAGE and the protein expression of ASAH1, ASAH2, ACER3, CerS2, CerS3, CerS6, 





 elongases (encoded by Elovl genes) was analyzed. The mRNA transcript levels of 
Elovl2, which catalyzes the elongation of polyunsaturated fatty acyl-CoA of up to 24 
carbons (450), were decreased by 7.6-fold in ASAH1KD cells (Figure 4.4C). Conversely, 
mRNA expression of Elovl7, which encodes a saturated very-long-chain fatty acid 
elongase (451), was induced by 2.7-fold (Figure 4.4C). Protein expression levels of 
ASAH1, ASAH2, SPHK1, and SPHK2 mirrored the changes in mRNA expression 
(Figure 4.4D). While CerS transcripts were increased in ASAH1KD cells, CerS protein 
levels, with the exception of CerS6, remained unchanged (Figure 4.4D), suggesting 
multiple levels of regulation of the CerS gene family. Of note, although ACER3 mRNA 
expression was induced in response to suppression of ASAH1 expression (Figure 4.4A), 
no statistically significant change in protein level was observed (Figure 4.4D). 
 These changes in sphingolipid gene expression prompted me to quantify the 
intracellular amounts of various sphingolipid species in ASAH1KD cells. LC-ESI-MS/MS 
analysis in WT and ASAH1KD cells revealed that total cellular SPH and S1P amounts 
were decreased by 30% and 16%, respectively, when ASAH1 was suppressed (Figure 
4.5A). Significantly, suppression of ASAH1 expression prevented the acute Bt2cAMP-
stimulated sphingolipid turnover that was observed in WT cells (Figure 4.5B) (295). 
ASAH1 knockdown altered the relative levels of distinct Cer and SM subspecies (Figure 
4.5C). The amounts of saturated long-chain (C18-24) Cer and unsaturated long-chain 
(C18:1) Cer were proportionally increased while C16-Cer and unsaturated very long-chain 
(C24:1 and C26:1) Cer were decreased in ASAH1KD cells compared to WT (Figure 4.5C). 
Similarly, long-chain (C18-22), very long-chain (C26), and unsaturated long-chain (C18:1) SM 
species were proportionally increased while C16-SM was decreased in ASAH1KD cells 
(Figure 4.5C). Intriguingly, the amounts of LacCer and HexCer were decreased by 40% 





Figure 4.5. ASAH1 knockdown leads to complex changes in steady-state sphingolipid content. A. The intracellular amounts of sphingosine (SPH), 
sphingosine-1-phosphate (S1P), and ceramide (CER) were quantified in H295R wild type (WT) and ASAH1KD (pre-treated with 5 µg/mL tet for 96 
h) cells by LC-ESI-MS/MS as described in Section 4.2. B. LC-ESI-MS/MS quantification analysis of the intracellular amounts of ceramide (CER), 
sphingomyelin (SM), sphingosine (SPH), sphingosine-1-phosphate (S1P), and hexosylceramide (HexCer) in H295R WT and ASAH1KD cells treated 
with 0.4 mM Bt2cAMP for 30 min. Data is graphed as fold change of sphingolipid content and normalized to untreated controls. C. The intracellular 
content of ceramide, sphingomyelin, lactosylceramide, and hexosylceramide subspecies was quantified in H295R WT and ASAH1KD cells by LC-
ESI-MS/MS. The relative distribution of different subspecies are represented with the chain length and number of double bonds depicted in the 
legend by x:y, respectively. Pie charts represent the relative changes in sphingolipid subspecie abundance between H295R WT and ASAH1KD 
cells. The number at the center of each chart refers to the total amount of each sphingolipid species quantified. 
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subspecies of LacCer and HexCer mirroring the pattern of acyl-chain composition 
decreases observed for SM subspecies (Figure 4.5C).   
 




 Several nuclear receptors regulate the transcription of steroidogenic genes (427). 
Quantitative RT-PCR analysis of genes encoding various nuclear receptors revealed 
that suppression of ASAH1 expression significantly increased the mRNA levels of 
NR4A1 and NR4A2 by 2.4- and 30.5-fold, respectively (Figure 4.6A). NR4A1 encodes 
NGFI-B/Nur77, which regulates the transcription of CYP21A2 (452) and StAR (439), 
Figure 4.6. ASAH1KD cells display altered expression of multiple steroidogenesis-
associated nuclear receptor genes. A. H295R wild type (WT) and ASAH1KD (pre-
treated with 5 µg/mL tet for 72 h) cells were treated with 0.4 mM Bt2cAMP for 18 h. 
Total RNA was isolated and the mRNA levels of NR5A1, NR4A1, NR4A2, NR4A3, 
NR0B1, and NR0B2 were quantified by qRT-PCR and normalized to the mRNA 
expression of β-actin. Data is graphed as mean +/- SEM of three separate 
experiments, each done in triplicate. Asterisks (*) indicate statistically significant 
differences from untreated WT cells (p < 0.05). B. H295R WT and ASAH1KD cell 
lysates were separated by SDS-PAGE and the protein expression of SF-1 (encoded 
by NR5A1), Dax-1 (NR0B1), Nur77 (NR4A1), Nurr1 (NR4A2), Nor-1 (NR4A3), SHP 
(NR0B2), and GAPDH was quantified by western blotting. 
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while NR4A2 (encodes Nurr1) activates CYP11B2 gene expression in response to 
angiotensin II (25). The transcription of NR4A3, which encodes the neuron-derived 
orphan receptor (Nor-1) and regulates CYP21A2 gene transcription (437), was induced 
by 2.1-fold in ASAH1KD cells (Figure 4.6A). Notably, ASAH1 suppression potentiated 
Bt2cAMP-induced NR4A1, NR4A2, and NR4A3 mRNA expression. In contrast to the 
induction observed for NR4A family members, ASAH1KD cells exhibited an 89% and 
66% decrease in NR0B1 (Dax-1) and NR0B2 (SHP, small heterodimer partner) mRNA 
transcripts, respectively (Figure 4.6A). Consistent with the changes in mRNA 
expression, Nur77, Nurr1 and Nor-1 protein levels were increased in ASAH1KD cells 
while Dax-1 protein expression was decreased under the same conditions (Figure 4.6B). 
Intriguingly, even though SHP mRNA expression was reduced in ASAH1KD cells (Figure 
4.6A), protein expression was increased by 1.9-fold (Figure 4.6B). Finally, although SPH 
is a ligand for SF-1 (47), reduced levels of this sphingolipid in ASAH1KD cells (Figure 
4.5A) did not affect the mRNA or protein expression of this receptor (Figure 4.6A and 
4.6B). 
 
4.3.7.  ASAH1 regulates intracellular cAMP levels and ACTH responsiveness 
  Because downregulation of ASAH1 altered the transcription of multiple cAMP-
regulated genes (Figures 4.2 and 4.6), I hypothesized that ASAH1 suppression 
increased cAMP amounts. To test this hypothesis, the amount of intracellular cAMP in 
WT and ASAH1KD cells under basal and ACTH-stimulated conditions was quantified. 
Unexpectedly, basal intracellular cAMP levels were decreased by 46% in ASAH1KD cells 
compared to WT (Figure 4.7). However, ASAH1KD cells displayed a significantly higher 
increase in the magnitude (6.1-fold) of intracellular cAMP produced in response to ACTH 




4.3.8.  ASAH1 knockdown affects histone H3 acetylation levels at target 
 promoters 
 
  Because ASAH1 suppression altered the transcriptional rate of multiple genes, I 
postulated that ASAH1 might alter nuclear patterns of histone acetylation. Western 
blotting analysis of histone H3 acetylation in WT and ASAH1KD cells revealed that 
suppression of ASAH1 resulted in a 1.7-fold increase in total acetyl-histone H3 levels 
(Figure 4.8A). Therefore, ChIP analysis in WT and ASAH1KD cells was carried out to 
quantify the relative amounts of acetylated histone H3 at the proximal promoter region of 
a subset of steroidogenic genes that exhibited altered mRNA expression in response to 
ASAH1 knockdown (Figures 4.2A, 4.2B, and 4.6A). Consistent with increased mRNA 
expression, acetyl-histone H3 levels at the proximal promoter region of StAR, Mc2R, 
NR4A2, and CYP17A1 genes were increased by 4.2-, 21.1-, 3.2-, and 4.1-fold 
respectively, in ASAH1KD cells compared to WT (Figure 4.8B). Further, a 8.6-fold 
decrease in histone H3 acetylation at the DAX-1 proximal promoter was observed in 
ASAH1KD cells (Figure 4.8B).  
Figure 4.7. ASAH1 regulates 
intracellular cAMP levels and 
ACTH responsiveness. H295R wild 
type (WT) or ASAH1KD (pre-treated 
with 5 µg/mL tet for 96 h) cells 
were treated with 50 nM ACTH for 
5 min. Intracellular cAMP levels 
were quantified by ELISA as 
described in Section 4.2. cAMP 
amounts are normalized to total 
cellular protein content and data 
graphed represents the mean +/- 
SEM of three experiments, each 
done in triplicate. Asterisks (*) and 
carats (^) indicate statistically 
significant differences from 
untreated controls within each 
group or from untreated WT 





Figure 4.8. Suppression of ASAH1 affects histone H3 acetylation levels. A. H295R wild type 
(WT) and ASAH1KD (pre-treated with 5 µg/mL tet for 96 h) cell lysates were isolated and 
separated by SDS-PAGE. Acetyl-histone H3 and total histone H3 levels were determined by 
western blotting. B. Graphical analysis of data obtained from western blotting studies of 
acetyl-histone H3 protein expression in WT and ASAH1KD cells. Data graphed represents 
the mean +/- STDEV of 3 separate experiments, each done in duplicate. H295R WT and 
ASAH1KD (pre-treated with 5 µg/mL tet for 96 h) cells were crossed linked with 1% 
formaldehyde and the sheared chromatin immunoprecipitated with an anti-acetyl histone H3 
antibody. Acetyl-histone H3 levels at the proximal promoter regions of StAR, Mc2R, 
CYP17A1, NR4A2, and DAX-1 genes were assessed by qPCR. Purified DNA was quantified 
by real time PCR and normalized to the ΔCt values of input DNA. Data is expressed as fold 
change over untreated WT controls.  
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4.4.  Discussion 
 In the zonae fasciculata and reticularis of the human adrenal cortex, steroid 
hormone biosynthesis requires the coordinate action of steroid hydroxylases and 
dehydrogenases (126,426,453), lipoprotein receptors (448,454), and cholesterol binding 
proteins (17,455-458). The transcription of most of these genes is regulated by ACTH, 
which upon binding to Mc2R activates a cAMP-signaling cascade. Sphingolipids, such 
as Cer, SPH, and S1P, regulate steroidogenesis by acting as secondary modulators of 
steroidogenic gene transcription (47,115,205-206,210) and/or steroidogenic regulatory 
pathways (175-176,202,204,207,212,396,459-460). Previous work from our group has 
demonstrated that dynamic sphingolipid metabolism is a component of ACTH/cAMP-
dependent steroidogenesis (75,461). 
 A hallmark of adrenocortical steroid hormone biosynthesis is the induction of 
steroidogenic gene transcription (Figure 4.2A) in response to chronic ACTH stimulation. 
The studies presented in this Chapter demonstrate that ASAH1 suppression mimics 
ACTH/cAMP-dependent CYP11A1, CYP17A1, CYP11B, and CYP21A2 gene expression 
and potentiates the effect of Bt2cAMP on CYP11A1 and CYP21A2 mRNA levels (Figure 
4.2B). Moreover, depletion of ASAH1 resulted in the upregulation of StAR, TSPO, HSL, 
and SR-BI transcription (Figure 4.2C), all of which encode proteins that are required for 
the cellular uptake of lipoproteins, the de-esterification of cholesteryl esters, and the 
transport of free cholesterol into the inner mitochondria membrane (7,12,16,462). The 
effect of ASAH1 suppression on the transcription of these steroidogenic genes is 
consistent with previously published data from our laboratory establishing SPH as an 
antagonist of SF-1 and suppressor of CYP17A1 transcription (298). Because SF-1 
regulates the transcription of CYP17A1, CYP11A1, StAR, Mc2R, and CYP11B1 
(264,432), lower SPH intracellular levels (Figure 4.5A) as a result of ASAH1 knockdown 
positively correlates with increased basal mRNA expression of these genes (Figure 
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4.4B). Altered steroidogenic gene expression in ASAH1KD cells can also be explained by 
higher mRNA and protein levels of the nuclear receptors Nur77 and Nor-1 (Figures 4.7A 
and 4.6B), both of which regulate CYP21A2 transcription (437,452). Nur77 also 
modulates StAR gene expression (439). Further, the expression of the transcription 
factor Dax-1 is significantly downregulated in ASAH1KD cells (Figures 4.6A and 4.6B). 
Dax-1 represses the transactivation potential of many nuclear receptors (463), including 
SF-1 (436,464), and its expression negatively regulates steroid hormone production at 
multiple levels (463,465-467). Furthermore, the absence of Dax-1 potentiates the ability 
of adrenal cells to respond to ACTH in vivo (435). Therefore, repression of this nuclear 
receptor may contribute to increased steroidogenic gene expression in ASAH1KD cells. 
The fact that not all SF-1-regulated genes are basally upregulated in ASAH1KD cells (e.g. 
3β-HSD) suggests that additional factors are required for inducing the expression of 
those genes. Consistent with mRNA and protein expression data (Figure 4.2), ASAH1KD 
cells secrete significantly higher levels of cortisol and DHEA than WT cells, both basally 
and in response to Bt2cAMP stimulation (Figure 4.3). ASAH1 knockdown also increased 
the magnitude of cAMP production in response to ACTH (Figure 4.7). This finding 
positively correlates with higher mRNA and protein expression of Mc2R (Figures 4.2C 
and 4.2D), the gene that encodes the cognate receptor for ACTH. 
 Significantly, ASAH1 suppression altered the amount of acetylated histone H3 at 
the proximal promoter region of multiple genes, including Mc2R, StAR, DAX-1, 
CYP17A1, and NR4A2 (Figure 4.8B). Lysine acetylation of histones is an epigenetic 
modification that is usually associated with active chromatin regions (468). Conversely, 
decreased mRNA and protein levels of DAX-1 in ASAH1KD cells (Figure 4.6) positively 
correlated with lowered amounts of acetylated histone H3 (Figure 4.8B). Sphingolipids 
are rapidly emerging as important mediators of various nuclear processes (444). 
Recently, Hait et al. (255) uncovered a novel role for nuclear SPHK2 and S1P in 
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regulating HDAC activity and histone acetylation. S1P was found to inhibit HDAC1 and 
HDAC2 enzymatic activity and enhance local histone H3 acetylation and transcription of 
target genes (255). Along this line of evidence, it would follow that lower ASAH1 
expression would result in lower S1P levels and thus decreased histone H3 acetylation. 
However, my data show that ASAH1 suppression leads to increased cellular amounts of 
acetylated histone H3 (Figure 4.8A) and an increase in the acetylation of histone H3 
levels at selected promoters (Figure 4.8B). Given that I observed no significant change 
in S1P levels in ASAH1KD cells (Figure 4.5A), this discrepancy between my findings and 
the work of Hait et al. may reflect cell-specific differences. Of note, intracellular S1P 
amounts remained unchanged in response to ASAH1 suppression despite an increase 
in SPHK1 and SPHK2 protein levels (Figure 4.4D), which is likely due to lower substrate 
(SPH) amount (Figure 4.5A).  
 ASAH1 knockdown had various effects on the transcription of sphingolipid genes 
(Figure 4.4). However, the changes observed in mRNA expression cannot fully explain 
the changes seen in the steady-state pool of sphingolipids (Figure 4.5). Total Cer and 
SM levels were unchanged in ASAH1KD cells, while the total amounts of LacCer and 
HexCer were significantly lower compared to WT cells (Figure 4.5B). As predicted, a 
reduction in SPH levels in ASAH1KD cells was observed (Figure 4.5A), however, this 
decrease was inconsistent with the lack of a significant change in total Cer levels. Given 
that ASAH1 catalyzes Cer hydrolysis and Cer degradation is the only source of cellular 
SPH (104), I anticipated that Cer would accumulate in these cells. Meroni et al. (205) 
previously reported that inhibition of ceramidase activity by (1S,2R)-d-erythro-2-(N-
myristoylamino)-1-phenyl-1-propanol (D-e-MAPP), an inhibitor of ACER3 (469), resulted 
in Cer accumulation and led to a decrease in testosterone secretion from rat gonadal 
Leydig cells. Although the cell system used in the current study differs from the one used 
by Meroni et al., the quantitative differences in Cer amounts when comparing these two 
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studies support the notion that each ceramidase isoform has unique cellular functions. 
This premise is supported by the differences in subcellular localization (94-99) and 
substrate specificity (96,100-103) of each ceramidase isoform. 
 The data presented in this Chapter indicate that ASAH1 knockdown had varied 
effect on sphingolipid homeostasis. Depletion of ASAH1 caused a shift in the acyl-chain 
lengths of Cer, SM, HexCer, and LacCer (Figure 4.5B). There was an accumulation in 
saturated long-chain (C18-24) Cer and SM species, a decrease in unsaturated C24:1- and 
C26:1-Cer,  and an overall reduction in C16-sphingolipids. A decrease in unsaturated very 
long-chain Cer species may be partially due to decreased mRNA levels of Elovl2 (Figure 
4.4C), which catalyzes the elongation of polyunsaturated fatty acyl-CoA of up to 24 
carbons (450), and lower CerS2 protein levels (Figure 4.4D), which uses very long-chain 
acyl-CoAs as substrates (449). It is equally probable that the protein levels and/or 
activity of fatty acyl-CoA elongases as well as the enzymatic activity of different CerS 
enzymes are increased in ASAH1KD cells and may contribute to the acyl-chain 
composition of sphingolipids in these cells. Interestingly, the levels of C16-Cer species 
are decreased in ASAH1KD cells despite an increase in CerS6 protein levels (Figure 
4.4D). Also, although ACER3 was recently reported to hydrolyze unsaturated long-chain 
C18:1-Cer (100), higher levels of this particular Cer subspecies in ASAH1KD cells were 
observed, which was inversely correlated to the levels of ACER3 mRNA expression in 
these cells (Figure 4.4A). The underlying mechanism for these changes in the 
sphingolipidome is unknown and further studies are necessary to elucidate the specific 
roles of ASAH1 in regulating sphingolipid acyl-chain composition. However, it is notable 
that similar unpredicted changes in sphingolipid content were recently observed by 
Mullen et al. (470) in response to CerS2 knockdown. Conversely, Park et al. (471) 
reported that the lipid backbone composition of Cer subspecies and fatty acyl-CoAs from 
mouse embryonic stem cells and embryoid bodies correlated fairly well with CerS and 
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Elovl genomic analysis. Thus, the changes in sphingolipid amounts resulting from 
sphingolipid gene knockdown are multifaceted and sometimes cannot be readily 
explained by changes in gene expression. Given that recently lipidomic analysis has 
revealed that Cer with varying fatty acyl-chain length may have distinct cellular functions 
(61-62), it is tempting to speculate that some of the physiological changes observed in 
response to ASAH1 suppression are partially due to a shift in the acyl-chain length of 
sphingolipid species.   
 Because ceramidases regulate the intracellular levels of two proliferation-
associated molecules, they have key implications in cell fate. ASAH1 is overexpressed 
in various cancers (110-113) while ASAH1 knockout leads to embryonic lethality in mice 
(109). Further, ACER3 and ASAH2 were both reported to modulate cell proliferation 
either by upregulating cyclin-dependent kinase inhibitor p21CIP1/WAF1 expression (100) or 
inducing cell cycle arrest at G0/G1 and retinoblastoma (Rb) protein dephosphorylation 
(472), respectively. Accordingly, the results presented in this Chapter suggest that 
ASAH1 controls the rate of cell proliferation in H295R cells (Figure 4.3B), at least in part, 
by decreasing the expression of multiple proliferation protein markers including β-
catenin, PCNA, and cyclin B2 (Figure 4.3C). Because ASAH1 suppression had no effect 
on cell viability (data not shown), apoptosis was excluded as a reason for reduced 
proliferation. The present study is consistent with my findings in MCF-7 breast cancer 
cells where I observed that suppression of ASAH1 expression by siRNA prevented 
genistein-induced cyclin B2 protein expression (Appendix 1) and further supports a role 
for ASAH1 in controlling cell growth, at least in part, through the regulation of 
proliferation-associated protein expression (Figure 4.3C). Additionally, emerging 
evidence suggest that LacCer levels positively correlate with various phenotypic 
changes including cell proliferation and migration (473-475). Therefore, lower LacCer 
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amounts in response to ASAH1 knockdown may also contribute to the decrease in 
proliferation of ASAH1KD cells.  
 In summary, this Chapter describes that ASAH1 knockdown leads to global 
changes in various classes of genes, including steroidogenic, nuclear receptors, and 
sphingolipid-metabolizing enzymes. ASAH1KD cells secrete significantly higher levels of 
cortisol and DHEA than WT cells, which positively correlate with higher mRNA 
expression of CYP11A1, CYP11B, CYP17A1, CYP21A2, StAR, TSPO, HSL, SR-BI, and 
Mc2R genes. These changes were largely the result of increased acetylation of histone 
H3 at the proximal promoters of these genes. ASAH1KD cells were also more sensitive to 
ACTH and displayed 6-fold higher intracellular cAMP accumulation upon hormone 
stimulation than WT cells, likely due to induced Mc2R expression (Figure 4.2D). 
Intriguingly, ASAH1 silencing resulted in the induction of all members of NR4A subfamily 
of nuclear receptors and the suppression of DAX-1 (Figure 4.6), indicating a novel role 
for this ceramidase in modulating nuclear receptor expression. Finally, I demonstrate 
that downregulation of ASAH1 causes a shift in sphingolipid metabolism towards Cer, 
SM, LacCer, and HexCer subspecies with long saturated fatty acyl-chain lengths. I 




Acid ceramidase represses steroidogenic factor-1-dependent gene transcription in 
H295R human adrenocortical cells by binding to the receptor  
 
5.1.  Introduction 
 ACTH regulates cortisol biosynthesis in the human adrenal cortex by activating a 
cAMP/PKA-dependent signaling pathway that leads to rapid cholesterol import and 
transport, as well as the transcriptional activation of genes required for steroid hormone 
production (27,31). The transcription of most steroidogenic genes is regulated by SF-1 
(NR5A1), which in response to ACTH signaling binds to target promoters and facilitates 
the recruitment of coactivator proteins (27,134,149,156,476). SF-1 is a member of the 
nuclear receptor superfamily of transcription factors (117) whose structure is divided into 
modular motifs: an amino-terminal conserved DNA binding domain (DBD) consisting of 
two zinc-binding modules, an intervening hinge region containing a ligand-independent 
activation domain (AF1), and a carboxy-terminal ligand-binding domain (LBD) containing 
a conserved AF-2 hexamer domain (LLIEML) that is critical for receptor activation (118) 
(Figure 1.5). The hinge region and LBD participate in transcriptional repression or ligand-
dependent activation. These domains serve as the interface for interactions between SF-
1 and numerous coregulatory proteins, including SRC-1 (119-120) and SMRT (121). 
Generally, coregulators bind to the AF1 and/or AF2 domains of nuclear receptors 
through LXXLL motifs (NR boxes), where X is any amino acid and L is a leucine (477-
478). Additional LXXLL-related motifs where L is substituted for an isoleucine, 
phenylalanine, or methionine have also been reported (169-170). 
The ability of SF-1 to bind to target promoters is regulated by post-translational 
modifications including phosphorylation (148-151), sumoylation (152-153), and 
acetylation (155-156,476), as well as protein-protein interactions (126,157-162). More 
recently, ligand binding has also been implicated in the regulation of SF-1 activity 
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(47,163-165,167). Crystallographic studies using bacterially expressed SF-1 have 
demonstrated that phospholipids are present in the ligand-binding pocket and that ligand 
binding is required for maximal activity of the receptor (163,165,167,244). Our laboratory 
has recently identified PA and SPH as endogenous ligands for SF-1 (47,164). PA acts 
as an agonist while SPH is an antagonist for the receptor. SPH is bound to SF-1 under 
basal conditions and prevents receptor binding to the CYP17A1 promoter, thus 
decreasing Bt2cAMP-stimulated CYP17A1 mRNA expression and DHEA synthesis (47). 
Further, as discussed in Chapter Four, I have uncovered a global role for ASAH1, an 
enzyme that produces SPH, in steroidogenic gene transcription in adrenocortical cells. 
ASAH1 knockdown induces the expression of multiple SF-1-target genes including 
StAR, Mc2R, and CYP17A1, and results in increased cortisol and DHEA secretion 
(Figure 4.3), which supports a role for ASAH1 in regulating the transactivation potential 
of SF-1.  
Because Cer degradation is the only source of cellular SPH (104), ASAH1 is not 
only essential for limiting Cer-induced signaling but also controlling the cellular functions 
of SPH and the counter-regulatory functions of Cer and S1P (83,105-106). Multiple 
factors regulate ceramidase activity including dexamethasone (72,479), PMA (480), and 
TNF-α (67,71,80). Additionally, in vivo studies have shown that ASAH1 requires 
sphingolipid activator proteins (SAP, saposin), mainly SAP-D, as cofactors for maximal 
activity (481). ASAH1 has been reported to localize to lysosomes (99) and to be 
secreted extracellularly from murine endothelial cells, macrophages, and human 
fibroblasts (98). This ceramidase is required for developmental because targeted 
disruption of the gene in mice leads to an early, embryonic lethal phenotype (109). In 
addition, a genetic deficiency in ASAH1 resulting in reduced enzymatic activity causes 
Farber’s disease, a lysosomal sphingolipid storage disorder (114).  
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 Based on previous findings from our group establishing SPH as an antagonist for 
SF-1 (47) and that SPH-mediated repression of CYP17A1 transcription is dependent on 
ASAH1 expression (47),  as well as  the role of ASAH1 in global steroidogenic gene 
expression and steroid hormone secretion (Chapter Four), the aim of the current study 
was to define the mechanism by which ASAH1 regulates SF-1 function in adrenocortical 
cells. In this Chapter I show that ASAH1 and its coactivator protein SAP-D are localized 
in the nuclei of H295R cells and that ACTH/cAMP signaling acutely increases ASAH1 
activity, concomitant with the nuclear metabolism of Cer and SPH. Significantly, ASAH1 
represses SF-1 activity by directly binding to the receptor through a functional LXXLL-
related motif. This interaction occurs on DNA and is strengthened by Bt2cAMP 
stimulation. Furthermore, the catalytic activity of ASAH1 is required for its ability to 
repress SF-1 function. Finally, I show that ASAH1 is recruited to the promoter of various 





5.2.  Materials and methods 
5.2.1. Cell culture 
  H295R adrenocortical cells and H295R ASAH1KD (ASAH1-knockdown) cells 
were cultured as described in Chapters Two and Four, respectively.  
 
5.2.2.  Nuclear extract purification and western blotting 
 H295R cells were sub-cultured into 100-mm dishes and cytoplasmic, nuclear 
envelope, and nucleoplasmic fractions were purified using the Nuclei Pure Isolation Kit 
(Sigma) following the manufacturer’s instructions. Aliquots (30 µg of protein) of 
cytoplasmic, nuclear envelope, and nucleoplasmic fractions were separated by SDS-
PAGE and transferred to PVDF membranes (Millipore, Temecula, CA).  Blots were 
probed with antibodies against SF-1 (Millipore), ASAH1 (HPA005468, Sigma), ASAH2 
(PRS4743, Sigma), ACER3 (sc-101848, Santa Cruz, St. Cruz, CA), saposin D (sc-
27024-R, Santa Cruz), lysosomal-associated membrane protein 1 (LAMP1) (sc-18822, 
Santa Cruz), P450c17α (sc-66849, Santa Cruz), or StAR (sc-25806, Santa Cruz). 
Expression was detected using an ECF Western blotting kit (Amersham Bioscience, 
Piscataway, NJ) and visualized by scanning blots on a Versa Doc 4000 imager (Bio Rad, 
Hercules, CA) 
  
5.2.3.  Immunostaining and confocal microscopy 
  Immunostaining and confocal microsopy were performed as described 
previously (164). Briefly, H295R cells were plated on glass cover slips, fixed, 
permeabilized, blocked with 1% BSA for 1 h, and then incubated with anti-ASAH1, anti-
ASAH2, anti-ACER3, or anti-saposin D antibodies (diluted 1:200 in 1% BSA) overnight, 
followed by incubation with secondary goat anti-rabbit rhodamine-conjugated IgG 
(Thermo Scientific) for 1 h. Cover slips were stained with 4,6’-Diamino-2-phenylindole 
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dihydrochloride (DAPI; Invitrogen) for 2 min and then mounted onto slides using 
Fluoromount G (Southern Biotech, Birmingham, AL). Confocal images were captured 
using a laser-scanning microscope (LSM 510; Zeiss, Thornwood, NY) equipped with 
argon and helium-neon laser with excitation wavelengths of 436 and 542 nm for DAPI 
and rhodamine, respectively.  
 
5.2.4.  In situ ceramidase activity assay 
 H295R wild type (WT) or ASAH1KD [pre-treated for 96 h with 5 µg/mL tetracycline 
(tet)] cells were sub-cultured into 100-mm dishes, incubated for 4 h with 4 µM NBD-12-
Cer {N-[12-(7-nitro-2-1,3-benzoxadiazol-4-yl-amino) dodecanoyl]-D-erythro-
sphingosine}, and then treated for 30 min to 6 h with 0.4 mM Bt2cAMP. After treatment, 
cells were harvested into lysis buffer [0.2% Triton X-100, 10 mM Tris-Cl pH 7.4, 1 mM 2-
mercaptoethanol, 1 mM EDTA, 15 mM NaCl, 1X protease inhibitor cocktail set I (EMD 
Biosciences)] and sonicated 5 times for 2 sec. Total lipids were extracted by adding 2.5 
mL chloroform/methanol (2/1, v/v), sonicating 5 times for 15 sec, and vortexing for 2 min. 
Samples were centrifuged (10 min at 4,000 rpm) and the organic phase dried under a 
stream of N2. Lipids were spotted on Silica Gel 60 thin-layer chromatography (TLC) 
plates (EMD chemicals Inc., Gibbstown, NJ). Plates were developed in 
chloroform:methanol:25% ammonium hydroxide (90:20:0.5, v/v/v) and visualized by 
fluorescence scanning on a VersaDoc 4000 imager (Bio-Rad). NBD-dodecanoic acid 
{12-[N-(7-nitro-2-1,3-benzoxadiazol-4-yl-amino) amino]-dodecanoic acid} formation was 
quantified and normalized to the protein content of each sample. 
 
5.2.5.  Analysis of sphingolipid species 
  Sphingolipid concentrations in H295R WT and ASAH1KD (pre-treated for 96 h 
with 5 µg/mL tet) nuclei were analyzed by liquid chromatography, electrospray ionization, 
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tandem mass spectrometry (LC-ESI-MS/MS) as described previously (446-447). Nuclei 
were purified using the Nuclei PURE Prep kit (Sigma) following the manufacturer’s 
instructions. 
 
5.2.6.  Transient transfection and reporter gene analysis 
  H295R cells were transfected with 100 ng pGL3-CYP17A1-2x57 reporter 
plasmid (126), 25 ng pCMV6myc/FLAG-SF1 (RC207577, Origene, Rockville, MD), 
and/or 50 ng pCMV6myc/FLAG-ASAH1-wild type (WT), pCMV6myc/FLAG-ASAH1-
LXXLL1, pCMV6myc/FLAG-ASAH1-LXXL5, 25 ng pBKCMV-SRC-1 or pCMX-SMRT 
using GeneJuice (EMD Biosciences). Cells were co-transfected with 1.5 ng of a Renilla 
luciferase plasmid under the control of the thymidine kinase (TK) promoter (pRL-TK, 
Promega, Madison, WI). Twenty-four h after transfection, cells were treated with 0.4 mM 
Bt2cAMP for 16 h. In some experiments, cells were pre-treated for 1 h with 0.5 µM or 5 
µM D-NMAPPD {N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)-ethyl]-
tetradecanamide} before treatment with Bt2cAMP. Firefly and Renilla luciferase activities 
were determined using a dual luciferase assay (Promega) and CYP17A1 reporter gene 
activity (pGL3, Firefly) was normalized to Renilla activity. 
 
5.2.7.  Coimmunoprecipitation (coIP) 
 For endogenous protein interaction assays, H295R cells were treated with 0.4 
mM Bt2cAMP for 30 min. coIP assays were also performed with tagged proteins by 
transfecting CV-1 monkey kidney cells with 5 µg of pCMV6-GFP-hSF-1 (RG207577, 
Origene) and pCMV6myc/FLAG-ASAH1 wild type (WT) or pCMV6myc/FLAG-ASAH1-
LXXLL1, pCMV6myc/FLAG-ASAH1-LXXLL5 mutant expression plasmids for 72 h. Cells 
were washed twice with PBS and harvested into RIPA buffer containing protease 
inhibitors (EMD Chemicals). Lysates were then sonicated 6 times for 5 sec followed by 
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centrifugation at 12,000 rpm for 15 min at 4°C. Samples were pre-cleared with 20 µL 
BSA (20 mg/mL) and immunoprecipitated overnight at 4°C on a tube rotator using 
protein A/G Plus agarose (Santa Cruz) and anti-SF1 (Millipore, for H295R lysates) or 
anti-FLAG (Sigma, for CV-1 lysates) antibodies. The immobilized protein complexes 
were washed twice in RIPA buffer and twice in PBS, and then separated by SDS-PAGE. 
Western blots were probed with anti-ASAH1, anti-saposin D, anti-SF1, or anti-GFP 
(Invitrogen) antibodies and expression was detected using an ECF Western Blotting Kit 
(GE Biosciences) and visualized using a VersaDoc 4000 imager (Bio-Rad).  
 
5.2.8.  In vitro binding assays 
  His-tagged SF-1 was expressed and purified from E. coli as previously 
described (482). ASAH1 was in vitro translated from the pCMV6-XL5-ASAH1 plasmid 
(RC212434, Origene) using the TNT Quick Coupled Transcription/Translation Systems 
kit (Promega). ASAH1 expression was confirmed by subjecting samples to SDS-PAGE, 
coomassie staining, and exposing the gel to a radioactive-imager screen. ASAH1 
expression was visualized by radioactive-imager scanning (FLA 7000, Fuji, Japan).  
Twenty µL of in vitro translated ASAH1 was incubated with 50 µL His-tagged 
immobilized SF-1, 10 µL BSA (10 mg/mL), and 1 mL buffer (4 M NaCl, 160 nM Tris-HCl, 
40 mM imidazole, pH 7.9) in a tube rotator for 24 h at 4°C. Complexes were washed 3 
times and subjected to SDS-PAGE and coomassie staining. Gel was dried, exposed to a 
phosphor-imager screen, and visualized by phosphor-imager scanning (Fuji, Japan). 
 
5.2.9. Site-directed mutagenesis 
  Mutagenesis was carried out using a Stratagene QuickChange site-directed 
mutagenesis kit (Stratagene, La Jolla, CA) and confirmed by sequencing. To mutate 
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putative nuclear receptor binding (LXXLL) motifs in ASAH1, the first and fourth leucines 
within each motif were mutated to alanine using the following primers: ASAH1-LXXLL1 
(5’- TAC CCA AGT GCC AGC GCG GCT TTC ACC GAG -3’), ASAH1-LXXLL5 (5’-GTG 
GGC ATG GCT ACA GGA GCT AAA CCA GGA-3’). To generate truncation mutants of 
ASAH1 [Δαsubunit (Δα) or Δβsubunit (Δβ)] the following primer sets were used: pACT-
ASAH1Δα (forward 5’-GGG ATC CGT CGA CTT ATG AAC TGC TGC ATC GGG-3’; and 
reverse 5’-TCT AGA TGA TAT CAA AAT GGT AAA TAATTC ATA-3’) and pACT-
ASAH1Δβ (forward 5’-GGG ATC CGT CGA CTT TGT ACT TCA ATA GTA GCA-3’; and 
reverse 5’-TCT AGA TGA TAT CAA CCA ACC TAT ACA AGG GTC-3’). 
 
5.2.10. Mammalian 2-hybrid assay  
 ASAH1 (full-length and truncation mutants) and SF-1 genes were cloned into the 
SalI and EcoRV sites of pBIND and/or pACT vectors (Promega). H295R cells were sub-
cultured into 24-well plates and transfected with the pG5 firefly luciferase reporter in 
combination with pBIND and pACT vectors expressing fusions of Gal4 DNA binding 
domain and VP16 activation domain, respectively, with ASAH1 (wild type, Δα, or Δβ) or 
SF-1. In some experiments, cells were co-transfected with 50 ng of SRC-1 or SMRT 
expression plasmids. The ratio of pG5 to pBIND to pACT in transient transfections was 
50 ng: 50 ng: 50 ng. Cells were incubated for 48 h before harvesting and assaying for 
dual luciferase activity.  
 
5.2.11. Chromatin immunoprecipitation (ChIP) 
  ChIP assay was performed as previously described (158). Briefly, H295R cells 
were sub-cultured into 150-mm dishes and then treated with 0.4 mM Bt2cAMP for 30 
min. After cross-linking with 1% formaldehyde, cells were harvested into RIPA buffer and 
 108 
lysates sonicated to obtain optimal DNA fragments lengths of 100-1000 bp (5 times for 
10 sec) followed by centrifugation at 12,000 rpm for 15 min at 4°C. The purified 
chromatin was pre-cleared with 1 µg IgG and immunoprecipitated overnight at 4°C on a 
tube rotator using 5 µg of primary antibody [anti-trimethyl(Lys20) histone H4 (Millipore), 
anti-RNA polymerase II CTD (Millipore), anti-SF-1 (07-618, Millipore), anti-ASAH1 
(HPA005468, Sigma), anti-SRC-1 (Millipore), and anti-HDAC1 (Millipore)] and 30 µL 
protein A/G Plus agarose (Santa Cruz). Real Time PCR was carried out using 20% of 
output, 5% input (diluted 1:4), the ABsolute qPCR SYBR Green Fluorescein Mix 
(Thermo Scientific), and the following primer sets: forward, 5’-GGC TGG GCT CCA GGA 
GAA TCT TTC TTC CAC-3’; reverse, 5’-CGG CAG GCA AGA TAG ACA GCA GTG 
GAG TAG-3’, which amplify the region of the CYP17A1 promoter from position -104 to 
+43 that encompass an essential SF-1 binding site. For determination of ASAH1 
enrichment at other gene promoters, the following primers were used: Mc2R (forward 5’-
TTG CCC AGA AAG TTC CTG CTT-3’, and reverse 5’-TTC TCC TGC TTG TGG TTA 
AGG-3’), and DAX-1 (forward, 5’-TCC AGC TTT TAA AGA GCA CCC GCC CCT-3’; and 
reverse 5’-CGG CGC CCG TAG CCC AGT TCT-3’), which amplify the proximal (-300 
bp) promoter region of each gene. For negative controls, primers for β-actin (forward, 5’-
TGC ACT GTG CGG CGA AGC-3’; and reverse, 5’-TCG AGC CAT AAA AGG CAA-3’) 
were used. PCR reactions were as follows: 1) 1 X 95°C, 15 min, 2) 60 X 95°C, 15 sec, 
55°C, 30 sec, 72°C, 30 sec, 3) 1 X 95°C, 30 sec, 60°C, 30 sec, 4) 80 X 60°C, 10 sec, 5) 
cool to 4°C. Output ΔCt values were normalized to input values. Some PCR reactions 
were resolved by 2% agarose gel electrophoresis. 
 
5.2.12. Sequential ChIP (re-ChIP) 
  H295R cells were sub-cultured into 150-mm dishes and treated with 0.4 mM 
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Bt2cAMP for 30 min. Cross-linking was performed by the addition of formaldehyde (final 
concentration of 1%) for 10 min with gentle shaking. The reaction was stopped by the 
addition of glycine (0.125 M final concentration) for 5 min, after which the cells were 
washed twice in PBS and harvested into RIPA buffer. Lysates were then sonicated to 
obtain optimal DNA fragments lengths of 100-1000 bp (5 times for 10 sec) followed by 
centrifugation at 12,000 rpm for 15 min at 4°C. Supernatant (50 µL) was retained as 
input. The purified chromatin was pre-cleared with 1 µg IgG and immunoprecipitated 
overnight at 4°C on a tube rotator using 5 µg of primary antibody [anti-SF-1 (07-618, 
Millipore) or anti-ASAH1 (HPA005468, Sigma)] and 30 µL protein A/G Plus agarose 
(Santa Cruz). The immobilized protein/DNA complexes were subjected to a series of 5-
min washes: three times in RIPA buffer, three times in RIPA buffer plus 500 mM NaCl, 
three times in washing buffer (10 mM Tris-Cl, pH 8.0; 0.25 M LiCl; 1 mM EDTA; 1mM 
EGTA; 1% Nonidet P-40; 1% sodium deoxycholate), and three times in Tris-EDTA (TE) 
buffer, pH 8.0. Protein/DNA complexes were released from agarose beads by the 
addition of 50 µL TE buffer containing 10 mM dithiothreitol (DTT) and incubation at 37°C 
for 30 min followed by centrifugation at 4,000 rpm for 5 min. Supernatants were 
transferred to new tubes and 1 mL RIPA buffer was added. Chromatin was then 
submitted to another round of immunoprecipitation using 5 µg of primary antibody [anti-
SF-1 (07-618, Millipore) or anti-ASAH1 (HPA005468, Sigma)] and 30 µL protein A/G 
Plus agarose (Santa Cruz) overnight at 4°C on a tube rotator. The immobilized 
protein/DNA complexes were subjected to a series of 5-min washes as described above. 
The crosslinks were reversed and protein digested using proteinase K (100 µg/mL). DNA 
was purified by phenol-chloroform extraction and ethanol precipitation. Real Time PCR 
was carried out using 20% of output, 5% input (diluted 1:4), the ABsolute qPCR SYBR 
Green Fluorescein Mix (Thermo Scientific), and the following primer sets: CYP17A1 
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(forward, 5’-GGC TGG GCT CCA GGA GAA TCT TTC TTC CAC-3’; reverse, 5’-CGG 
CAG GCA AGA TAG ACA GCA GTG GAG TAG-3’) or StAR (forward 5’-GCA GTG TGA 
GGC AAT CGC TCT-3’, and reverse 5’-TGT TTC CTG GCA AAT GTG GCA-3’). For 
negative controls, primers for β-actin (forward, 5’-TGC ACT GTG CGG CGA AGC-3’; 
and reverse, 5’-TCG AGC CAT AAA AGG CAA-3’) were used. PCR reactions were as 
follows: 1) 1 X 95°C, 15 min, 2) 40 X 95°C, 15 sec, 52°C, 30 sec, 72°C, 30 sec, 3) 1 X 
95°C, 30 sec, 60°C, 30 sec, 4) 80 X 60°C, 10 sec, 5) cool to 4°C. Output ΔCt values 
were normalized to input values. Some PCR reactions were resolved by 2% agarose gel 
electrophoresis. 
 
5.2.13. Statistical analysis 
  One-way analysis of variance and Tukey’s multiple comparison tests were 
performed using GraphPad InStat software (GraphPad Software Inc., San Diego, CA).  
Significant differences from a compared value were defined as p < 0.05 and denoted by 
asterisks (*), carats (^), and pound (#).  
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5.3. Results 
5.3.1.  ASAH1 and SAP-D are expressed in the nucleus of H295R adrenocortical 
 cells 
 
 Our group has previously shown that SPH is an antagonist for SF-1 and 
represses the transcription of CYP17A1 (47). Moreover, as described in Chapter Four, 
ASAH1 silencing confers increased steroidogenic gene expression and hormone 
secretion. However, the mechanism by which SPH production is controlled and the 
parameters governing ligand binding are unknown. Because ceramidase activity is the 
only source of SPH (42,104) and SF-1 is a nuclear protein, confocal microscopy and 
western blotting were used to determine the subcellular localization of ceramidases in 
H295R cells. As shown in Figure 5.1A, ASAH1 and ASAH2 are expressed in the nuclear 
envelope and nucleoplasm while ACER3 is cytoplasmic. Furthermore, the ASAH1 
coactivator protein SAP-D (483-484) is expressed in the same subcellular fractions as 
ASAH1 (Figure 5.1A). Because ASAH1 has optimal in vitro activity in acidic pH, it was 
Figure 5.1. ASAH1 and SAP-D are expressed in the nucleus of H295R cells. A. H295R 
cells were sub-cultured into 100-mm dishes for 72h and cytosol, nuclear envelope (NE), 
and nucleoplasmic (NP) fractions were isolated as described in the Section 5.2. Lysates 
(30 µg of protein) were separated by SDS-PAGE followed by western blotting analysis 
using ASAH1, ASAH2, ACER3, SF-1, saposin D, LAMP1, P450c17α, or StAR 
antibodies. B and C. H295R cells were plated onto glass coverslips, fixed, permeabilized, 
and incubated with anti-ASAH1, anti-saposin D, anti-ASAH2, or anti-ACER3 antibodies 
overnight followed by a 2-min incubation with the nuclear marker DAPI. Coverslips were 
washed and incubated with antirhodamine and mounted, and immunofluorescence was 
detected by confocal microscopy.  
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classified as a lysosomal protein (99). Therefore, to confirm the purity of the nuclear 
extracts, I determined the expression of lysosomal-associated membrane protein 1 
(LAMP1), P450c17α (microsomal), and StAR (mitochondrial), all of which were found in 
their predicted subcellular fractions (Figure 5.1A). As expected, SF-1 is primarily 
localized in the nuclear envelope fraction with slight expression in the nucleoplasmic 
fraction. Confocal analysis confirmed that ASAH1 and SAP-D are expressed in the 
nuclei of H295R cells (Figure 5.1B).   
 
5.3.2.  Bt2cAMP acutely stimulates ASAH1 activity 
 Because cortisol biosynthesis is primarily regulated by the ACTH/cAMP pathway 
and ACTH signaling induces Cer turnover in adrenocortical cells (75), I next investigated 
the effect of ACTH/cAMP signaling on ceramidase activity. H295R wild type (WT) cells 
were incubated with 4 µM NBD-12-Cer for 4 h and then treated with 0.4 mM Bt2cAMP. 
Whole lysates were purified for in situ ASAH1 activity assays. As shown in Figure 5.2A, 
30 min of Bt2cAMP stimulation increased ceramidase activity by 6-fold. In order to 
determine the role of ASAH1 in Bt2cAMP-stimulated ceramidase activity, ASAH1KD cells 
described in Chapter Four (Section 4.2) were used. Tet-treated (96 h) ASAH1KD cells 
were incubated with 4 µM NBD-12-Cer for 4 h and then treated with 0.4 mM Bt2cAMP. 
As shown in Figure 5.2A, no increase in ceramidase activity was observed in response 
to Bt2cAMP in ASAH1KD cells. In agreement with this finding, mass spectrometric 
analysis of nuclear Cer, SPH, and S1P concentrations in WT and ASAH1KD cells 
revealed that ASAH1 suppression resulted in an overall reduction in nuclear 
concentrations of all three sphingolipid species; the most significant decrease being in 
SPH levels which were reduced by 85% in ASAH1KD cells (Figure 5.2B). Furthermore, 
Bt2cAMP induced SM and Cer turnover as well as SPH and S1P accumulation in WT 
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cells whereas no significant change in the nuclear amounts of these sphingolipid species 
was observed in ASAH1KD cells (Figure 5.2B). 
 
5.3.3. ASAH1 overexpression attenuates SF-1-dependent CYP17A1 reporter gene 
 activity 
 
 Next, I determined the role of ASAH1 in modulating CYP17A1 gene expression 
in response to ACTH/cAMP signaling by carrying out reporter gene assays using an 
ASAH1 expression plasmid and a CYP17A1 reporter gene construct. As previously 
shown, SF-1 increased both basal and Bt2cAMP-stimulated CYP17A1 reporter gene 
activity by 2.4- and 9.8-fold, respectively (Figure 5.3A). ASAH1 suppressed Bt2cAMP-
Figure. 5.2.  Bt2cAMP increases nuclear ASAH1 activity. A. H295R wild type (WT) and 
ASAH1KD (pre-treated for 96 h with 5 µg/mL tetracycline-tet) cells were treated for 30 min, 2, 
or 6 h with 0.4 mM Bt2cAMP and nuclear extracts were isolated as described in Section 5.2. 
H295R WT or ASAH1KD nuclear extracts (50 µg) were incubated with 2 µl of 1 mM NBD-12-
Cer in acetate buffer (pH 4.5) at 37°C for 2 h. Reactions were stopped and lipids were 
extracted and spotted on TLC plates. Plates were developed and visualized by fluorescent 
scanning. NBD-dodecanoic acid formation was quantified and normalized to the protein 
content of each sample. Data graphed represents mean ± SEM of 3 separate experiments, 
each performed in duplicate. Inset: Representative western blot of controls and tet-treated 
H295RKD cells demonstrating decreased ASAH1 protein levels. *Statistically different from 
untreated control group, p < 0.05. B. H295R WT or ASAH1KD (pre-treated for 96 h with 5 
µg/mL tet) cells sub-cultured into 100-mm dishes and sphingosine (SPH), ceramide (CER), 
sphingomyelin (SM), and sphingosine-1-phosphate (S1P) concentrations in purified nuclei 
were quantified by LC-ESI-MS/MS using appropriate standards. Data graphed represents 
fold change in sphingolipid content and are normalized to WT untreated controls.  
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stimulated and SF-1-dependent CYP17A1 promoter activity in unstimulated and 
Bt2cAMP-treated cells (Figure 5.3A). 
 
5.3.4.  ASAH1 interacts directly with SF-1 
 Based on the nuclear localization of ASAH1 (Figure 5.1), the effect of ASAH1 on 
SF-1-stimulated CYP17A1 reporter gene activity (Figure 5.3A), and the role of SPH as 
an antagonist for SF-1 (47), I hypothesized that ASAH1 modulates SF-1 activity by 
directly binding to the receptor. To test this hypothesis, coimmunoprecipitation assays 
were carried out, which revealed that endogenous ASAH1 and SAP-D co-
immunoprecipitate with SF-1 (Figure 5.3B). Additionally, these proteins also interacted in 
vitro using GFP- and FLAG-tagged SF-1 and ASAH1 plasmids, respectively (Figure 
5.3C). Importantly, ASAH2, which is also localized in the nuclei of H295R cells (Figure 
5.1A), failed to interact with SF-1 (Figure 5.3C). To further investigate the interaction 
between SF-1 and ASAH1, in vitro pull-down assays using bacterially expressed His-
tagged SF-1 and in vitro translated 35S-ASAH1 were carried out. As shown in Figure 
5.3D (lower panel), SF-1 copurifies with radiolabelled ASAH1 (lane 3), confirming a 
direct interaction between the two proteins.  
 
5.3.5.  Mapping the ASAH1 regions that interacts with SF-1 
 In silico analysis of ASAH1 revealed 7 putative LXXLL-related motifs (Figure 
5.3E). To test whether ASAH1 binds to SF-1 through one of these motifs, site-directed 
mutagenesis was carried out to mutate these regions as described in Section 5.2.9. As 
shown in Figure 5.3F, ASAH1 harboring a mutation of LXXLL1 (NR1) (located in the α 
subunit of ASAH1) was unable to interact with the receptor, indicating that this region is 
required for mediating the binding of ASAH1 to SF-1. Mutation of LXXLL5 (located in the 
β subunit of ASAH1) modestly reduced the interaction between ASAH1 and SF-1 but to 
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Figure. 5.3. ASAH1 binds to SF-1. A. H295R cells were transfected with pGL3-CYP17A1-
2x57 and expression plasmids for ASAH1 and SF-1. Cells were then treated with 0.4 mM 
Bt2cAMP for 16 h and harvested for dual luciferase assays. Data are expressed as fold 
increase in pGL3-CYP17A1 reporter gene activity and represents the mean ± SEM of 3 
separate experiments, each performed in triplicate. Asterisks (*) and carats (^) denote 
statistically significant differences (p < 0.05) from untreated control group or treated SF-1-
transfected group, respectively. B. H295R cells were treated with 0.4 mM Bt2cAMP for 30 
min and lysates were subjected to immunoprecipitation using an anti-SF1 antibody and 
protein A/G agarose. Immobilized proteins were washed, separated by SDS-PAGE, and 
analyzed by western blotting. Blots were hybridized to anti-ASAH1 or anti-saposin D 
antibodies (top two panels). Ten % inputs were subjected to SDS-PAGE and western 
blotting using an antibody against SF-1 (lower panel). C. H295R cells were transfected with 
5 µg pCMV6-GFP-SF-1 and pCMV6myc/FLAG-ASAH1 or pCMV6myc/FLAG-ASAH2 
expression plasmids and lysates subjected to IP with an anti-FLAG antibody and protein 
A/G agarose. Immobilized proteins were washed and separated by SDS-PAGE followed by 
western blotting analysis using an anti-GFP antibody (bottom panel). Ten % inputs were 
subjected to SDS-PAGE and western blotting using an antibody against FLAG (top and 
middle panels) D. His-tagged SF-1 was bacterially expressed from E. coli and ASAH1 was 
in vitro transcribed/translated from the pCMV6-XL5-ASAH1 vector. Twenty µg of in vitro 
translated 35S-ASAH1 was incubated with 50 µL His-tagged SF-1 in a tube rotator for 24 h 
at 4°C. SF-1/ASAH1 complexes were then subjected to SDS-PAGE and coomassie 
staining. Gel was dried, exposed to a radioactive-imager screen, and visualized by 
radioactive-imager scanning. E. Schematic representation of the putative LXXLL (NR)-
related motifs (underlined/bold) in ASAH1. The β subunit sequence is underlined and 
putative NR motifs are highlighted. NR motifs in red were mutated using site-directed 
mutagenesis as described in Section 5.2. F. H295R cells were transfected with 10 µg 
pCMV6-GFP-SF-1 and pCMV6myc/FLAG-ASAH1 wild type (WT) or –LXXLL1 (NR1) or -
LXXLL5 (NR5) mutant expression plasmids and lysates subjected to IP with an anti-FLAG 
antibody and protein A/G agarose. Immobilized proteins were washed and separated by 
SDS-PAGE followed by western blotting analysis using an anti-SF-1 antibody (top panel). 
Ten % inputs were subjected to SDS-PAGE and western blotting using antibodies against 
FLAG and SF-1 (lower panel). 
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a much lesser extent than LXXLL1 (Figure 5.3F). Consistent with this finding, reporter 
gene assays revealed that mutation of LXXLL1 rendered ASAH1 incapable of repressing 
SF-1/Bt2cAMP-dependent CYP17A1 promoter activity (Figure 5.4A) whereas mutation of 
LXXLL5 in ASAH1 had no effect on the ability of the ceramidase to suppress SF-1 
activity (Figure 5.4A). 
 In order to map additional interacting regions on ASAH1 that are involved in 
binding to SF-1, truncation mutants of ASAH1 were generated by cloning the primary 
genomic sequence of the α and β subunits of ASAH1 into the pACT vector. Mammalian 
two-hybrid assays in H295R cells were then carried out to test the interaction between 
full-length, Δα, or Δβ ASAH1 with SF-1. Consistent with coIP studies (Figure 5.3F), 
ASAH1Δα interacts with the receptor, but, surprisingly, ASAH1Δβ had a 2-fold stronger 
interaction for the receptor than ASAH1Δα (Figure 5.4B). This suggests that additional 
LXXLL motifs (or other regions) within the β subunit of ASAH1 are also involved in 
mediating the binding of ASAH1 to SF-1. 
 Because the transcriptional potential of SF-1 is potently influenced by its 
interaction with various coregulatory proteins (158), reporter gene assays were carried 
out to determine the effect of ASAH1 expression on the ability of coregulators to 
modulate SF-1-dependent CYP17A1 promoter activity. As shown in Figure 5.4C, ASAH1 
not only inhibited the ability of SRC-1 to potentiate SF-1-dependent promoter activity but 
also potentiated the repressory activity of SMRT. The ability of these coregulators to 
alter the interaction between ASAH1 and SF-1 was tested using mammalian 2-hybrid 
assays. Unexpectedly, SMRT significantly abrogated the interaction between full-length 
ASAH1 and SF-1 and completely prevented the interaction between ASAH1Δα and the 
receptor (Figure 5.4B). While SRC-1 strengthened the interaction between full-length  
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Figure. 5.4. LXXLL-mediated 
ASAH1 binding to SF-1 affects 
coregulator activity. A. H295R 
cells were transfected with 
pGL3-CYP17A1 and expression 
plasmids for SF-1, ASAH1-WT 
(wild type), ASAH1-NR1 
(LXXLL1 mutant), or ASAH1-
NR5 (LXXLL5 mutant). Cells 
were treated with 0.4 mM 
Bt2cAMP for 16 h and harvested 
for dual-luciferase assays. Data 
are expressed as fold increase in 
pGL3-CYP17A1 reporter gene 
activity and represent the mean 
± SEM of 3 separate 
experiments, each performed in 
triplicate. (*), (^), and (#) denote 
statistically significant differences 
from untreated controls within 
each group, treated SF-1-
transfected group, or untreated 
controls (-), respectively. B. 
H295R cells were transfected 
with pGL5luc, pACT, and pBIND 
(empty vectors) or pGL5luc, 
pBIND-SF-1 and pACT-ASAH1, 
pACT-ASAH1Δα, or pACT-
ASAH1Δβ plasmids in the 
presence or absence of 
expression plasmids for SRC-1 
or SMRT. Transfected cells were 
harvested after 48 h and 
luciferase activity quantified by 
luminometry. Data graphed 
represents the mean ± SEM of at 
least 3 separate experiments, 
each performed in triplicate. C. 
H295R cells were transfected 
with pGL3-CYP17A1 and 
expression plasmids for SF-1, 
ASAH1, SRC-1, and SMRT. 
Cells were treated with 0.4 mM 
Bt2cAMP for 16 h and harvested 
for dual-luciferase assays. Data 
are expressed as fold increase in 
pGL3-CYP17A1 reporter gene 
activity and represent the mean 
± SEM of 3 separate 
experiments, each performed in 
triplicate. (*), (^), and (#) denote 
statistically significant differences 
from untreated controls within 
each group, treated SF-1-
transfected group, or as shown 
in figure, respectively. 
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ASAH1 and SF-1 by 1.4-fold, neither coregulator affected the interaction between 
ASAH1Δβ and SF-1 (Figure 5.4B). 
 
5.3.6.  The catalytic activity of ASAH1 is required for its repressory function 
 To determine whether ceramidase activity (SPH production) is required for the 
repressive effect of ASAH1, H295R cells were pre-treated with the ceramidase inhibitor 
D-NMAPPD (485) and the ability of ASAH1 to inhibit SF-1 activity was assessed in 
reporter gene assays. As shown in Figure 5.5, inhibiting the catalytic activity of ASAH1 
rendered the ceramidase unable to suppress SF-1/Bt2cAMP-induced CYP17A1 reporter 


























Figure 5.5. A catalytically active ASAH1 is required for suppression of SF-1 
activity. H295R cells were transfected with pGL3-CYP17A1 and expression 
plasmids for SF-1 and ASAH1. Cells were pre-treated for 1 h with 0.5 µM or 5 
µM D-NMAPPD followed by treatment with 0.4 mM Bt2cAMP for 16 h. Cells 
were then harvested for dual-luciferase assays. Data are expressed as fold 
increase in pGL3-CYP17A1 reporter gene activity and represent the mean ± 
SEM of 3 separate experiments, each performed in triplicate. (*), (^), and (#) 
denote statistically significant differences (p < 0.05) from untreated controls 




5.3.7.  Bt2cAMP promotes the recruitment of ASAH1 to multiple steroidogenic 
 gene promoters 
 
 To examine the recruitment of ASAH1 to the endogenous CYP17A1 promoter, 
ChIP assays were carried out using chromatin isolated from H295R cells treated with 0.4 
mM Bt2cAMP for 30 min. The primer set used amplifies the promoter region -104/+43, 
which contains a key ACTH/cAMP-responsive SF-1 binding site at -57/-37 (158). 
Elevated ASAH1 occupancy on the promoter was observed after Bt2cAMP stimulation, 
which correlated with the relative enrichment of SF-1-bound CYP17A1 promoters 
(Figure 5.6A). Consistent with transcriptional initiation, Bt2cAMP promoted the 
recruitment of RNA Polymerase II and increased the levels of tri-methylated histone H4 
at lysine 20 (H4K20). Importantly, neither ASAH2 nor ACER3 were detected in this 
region of the CYP17A1 promoter under these conditions (data not shown). To 
investigate whether ASAH1 and SF-1 occupy the same region of the promoter, 
sequential immunoprecipitation (reChIP) assays were carried out. As shown in Figure 
5.6B, these two proteins exist as a complex on the CYP17A1 and StAR promoters. 
Interestingly, the pattern of complex formation appears to be promoter-specific. Bt2cAMP 
stimulation induced ASAH1/SF-1 complex formation at the CYP17A1 promoter (Figure 
5.6B, left panel) while it reduced protein-protein interaction at the StAR promoter (Figure 
5.6B, right panel). Finally, to examine the recruitment of ASAH1 to additional SF-1-
regulated promoters, DAX-1 and Mc2R, ChIP assays were carried out. The primers used 
were designed to amplify the proximal promoter region of each gene and encompass at 
least one SF-1 binding site. As shown in Figure 5.6C, Bt2cAMP stimulation promoted the 
recruitment of ASAH1 to both promoters, but the fold change in ASAH1 recruitment, 
compared to SF-1 enrichment, was promoter-specific. At the Mc2R promoter, ASAH1 
occupancy was 3.1-fold higher than SF-1 under basal conditions and Bt2cAMP 
stimulation promoted a 12-fold increase in SF-1 enrichment compared to a 2.5-fold 
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increase in ASAH1 occupancy (Figure 5.6C, left panel). Conversely, both SF-1 and 
ASAH1 had equivalent levels of occupancy at the DAX-1 promoter in unstimulated cells, 
but the fold-increase in ASAH1 enrichment (56-fold) in response to Bt2AMP was 
significantly higher than SF-1 recruitment (5-fold) (Figure 5.6C, right panel).  
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Figure. 5.6. Bt2cAMP promotes the recruitment of ASAH1 to multiple 
steroidogenic gene promoters. A. H295R cells were treated with 0.4 mM 
Bt2cAMP for 30 min, cross-linked with 1% formaldehyde, and the sheared 
chromatin immunoprecipitated (IP) using antibodies against SF-1, 
ASAH1, SRC-1, trimethyl-H4K20, RNA Pol II, and HDAC1. The relative 
amount of IP promoter fragments was normalized to their respective 
levels in the input DNA. Inset: representative agarose gels of the PCR 
products obtained for output and input DNA. B. H295R cells were treated 
with 0.4 mM Bt2cAMP for 30 min, cross-linked with 1% formaldehyde, and 
reChIP assays were carried out as described in Section 5.2. The IP DNA 
fragments were analyzed by qPCR with primers spanning the proximal 
promoter regions (containing at least one SF-1 binding site) of CYP17A1 
(left panel) and StAR (right panel) genes. The relative amount of IP 
promoter fragments was normalized to their respective levels in the input 
DNA. Inset on left panel: representative agarose gels of the PCR products 
obtained for input DNA (IN, top panel), ASAH1-bound (OUT, middle 
panel), and reChIP for SF1 (reChIP, bottom panel) chromatin. C. H295R 
cells were treated with 0.4 mM Bt2cAMP for 30 min, cross-linked with 1% 
formaldehyde, and the sheared chromatin IP using antibodies against SF-
1 or ASAH1. The IP DNA fragments were analyzed by qPCR with primers 
spanning the proximal promoter regions of DAX-1 and Mc2R genes. The 
relative amount of IP promoter fragments was normalized to their 
respective levels in the input DNA and is graphed as fold enrichment over 






5.4.  Discussion 
 
 A growing body of literature supports the role of sphingolipid metabolism in the 
regulation of steroid hormone production (440). Our group has previously identified the 
role of SPH as an antagonist for SF-1 (47). However, because the mechanisms that 
control ligand availability are unknown, I sought to determine the role of ASAH1, a SPH-
generating enzyme, in regulating SF-1 function. The results presented in this Chapter 
demonstrate that ASAH1 is expressed in the nucleus of H295R cells and its activity is 
acutely regulated by ACTH/cAMP signaling. ASAH1 represses the transcriptional 
potential of SF-1 by directly binding to the receptor on the promoter of multiple 
steroidogenic genes. Significantly, the interaction between ASAH1 and SF-1 occurs 
through a functional LXXLL-related motif, which is essential for conferring ASAH1-
dependent repression of SF-1.  
 Mounting evidence has linked multiple sphingolipid species to various nuclear 
processes (reviewed in (444)). Due to the hydrophobic nature of most sphingolipids, the 
nuclear expression of sphingolipid enzymes suggest that there is a dynamic and 
localized production of bioactive lipids, which may have unique roles in nuclear 
processes that are independent from their cytoplasmic functions. The present study 
revealed that ASAH1 and its coactivator protein SAP-D are expressed in the nucleus of 
H295R cells (Figure 5.1), which expands the likelihood of local sphingolipid metabolism 
in these cells. In fact, mass spectrometric analysis revealed that ACTH/cAMP signaling 
promotes rapid nuclear SM and Cer turnover with a concomitant accumulation of SPH 
and S1P in an ASAH1-dependent manner (Figure 5.2).  
 Because ASAH1 was characterized as a lysosomal protein, the nuclear 
localization of ASAH1 represents a novel concept. Nuclear import of proteins is usually 
based on the presence of a basic amino acid sequence designated as the nuclear 
localization signal (NLS), which mediates binding to importins and translocation through 
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the nuclear pore complex (NPC) (486). In addition to this ‘classical’ mechanism of 
protein nuclear import, other pathways for the transport of non-NLS-containing proteins 
into the nucleus have been described. One such mechanism is the nuclear import of 
glycoproteins via a mechanism that utilizes sugar-binding carrier proteins (e.g. lectins) 
(487). Given that ASAH1 contains no NLS sequences but is glycosylated at multiple 
residues during processing (99), it is possible that sugar-binding proteins mediate its 
nuclear import in H295R cells. Alternatively, it was recently shown that nuclear import of 
ERK, which does not contain a canonical NLS, is mediated by casein kinase II-
dependent phosphorylation of three residues (488), which promote ERK binding to 
importin 7 and translocation through NPCs (489). Notably, probing the subcellular 
localization of ASAH1 in other cell lines revealed that this ceramidase is nuclear in 
murine Y-1 adrenocortical cells whereas it is cytoplasmic in MCF-7 breast cancer cells 
(Lucki and Sewer, unpublished observations), suggesting that the nuclear functions of 
ASAH1 are cell-type specific. 
 The transcriptional activity of nuclear receptors is influenced by their ability to 
interact with numerous coregulator proteins. Conserved sequences containing a nuclear 
receptor (NR) motif of LXXLL (where X is any amino acid and L is a leucine that can be 
replaced by an isoleucine, methionine, or phenylalanine) (168-170,174), LXX-(I/H)-IXXX-
(I/L) helix (490), or (L/I)-XX-(I/V)-I (CoRNR) box (491) have been implicated in receptor-
corepressor interaction. Studies described in this Chapter demonstrate that ASAH1 is a 
novel coregulator of SF-1 that represses receptor activity by a direct protein-protein 
interaction involving an LXXLL-related motif in the α subunit of ASAH1. Site directed 
mutagenesis revealed that this motif is required not only for interaction with the receptor 
(Figure 5.3F) but also for the enzyme to repress SF-1 activity (Figure 5.4A). The fact that 
ASAH1 co-localizes with SF-1 on the promoter of the CYP17A1 and StAR genes (Figure 
5.6B) is consistent with a coregulator function. Coregulators are recruited to DNA by 
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nuclear receptors and either have intrinsic catalytic properties or recruit enzymatic 
protein complexes (e.g. HDAC, histone methyltransferases or acetyltransferases) to 
mediate chromatin and/or nuclear receptor modifications that influence gene 
transcription. Coactivators enhance nuclear receptor-mediated transcription while 
corepressors repress gene expression, primarily through their interaction with 
unliganded nuclear receptor (492). 
 The molecular determinants of SF-1 interaction with various coregulators, such 
as Dax-1 (122,493-494), SRC-1 (119), GRIP1 (149), peroxisome proliferator-activated 
receptor γ (PPARγ coactivator 1α (PGC-1α) (495), and DGKθ (164), have been 
described. Suzuki et al. (493) and Zhang et al. (170) proposed a model for Dax-1-
dependent SF-1 or ERα transcriptional repression, respectively, where Dax-1 binding to 
nuclear receptor competes with coactivators (e.g. SRC-1) as well as recruits 
corepressors (e.g. NCoR).  Because my data show that ASAH1 expression prevented 
SRC-1 from upregulating SF-1-dependent CYP17A1 promoter activity while potentiating 
SMRT repressory activity, it is possible that the underlying mechanism by which ASAH1 
suppresses SF-1 function is similar to Dax-1.  
 Significantly, pharmacological inhibition of ASAH1 rendered the enzyme 
incapable of repressing SF-1. Collectively, these findings suggest that the co-repressive 
function of ASAH1 requires not only an interaction with SF-1 but also a catalytically-
competent enzyme. This premise is consistent with my hypothesis that ASAH1 controls 
SF-1 function by regulating ligand (i.e. SPH) availability, although in vivo and in vitro 
biophysical studies of the ligand-binding event are necessary to fully prove this theory. 
Notably, our group has previously reported an LXXLL-dependent interaction between 
SF-1 and DGKθ (164), the enzyme that produces the SF-1 agonist PA. DGKθ activity 
and binding to SF-1 are required events for Bt2cAMP-dependent CYP17A1 mRNA 
expression (164). My current findings lend support to the reciprocal regulation of SF-1 by 
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ASAH1 is response to ACTH/cAMP signaling where ASAH1 binding to SF-1 represses 
receptor activity possibly by facilitating ligand exchange (i.e. the exchange of PA for 
SPH) and/or promoting corepressor recruitment (e.g. SMRT) (Figure 5.7). It is counter-
intuitive to think that activation of the ACTH/cAMP signaling cascade, which is the main 
activator of steroidogenic gene transcription, would stimulate ASAH1 DNA recruitment 
and SF-1 binding. However, because SF-1-containing transcriptional complex assembly 
at target promoters is dynamic and cyclical, as demonstrated by Winnay et al. (161) and 
our group (158), it is probable that ACTH evokes a spatio-temporal transcriptional 
regulatory mechanism where a cyclic, reciprocal exchange of coactivators and 
corepressors ensures optimal target gene transcription. In addition, because SPH is an 
activator of DGK (496-497), it is also possible that ACTH/cAMP-dependent nuclear 
ASAH1 acitivity plays a role in controlling DGKθ activity. Temporal ChIP experiments will 
be imperative to dissect the temporal order of DGKθ and ASAH1 DNA recruitment during 
SF-1-mediated transcription. In addition, determining whether ASAH1 promoter 
recruitment is dependent on SF-1 expression or vice-versa is central to fully understand 
the inter-regulation between these two proteins. These studies are currently being 
undertaken.  
 Notably, the ability of various nuclear receptors, including estrogen receptor (ER) 
β (498), PPARγ (499), and SF-1 (121), to interact with coregulatory proteins is regulated 
by phosphorylation. Therefore, it is possible that post-translational modifications of SF-1 
may be involved in temporally regulating the receptor’s affinity for ASAH1 in response to 
ACTH stimulation. Phosphorylation of SF-1 at Ser203 enhances the receptor’s ability to 
interact with GRIP1 and SMRT (121). Because these coregulators play opposite roles in 
gene transcription, additional layers of regulation as well as the recruitment of other 
coregulators (e.g. histone methyltransferases, acetyltransferases), possibly ASAH1, 
dictates the nature of the complex formed (e.g. coactivator or corepressor) and 
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transcriptional outcome (e.g. activation or repression). In summary, experiments in this 
Chapter defined the role of ASAH1 as a corepressor of SF-1 in H295R adrenocortical 
cells.     
   
Figure 5.7. Schematic model of the mechanism of ASAH1 repression of 
SF-1. ACTH/cAMP signaling promotes ASAH1 recruitment to SF-1-target 
promoter, where it interacts with SF-1 through a functional LXXLL motif. 
SF-1 binds to its cognate response element on DNA upon ACTH 
stimulation. ASAH1 binding to the receptor suppresses its transcriptional 
function on the CYP17A1 promoter by producing the antagonist SF-1 
ligand sphingosine (SPH). ASAH1 may also mediate the recruitment 
and/or potentiate the activity of the corepressor SMRT (silencing mediator 
for retinoid or thyroid-hormone receptors). Other factors (e.g. HDACs, 
histone methyltransferases) may stabilize or modify the interaction among 






6.1.  ASAH1 as a key regulatory factor in adrenocortical steroidogenesis 
 Sphingolipids have a multitude of biological functions. The amounts of different 
sphingolipid species within a cell are controlled by a series of enzymes that are 
regulated by multiple factors. Therefore, the sphingolipid metabolic profile in a cell at any 
given point in time is comprised of a unique set of bioactive sphingolipids that are 
dynamically changing in response to changes in the intracellular and extracellular 
environments. Cer, SPH, and S1P regulate gonadal and adrenal steroidogenesis by 
participating in signaling cascades to control steroidogenic gene expression and steroid 
hormone output (51,75,188,238,482). The intracellular concentrations of these 
metabolites are regulated by the actions of multiple enzymes, including ceramidases. 
These enzymes play an integral role in maintaining proper cellular function not only by 
controlling SPH and S1P levels but also limiting the signaling properties of Cer. Our 
laboratory has previously demonstrated that SPH antagonizes the transactivation 
potential of SF-1 and shown that suppression of ASAH1 expression mimics 
ACTH/cAMP-dependent CYP17A1 transcription in H295R cells, thus suggesting a role 
for ASAH1 in the regulation of adrenocortical steroidogenesis. Furthermore, we have 
found that ACTH rapidly changes the sphingolipid profile of adrenocortical cells, whereby 
complex sphingolipids (i.e. SM and Cer) are catabolized and S1P is produced.  
 Although the precise mechanism by which ACTH regulates sphingolipid 
metabolism is unclear, our previous findings suggest that the dynamic changes in 
bioactive sphingolipids elicited by ACTH are important in the regulation of steroid 
hormone biosynthesis. Therefore, I hypothesized that ASAH1 is an effector molecule in 
the ACTH/cAMP signaling pathway. Furthermore, because ASAH1 controls the 
intracellular concentrations of SPH, a ligand for SF-1 (115), I postulated that ASAH1 
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modulates steroidogenic gene transcription by controlling the transcriptional activity of 
SF-1. Defining the molecular mechanisms underlying ASAH1 function in ACTH-
dependent adrenocortical steroidogenesis was the central aim of this dissertation.  
 In the studies detailed in Chapters Two, Three, Four, and Five the following 
questions were addressed: 1) What is the role of S1P in the regulation of acute cortisol 
biosynthesis? 2) Does ACTH/cAMP signaling regulate ASAH1 transcription? If so, what 
transcriptional factors control promoter activity? 3) What is the effect of ASAH1 
suppression on global gene expression, sphingolipid metabolism, and steroidogenic 
capacity of adrenocortical cells? 4) How does ASAH1 modulate the transactivation 
potential of SF-1? 
 In Chapter Two, I characterized the molecular mechanism by which S1P, the bi-
product of ASAH1 activity, activates HSL and induces StAR expression, which 
culminates in the upregulation of cortisol synthesis. Chapter Three focused on the 
functional characterization of the ASAH1 promoter and established CREB as an 
essential transcriptional regulator of the ASAH1 gene. Moreover, I found that the 
ACTH/cAMP pathway chronically induces ASAH1 protein expression and enzymatic 
activity. In Chapter Four, a novel function of ASAH1 as a global regulator of 
adrenocortical gene expression was uncovered. With the use of an ASAH1 knockdown 
adrenocortical cell line, I demonstrated that ASAH1 expression is essential for optimal 
transcription of multiple steroidogenic and nuclear receptor genes, all of which are 
important for cholesterol transport and/or steroid hormone metabolism. Accordingly, 
suppressing ASAH1 altered the amount of cortisol and DHEA produced by these cells. I 
further showed that ASAH1 silencing altered the cellular amounts of acetylated histone 
H3, which suggests that ASAH1 plays a role in the epigenetic regulation of gene 
expression. Consistent with these findings, experiments in Chapter Five identified 
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ASAH1 as a nuclear protein in H295R cells and characterized its role as a corepressor 
of SF-1. 
 The overall conclusions of the studies presented in this dissertation are: (1) S1P 
is a pleiotropic regulatory factor of adrenocortical function that mediates cholesterol 
transport, and cortisol production, by promoting HSL activation and inducing StAR 
expression. (2) ACTH/cAMP signaling promotes CREB-dependent transcription of the 
ASAH1 gene. (3) ASAH1 is a negative regulator of steroidogenic gene expression and 
adrenocortical steroidogenesis. (4) ASAH1 is a novel SF-1 corepressor in adrenocortical 
cells. 
 
6.2.  The role of S1P as a paracrine factor in adrenocortical cells 
 The versatility of S1P-mediated cellular responses arrises from the fact that this 
metabolite not only acts as an intracellular second messenger but also is secreted from 
cells and activates signaling through multiple cell-surface S1PRs (Figure 1.8). S1P is an 
intermediate linking various extracellular factors and their respective biological functions. 
For example, S1P mediates various TNF-α-dependent pro-inflammatory effects, 
including priming of neutrophils (500) and NF-κB activation (501). Similarly, prolactin 
(502) and 17β-estradiol (E2) (192) promote breast cancer cell growth through the 
upregulation of SPHK activity and S1P production. Furthermore, it was recently shown 
that the adipocyte-derived secretory factor adiponectin promotes cell survival by 
triggering S1P production (503). Given the pleiotropic functions of S1P and the array of 
factors that modulate its production, experiments described in Chapter Two were 
focused on defining the role of S1P during the acute phase (Section 1.1) of ACTH-
dependent steroidogenesis. 
 Previous work form our laboratory has established S1P as a secondary factor to 
ACTH in the upregulation of CYP17A1 gene transcription (115). The intricate molecular 
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details of this regulation include rapid ACTH-stimulated S1P production and secretion, 
and S1PR-dependent cleavage and nuclear translocation of the transcription factor 
SREBP1. Once in the nucleus, SREBP1 binds to the CYP17A1 promoter and drives 
gene transcription (115). ACTH/cAMP signaling activated SPHK after 15 min and 
increased extracellular S1P was seen 30 min after stimulation. The effect of S1P on 
SREBP1 cleavage and CYP17A1 transcription were both time-dependent: maximal 
SREBP1 maturation (i.e. cleavege) was observed 4 h after S1P stimulation while 
increased CYP17A1 mRNA expression was seen after 6 h. 
 The findings of the present work expand the role of S1P as a regulator of 
adrenocortical cell function by characterizing the mechanism by which S1P acutely 
increases cortisol production. S1P acutely induces the transcription of multiple 
cholesterol transport-related genes, including StAR, TSPO, LDLR, and SR-BI (Figure 
2.2), and rapidly stimulates the phosphorylation (i.e. activation) of HSL (Figure 2.6). 
Induction of LDLR and SR-BI expression increase the import of cholesteryl esters. HSL 
catalyzes the obligatory cleavage of imported cholesteryl esters, and StAR and TSPO 
facilitate movement of free cholesterol into the inner mitochondrial membrane, where its 
metabolism into steroid hormone begins (Section 1.1). Significantly, the current work 
identified S1P as a novel regulator of StAR gene expression via the activation of the 
MAPK/ERK pathway. Because StAR transcription is regulated by the bZIP family of 
transcription factors (e.g. CREB) (22,504) and S1P mediates CREB activitation (505), it 
is likely that CREB is recruited to the StAR promoter in response to S1P stimulation. 
Furthermore, given that sphingolipid-mediated SREBP1 cleavage (506) has been shown 
to mediate StAR transcription (507) and previous work from our group shows that S1P 
activates SREBP1 in H295R cells (115), it is plausable that SREBP1 is also recruited to 
the StAR promoter in response to S1P stimulation in H295R cells. Given the essential 
role of StAR in inner mitochondrial cholesterol import (the rate-limiting step in steroid 
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hormone production), my findings lend support to the integral role of S1P in maintaining 
optimal steroid hormone output during the acute phase of steroid hormone biosynthesis 
(Section 1.1). Collectively, we can envision S1P as a multi-functional stimulator of 
adrenal steroidogenesis: it indirectly modulates acute cholesterol transport into the inner 
mitochondrial membrane by regulating HSL activity and StAR expression (Chapter Two) 
while promoting chronic cholesterol metabolism by inducing CYP17A1 gene expression 
(115). 
 There are multiple potential implications for the actions of S1P in adrenocortical 
cells. Because S1P is secreted from some cell types, pathophysiological conditions that 
promote dysregulated S1P production/secretion often have a systemic effect and, 
therefore, may affect adrenal function. For example, sphingolipid metabolism in adipose 
tissue and plasma S1P levels are increased in genetically obese mice (508), suggesting 
that S1P-dependent cortisol production may be a catalyst for obesity. Similarly, S1P 
concentrations are also increased in a mouse model of diabetic nephropathy (509). Mast 
cells and platelets are known to upregulate the generation of S1P following immune 
stimulation (510-511). Hence, increased plasma concentrations of S1P may serve to 
damper or adjust the immune response by promoting the secretion of cortisol. 
Concurrently, persistent activation of the inflammatory response is associated with the 
etiology of cancer (reviewed in (512)) and many tumors are characterized by an 
overexpression of SPHK1 (513-518). As a result, S1P secreted from cancer cells due to 
hyperactive SPHK1 not only exerts tumorigenic effects (i.e. promotion of cell motility and 
growth, angiogenesis, etc.) but may also affect, in a systemic level, cortisol production. 
This is an intriguing premise because it suggests that S1P produced as a bi-product of 
inflammation not only acts to regulate the inflammatory response in immune cells, which 
is well established (519), but may also modulate inflammation by promoting cortisol 
biosynthesis. Consistent with this theory, studies have shown that glucocorticoids protect 
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cells from apoptosis through S1P-mediated mechanisms (520-523), suggesting a mutual 
relationship between S1P and glucocorticoids.  
 
6.3.  ACTH/cAMP-dependent transcriptional regulation of the ASAH1 gene 
 Most sphingolipid-related research has focused on the effects of these bioactive 
lipids on cellular processes, with transcriptional regulation of sphingolipid-metabolizing 
enzymes being less studied. However, based on a series of recent studies, it is 
becoming increasingly evident that regulation of sphingolipid gene expression is an 
integral mechanism by which various physiological factors control sphingolipid 
metabolism. In the present work, I show that ACTH/cAMP signaling chronically induces 
transcription of the ASAH1 gene (Figure 3.1), concomitant with an increase in protein 
expression (Figure 3.7). I also established CREB as an essential activator of this gene 
(Figure 3.4). To date, promoter analysis of some sphingolipid genes have been reported, 
including CERK (223), SPL (524), SGPP2 (222), SPTLC2 (419), ganglioside GM3 
synthase (420), Cer glucosyltransferase (421), neutral SMase2 (525), and ASAH2 (422).  
 Park et al. (425) has previously defined the structural units of the murine ASAH1 
gene and demonstrated that KLF6, Sp1, NF-κB, and AP2 can bind the promoter in vitro.  
However, prior to the present work, no functional characterization of this promoter has 
been reported. To this end, I demonstrate the binding of CREB, and the subsequent 
recruitment of the coactivator CBP/p300, to multiple regions of the human ASAH1 
promoter (Figure 3.6). Importantly, the indispensable role of CREB in mediating 
ACTH/cAMP-induced ASAH1 mRNA expression was established by selectively 
suppressing CREB expression by RNAi (Figure 3.4) and by utilizing a dominant-negative 
expression plasmid (Figure 3.3). Of note, CREB has also been previously implicated in 
the regulation of the CERK gene in JEG-3 human placental choriocarcinoma cells (526). 
Although the physiological significance of CREB-dependent CERK regulation is 
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unknown, it suggests that ACTH/cAMP signaling regulates the transcription of multiple 
sphingolipid genes. 
  In silico analysis of the ASAH1 promoter revealed putative binding sites for 
additional transcription factors, such as ER and Sp1. In fact, I have shown that, in MCF-
7 breast cancer cells, ERα and Sp1 bind to the ASAH1 promoter and induce gene 
transcription in response to stimulation with the phytoestrogen genistein (Figure 6.1). A 
detailed description of this regulation is presented in Appendix 1. Interestingly, the 
ASAH1 promoter also contains a putative binding site for the glucocorticoid receptor 
(GR) and treatment of adrenocortical cells with the synthetic glucocorticoid 
dexamethasone induces ASAH1 mRNA expression (Lucki et al., upublished 
observation) (Figure 6.1). Dexamethasone-induced ASAH1 expression was previously 
reported in mice muscle tissue (527). Therefore, it is possible that ASAH1 is part of a 
local negative feedback loop that controls cortisol production. Of note, dexamethasone 
has also been shown to upregulate SPHK1 activity and ASAH2 expression in rat 
Figure 6.1. ASAH1 promoter regulation by various transcription factors. ACTH/cAMP, 
genistein, and dexamethasone induce ASAH1 mRNA expression. Arrows indicate the 
transcription factors that are recruited to the ASAH1 promoter in response to each stimulus. 
Solid arrows indicate that protein association with DNA has been reported whereas the 
dashed arrow indicates that transcription factor DNA recruitment is yet to be established. 
Abbreviations: glucocorticoid receptor (GR), specificity protein 1 (Sp1), estrogen receptor α 
(ERα), cAMP response element binding protein (CREB), CREB binding protein (CBP/p300). 
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mesangial cells (521), thus suggesting an intricate relationship between glucocorticoids 
and SPH/S1P levels. 
  Because CREB regulates the expression of numerous genes, it is possible that 
additional extracellular cues that trigger intracellular cAMP production may also influence 
ASAH1 gene expression. For example, PMA- (528) and insulin-like growth factor 1-
stimulated (529) StAR gene transcription are dependent on the activation of CREB 
through the PKC pathway. Interestingly, as stated previously, S1P promotes CREB 
phosphorylation (i.e. activation) through the activation of the MAPK signaling cascade 
(505). Likewise, S1P inhibits cAMP production by activating signaling through Gαi-
coupled S1PRs (197-199). In theory, these pathways would reciprocally influence 
ASAH1 gene transcription. The possibility that S1P may play a role in ASAH1 
transcription is relevant to the context of the present work because this would imply that 
S1P modulates cortisol biosynthesis not only by inducing StAR (Chapter Two) and 
CYP17A1 (115) transcription but also by regulating ASAH1 gene expression. Given that 
S1P is formed by the action of ASAH1, this suggests a potential feed-forward 
mechanism between S1P signaling and ASAH1 expression. The intricate details of this 
potential crosslink between S1P signaling and ASAH1 expression are yet to be 
investigated. Nonetheless, it is evident that the range of possible sphingolipid-mediated 
regulatory mechanisms of adrenocortical steroidogenesis is vast and a lot of 
interconnections are likely to exist.       
 
6.4.  ASAH1 as a global regulator of adrenocortical gene transcription 
 As discussed previously, nuclear sphingolipid metabolism is a fairly recent 
concept, but emerging research is uncovering many roles for sphingolipids in nuclear 
processes. However, the concept of sphingolipid-metabolizing enzymes serving as 
transcriptional regulators is largely unexplored. Arguably, the most significant 
 136 
demonstration of sphingolipid-mediated transcriptional regulation was recently provided 
by Hait et al. (255). The authors revealed a novel role for nuclear SPHK2 as an inhibitor 
of HDAC1/2 and an epigenetic regulator of gene expression in MCF-7 breast cancer 
cells. SPHK2-generated S1P binds to HDAC1/2 and inhibits deacetylase activity, 
resulting in increased histone H3 acetylation and upregulation of p21CIP1/WAF1 gene 
expression (255). Interestingly, in contrast to the effect of S1P, C18-Cer was shown to 
activate HDAC (530-531). My data suggest that ASAH1 also modulates post-
translational modification of histones because suppression of ASAH1 expression led to 
increased levels of acetylated histone H3 at the proximal promoter region of multiple 
steroidogenic genes (Figure 4.8). Because ASAH1 silencing resulted in a decrease in 
nuclear S1P levels (Figure 4.5), my findings are not in agreement with Hait et al. 
However, this discrepancy may be due to cell-type specific differences because, in 
contrast to the nuclear expression of ASAH1 in H295R cells (Figure 5.1), I found that 
ASAH1 is localized in the cytoplasm of MCF-7 cells (Lucki and Sewer, unpublished 
observation). Although the present work does not provide direct evidence for the 
regulation of HDACs and/or histone acetylases by ASAH1, it is tempting to speculate 
that similar to S1P-mediated inhibition of HDAC activity (255), ASAH1 may play a role in 
regulating the activity of histone modifying enzymes.  
 A significant finding of the current work was the effect of ASAH1 silencing on the 
transcription of members of the NR4A and NR0B subgroups of nuclear receptors (Figure 
6.2). ASAH1 is a negative regulator of NR4A genes because suppressing the expression 
levels of this enzyme resulted in a significant increase in their transcriptional rate (Figure 
4.6). Conversely, ASAH1 is a positive regulator of NR0B gene expression (Figure 4.6). 
Members of the NR4A subfamily of nuclear receptors, namely Nur77, Nurr1, and Nor-1, 
have recently emerged as key regulators of metabolic functions and are involved in 
various physiological processes, including apoptosis (532-533), oncogenesis (534), and 
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steroidogenesis (437,535-538). In steroidogenic cells, Nur77 has been implicated in the 
regulation of the StAR (536-537), and 3β-HSDII (538) genes. Similarly, Nur77 and Nurr1 
activate CYP21A2 (437,535) and CYP11B2 (539) transcription. Because I show that 
ASAH1 suppression results in increased mRNA and protein expression of Nur77 and 
Nurr1 (Figure 4.6) concomitant with the upregulation of StAR and CYP21A2 gene 
expression (Figure 4.2), it is plausible to speculate that at least some of the effects 
resulting from ASAH1 knockdown are mediated by these nuclear receptors. Of note, 
Nur77 overexpression was shown to attenuate proliferation of smooth muscle cells 
(540), which is consistent with the effect of ASAH1 knockdown on the proliferation rate 
of adrenocortical cells (Figure 4.3). 
 Similarly, Dax-1 (encoded by NR0B1) is a well-established repressor of SF-1 
activity (122,435-436,494). Therefore, lower mRNA transcript levels (and protein 
expression) of this transcription factor in response to ASAH1 knockdown positively 
correlate with higher expression of SF-1-regulated genes, including StAR, CYP17A1, 
CYP11A1, and Mc2R (Figure 4.2). Interestingly, ChIP experiments revealed that ASAH1 
is recruited to the DAX-1 proximal promoter in response to Bt2cAMP stimulation (Figure 
5.6), suggesting that ASAH1 is a transcriptional regulator of this gene. Therefore, it is 
possible that the transcriptional regulation of steroidogenic genes by ASAH1 is partially 
mediated by the modulation of DAX-1 expression (Figure 6.2).  
 Analogous to Dax-1, SHP (NR0B2) functions as a corepressor for other nuclear 
receptors (541). SPH is implicated in bile acid synthesis and cholesterol homeostasis 
(542-544), but a role for this receptor in steroid hormone biosynthesis is yet to be 
described. Based on the effect of ASAH1 knockdown on SHP gene expression, an 
intriguing hypothesis of further study is that SHP is a sphingolipid-regulated gene. This 
may have physiological implications in the liver where SHP plays integral roles in bile 
acid synthesis and lipid, cholesterol, and glucose metabolism (543). SHP has a 
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protective effect in liver fibrosis (545) whereas it promotes dyslipidemia (546) and, 
consequently, the development of non-alcoholic fatty liver disease (547). Hence, one 
can imagine a potential role for ASAH1 in the etiology of these conditions. Because SF-1 
is a transcriptional activator of both DAX-1 (548-549) and SHP (550), my data indicate 
that SF-1 requires additional proteins to induce the expression of these genes and that 
ASAH1 expression (or secondary factors controlled by ASAH1) is essential for the 
transcription of these genes.   
Figure 6.2. ASAH1 is a global regulator of gene transcription in H295R cells. Schematic 
representation of the different classes of genes affected by ASAH1 knockdown and their 
involvement in diverse biological processes, such as steroid hormone production (cortisol and 
dehydroepiandrosterone, DHEA) and cell growth. Steroidogenic genes encode cholesterol-
metabolizing/transport proteins that directly affect steroid hormone production (solid arrow) 
whereas the protein products of nuclear receptor and sphingolipid genes modulate cell growth 
indirectly by affecting the expression and/or activity of other genes/enzymes (dashed arrow). 
NR4A and NR0B genes can also indirectly control cortisol/DHEA synthesis by regulating the 
transcription of steroidogenic genes (grey dashed arrow).      
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 In addition to regulating the expression of steroidogenesis-related genes, ASAH1 
expression also affects the sphingolipid metabolic pathway at the transcriptional level 
(Figure 6.2). Interestingly, my data suggest that ASAH1 is an important factor in 
regulating overall sphingolipid levels because suppression of ASAH1 resulted in a 
decrease in the cellular levels of most sphingolipid species quantified, including SPH, 
S1P, HexCer, and LacCer (Figure 4.5). In nuclei, SM and Cer levels were also 
decreased in response to ASAH1 suppression (Figure 5.2). Notably, the fold change 
decrease in sphingolipid levels varied among the different species, with 
glycosphingolipids (i.e. HexCer and LacCer) being the most affected by ASAH1 
knockdown. Transcriptional analysis of sphingolipid genes, for the most part, did not 
positively correlate with the observed changes in the steady-state intracellular 
sphingolipid profile of these cells. Nonetheless, it is plausible to consider that ASAH1 
may modulate sphingolipid flux by regulating SPTLC2 gene expression (Figure 4.4). The 
SPT holoenzyme, consisting of SPTLC1 and SPTLC2 subunits, catalyzes the initial and 
rate-limiting step in de novo sphingolipid biosynthesis (Figure 1.2). Although both 
subunits are essential for catalytic activity (551), SPTLC2 is the only subunit capable of 
binding the required pyridoxal 5’-phosphate cofactor (552). Therefore, based on the 
importance of SPTLC2 in forming a catalytically competent enzyme, it is logical that 
global reduction in sphingolipid levels stems, at least in part, from reduced SPTLC2 
mRNA expression in response to ASAH1 silencing. In order to compensate for impaired 
de novo sphingolipid synthesis (as a result of decreased SPTLC2 expression), the cell 
increases the breakdown of complex sphingolipids (e.g. HexCer and LacCer), thus 
resulting in a net decrease in the cellular amounts of these lipids. Another unexpected 
finding was a 20% reduction in whole-cell Cer levels (Figure 4.5) and a 40% decrease in 
nuclear Cer (Figure 5.2) even though multiple CerS isoforms were transcriptionally 
induced in response to ASAH1 suppression (Figure 4.4). Interestingly, Mullen et al. (553-
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554) recently reported that selective knockdown of distinct CerS isoforms results in the 
accumulation of HexCer, which is in contrast to the levels of this species in ASAH1KD 
cells. A detailed discussion of this aspect of sphingolipid regulation and the potential 
physiological implications of perturbed sphingolipid homeostasis is presented later in this 
Chapter.  
 
6.5.  ASAH1 as a novel SF-1 coregulator   
 SF-1 is a master regulator of cell-selective gene transcription within the 
endocrine system and extensive research has established the roles of this receptor in 
gene expression, cell differentiation, development, and disease (555-557). Nevertheless, 
an important question that remains unresolved is: what mechanisms regulate SF-1 
function? Multiple post-translational modifications, transcription factors, and coregulators 
that control receptor activity have been identified. The detection of phospholipids in the 
receptor LBD (163,167) and findings from our own group demonstrating that PA and 
SPH are capable of modulating the transactivation potential of SF-1 (47,164) added 
ligand binding as yet another mechanism of receptor regulation. To this end, the present 
work provides significant evidence for the role of ASAH1 as a novel coregulator of SF-1 
in adrenocortical cells. I show that ASAH1 is a nuclear protein in H295R cells (Figure 
5.1) and ACTH/cAMP signaling promotes its recruitment to various steroidogenic gene 
promoters where it forms a complex with SF-1 (Figure 5.6). Additionally, ASAH1 
suppresses the transcriptional activity of SF-1 and disrupts the ability of coactivators to 
enhance SF-1-dependent target promoter activity (Figure 5.4).       
 Although SF-1 binds to target DNA as a monomer (147), its activity is potently 
modulated by its interaction with numerous proteins, including coactivators/corepressors 
(e.g. p160 family of coactivators, CBP/p300, SMRT, NCoR1) as well as other 
transcription factors (e.g. NF-κB, SHP, Dax-1, GR, Sp1) and proteins (e.g. β-catenin, 
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polypyrimidine tract-binding protein-associated splicing factor, p54/NonO) that either 
induce or repress receptor activity (reviewed in (556)). Generally, coregulators bind to 
nuclear receptors through LXXLL or LXXLL-related [(L/I)-XX-(I/V)-I and L-XXX-(I/L)-XXX-
(I/L)(478)] motifs, where X is any amino acid and L is a leucine (477-478) that can also 
be substituted for an isoleucine, phenylalanine, or methionine (169). Although the 
molecular basis of interaction between coactivators or corepressors with nuclear 
receptors is similar, an important difference between them is that coactivators require 
the AF-2 core (i.e. LLIEML hexamer domain (118)) for interaction (558-559) while 
corepressors do not (490-491,560). ASAH1 has multiple putative LXXLL motifs that may 
mediate its interaction with SF-1. Based on mammalian 2-hybrid studies using truncation 
mutants of ASAH1, it is likely that multiple functional LXXLL motifs (at least one motifs in 
each subunit) are involved in SF-1 binding (Figure 5.4B). Accordingly, coIP studies 
revealed that mutation of an LXXLL motif in the α subunit of ASAH1 prevents its 
interaction with SF-1 (Figure 5.3F). Significantly, mutation of this motif rendered ASAH1 
incapable of suppressing SF-1/Bt2cAMP-dependent CYP17A1 promoter activity (Figure 
5.4A), indicating that receptor binding through this motif is essential for ASAH1 function. 
Of note, our laboratory has previously demonstrated that DGKθ, the enzyme that 
generates the SF-1 agonist PA, interacts with the receptor through multiple LXXLL 
motifs (164). Mutation of these motifs attenuates the synergistic activation of CYP17A1 
promoter activity, indicating that a direct interaction between DGKθ and the receptor is 
important for SF-1-dependent gene transcription (164). Experiments in Chapter Five 
demonstrated that the same is true for the interaction between ASAH1 and SF-1. 
Studies aimed at mapping additional interacting regions of ASAH1 and SF-1 are an 
active area of investigation. 
 Significantly, in support of a coregulatory role for ASAH1, re-ChIP studies 
revealed that ASAH1 binds to SF-1 on the proximal promoter of the CYP17A1 and StAR 
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genes (Figure 5.6), hence modulating receptor function on DNA. Because ASAH1 is also 
recruited to other SF-1-target genes, such as Mc2R and DAX-1 (Figure 5.6), it is 
tempting to speculate that a complex between ASAH1 and SF-1 also forms at these 
promoters. Importantly, the fact that ASAH1 knockdown induces the mRNA expression 
of these genes (Figures 4.2 and 4.6) is consistent with a repressory function of ASAH1 
on SF-1 activity (i.e. ASAH1 suppression results in decreased SPH levels, which leads 
to increased SF-1 activity and SF-1-dependent gene expression). However, because 
ASAH1 suppression also altered the transcriptional rate of genes that are not known as 
SF-1-regulated, such as sphingolipid (Figure 4.4) and NR4A (Figure 4.6) genes, there 
must be multiple mechanisms (in addition to regulating SF-1 activity) by which ASAH1 
affects global gene expression. As will be discussed later in this Chapter, modulation of 
intracellular sphingolipid levels may be one of these mechanisms.   
 My data suggest that ASAH1 is functioning as a repressor of SF-1. There are at 
least three possible ways by which ASAH1 may be inhibiting SF-1 function: (1) ASAH1 
suppresses SF-1 function by promoting SPH delivery to the receptor. The fact that 
ASAH1 was unable to abrogate SF-1-dependent CYP17A1 promoter activity in the 
presence of the ceramidase inhibitor D-NMAPPD (485) (Figure 5.5) suggests that the 
catalytic activity of ASAH1 (SPH production) is required for the repressive function of 
ASAH1. However, further in vivo and in vitro biophysical analysis of the ligand-binding 
event is necessary to prove this hypothesis; (2) binding of ASAH1 to the receptor 
prevents interaction with coactivators. This is illustrated by reporter gene assays where 
co-expression of ASAH1 and SRC-1 suppresses coactivator-mediated SF-1-induced 
CYP17A1 promoter activity (Figure 5.4); (3) ASAH1 binding to SF-1 promotes the 
recruitment of and/or interaction with corepressor complexes that prevent the receptor 
from inducing transcription. This hypothesis is partially supported by the observation that 
ASAH1 potentiates the repressory activity of the corepressor SMRT (Figure 5.4). In 
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agreement, SPH has the same effect on SMRT activity (47). Notably, Dax-1 inhibits SF-
1-mediated gene transcription by binding to the receptor through functional LXXLL motifs 
(493) and acting as an adaptor that recruits other factors, such as the corepressor 
NCoR, to SF-1 (122). It is tempting to speculate that ASAH1 is functioning in a smilar 
manner as Dax-1 to inhibit SF-1 activity. Analysis of transcription complex assembly on 
the CYP17A1 (158) and Mc2R (161) promoters revealed that the formation of SF-1-
containing complexes is cyclical and dynamic. Therefore, in order to fully understand the 
regulatory role of ASAH1 in SF-1-dependent steroidogenic gene transcription, temporal 
ChIP experiments are necessary to capture the timing and order of ASAH1 recruitment 
to DNA. ChIP-seq analysis will also be significant to identify ASAH1 binding sites across 
the genome. Equally important are studies in other cell types to establish ASAH1 
function across different tissues. Nonetheless, what can be concluded from my 
experiments is that ACTH/cAMP signaling promotes the recruitment of ASAH1 and 
binding to SF-1 at the proximal promoter region of target genes whereby ASAH1 
mediates transcriptional repression.    
    
6.5.1.  Incorporation of our current findings to the model of phospholipid and 
 sphingolipid binding and SF-1 function  
 
 As stated previously, there is compelling evidence for an integral role of ligand 
binding in regulating the ability of SF-1 to activate target gene expression (163-165,167). 
However, the mechanistic details of ligand binding as well as how this aspect of SF-1 
regulation integrates with post-translational modifications and coregulator binding 
remains elusive. Even though considerable research is necessary to elucidate the 
molecular underpinnings of SF-1 regulation, our laboratory is actively investigating the 
role of ligands in controlling receptor function. To this end, the identification of PA and 
SPH as ligands for SF-1 (47,164), suggests that ligands are dynamically exchanged 
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under different cellular conditions. We have shown that Bt2cAMP stimulates nuclear 
DGKθ activity, which is required for SF1-/ Bt2cAMP-dependent CYP17A1 transcription 
(164). Accordingly, suppression of DGKθ expression attenuates Bt2cAMP-stimulated 
CYP17A1 mRNA expression and inhibiting DGKθ activity attenuates SF-1 recruitment to 
the CYP17A1 promoter (164). Because we have also found that DGKθ directly interacts 
with SF-1 through multiple LXXLL motifs (164), we postulated that this interaction 
facilitates PA delivery to the receptor’s ligand binding pocket. Conversely, SPH is bound 
to the receptor under unistimulated conditions and activation of the ACTH/cAMP 
pathway promotes SPH dissociation from the receptor (47) and possibly promotes PA 
binding (561). Additionally, SPH antagonizes SRC-1-dependent upregulation of SF-1-
mediated CYP17A1 gene expression (47) and disrupts the interaction of SF-1 with SRC-
1 and GCN5 (158). To build upon these earlier findings, experiments in this dissertation 
provide evidence for the integration of ASAH1 into the model of SF-1 transcriptional 
regulation by ligands.      
 The current work demonstrates that ACTH/cAMP signaling rapidly activate 
nuclear ASAH1 activity (Figure 5.2), promotes its recruitment to target gene promoters 
(Figure 5.6), including CYP17A1, and triggers the formation of a complex with SF-1 on 
DNA (Figure 5.6). In parallel, ASAH1 expression suppresses basal and SF-1/Bt2cAMP-
dependent CYP17A1 promoter activity (Figure 5.3A) as well as abrogates the ability of 
SRC-1 to upregulate SF-1-dependent CYP17A1 promoter activity (Figure 5.4C). 
Because SPH attenuates the transcriptional activity of SF-1 and Bt2cAMP stimulation 
promotes SPH dissociation from the receptor (47), it is counter-intuitive to think that 
ACTH/cAMP signaling, which activates steroidogenic gene transcription, is promoting an 
interaction between ASAH1 and SF-1 at target promoters. However, as stated 
previously, SF-1-containing complex assembly on DNA is dynamic and cyclical 
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(158,161). In addtion, the potential role of post-translational modifications in modulating 
ASAH1 activity should also be considered. Tyrosine phosphorylation has been 
suggested to modulate ASAH1 activity (562-563). Likewise, we have found by mass 
spectrometry that ASAH1 is basally phosphorylated at multiple residues, including 
tyrosine 289, which is acutely phosphorylated in response to Bt2cAMP treatment (Lucki 
et al., unpublished observation). Hence, I postulate that additional studies are necessary 
to determine the spatio-temporal parameters that govern protein-protein and protein-lipid 
interactions as well as to fully understand how DGKθ and ASAH1, in response to 
ACTH/cAMP stimulation, reciprocally control SF-1 activity, and in turn, gene 
transcription. Dammer et al. (158) described the cyclical recruitment of SF-1 and 
coregulatory complexes to the CYP17A1 promoter in response to Bt2cAMP treatment in 
adrenocortical cells. SF-1 is maximally enriched on DNA 60 min after stimulation with 
agonist. SRC-1 and GCN5 recruitment closely follows the kinetics of SF-1 binding (158). 
In addition, the authors demonstrate that SPH disrupts the cooperativity among SF-1, 
SRC-1, and GCN5 as well as alters the kinetics of SF-1 DNA recruitment (158), 
suggesting that SPH suppresses the transcriptional activity of SF-1 not only by inhibiting 
its recruitment to DNA but also by promoting coactivator complex disassembly. 
 Based on these findings, I propose a model where activation of the ACTH/cAMP 
pathway rapidly promotes DGKθ binding and PA delivery to SF-1, thus activating the 
receptor (i.e. promoter binding and recruitment of coactivator complexes) (Figure 6.3). 
Shortly after, ASAH1 is recruited to promoter DNA where it forms a complex with SF-1. 
This interaction facilitates SPH delivery to the receptor, potentially decreasing the 
receptor’s affinity for coactivators and promoting receptor ejection from DNA (Figure 
6.3). Interestingly, SPH is an activator of DGK (496-497). Thus, an intriguing hypothesis 
is that SPH may play a dual role in SF-1 regulation: a direct role by serving as an 
antagonist for the receptor and an indirect role as an activator of DGK, and thus, PA 
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production. However, this premise is yet to be tested. Likewise, the kinetic details of 
protein complex assembly and the temporal parameters that define SF-1 ligand binding 
is the subject of intense research. Studies centered at this aspect of receptor regulation 
are being undertaken.   
 
 
Figure 6.3. Proposed model for the role of ligand binding in regulating SF-1 activity. (1) Protein kinase A 
(PKA) activation in response to adrenocorticotropin (ACTH) stimulation activates diacylglycerol kinase θ 
(DGKθ) and promotes phosphatidic acid (PA) binding to SF-1, which activates the receptor. SF-1 binds to 
DNA, recruits coactivator complexes, and activates transcription. (2) After one transcription cycle, 
ACTH/cAMP signaling promotes ASAH1 recruitment and binding to SF-1 at the promoter of target genes. 
ASAH1 generates sphingosine (SPH), which disrupts the interaction of SF-1 with coactivators and 
promotes receptor ejection from DNA as well as its association with corepressor proteins, such as SMRT 
(silencing mediator for retinoid and thyroid-hormone receptors), HDAC (histone deacetylase), Sin3A. 
Abbreviations: steroid receptor coactivator (SRC), polypyrimidine tract-binding protein-associated splicing 
factor (PSF), general control nonderepressor 5 (GCN5).     
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6.5.2.  Alternative mechanisms of ASAH1 function in adrenocortical cells 
 The fact that ASAH1 regulates SF-1 transcriptional activity by directly binding to 
the receptor (Figure 5.3) raises the premise that this interaction facilitates SPH delivery 
to the receptor. However, although I provide indirect experimental evidence that 
supports this hypothesis, as stated previously, specific in vitro and in vivo biophysical 
analysis of the ligand delivery and binding events is imperative for proving this theory. 
Furthermore, the global effects of ASAH1 silencing on gene expression, sphingolipid 
metabolism, and steroidogenic capacity in adrenocortical cells suggest that ASAH1 may 
have additional regulatory functions beyond its coregulator role. For example, as 
discussed in Section 6.4, the fact that ASAH1 regulates the expression of NR4A and 
NR0B genes, all of which have multiple gene targets, indicates that ASAH1 has the 
potential to indirectly regulate a wide array of genes in various biological processes. 
Pleiotropic functions of sphingolipid enzymes are emerging as a common theme in 
sphingolipid research. For example, SPHK2 not only functions as a secondary 
coregulator in gene transcription (255) but also promotes cell survival by increasing Cer 
production through the sphingolipid salvage pathway (190) (Section 1.3).  
 
6.6.  Implications for the nuclear localization of ASAH1 on its functions  
  Due to the hydrophobic nature of most sphingolipid species, 
compartmentalization of sphingolipid metabolism, and subsequently signaling, is an 
important theme in sphingolipid biology (93). In this manner, Cer localized at the plasma 
membrane, for example, participates in distinct signaling pathways than mitochondrial 
Cer (39,554,564-567). Accordingly, induction of apoptosis in rat hepatocytes occurs 
through the selective accumulation of nuclear Cer due to the activation of ceramidase 
and neutral SMase at the NE (253). Accumulation of nuclear Cer was also observed in 
Jurkat T cells in response to Fas ligand-dependent activation of nuclear neutral SMase 
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and concomitant inhibition of nuclear SM synthase (261). Consequently, the nuclear 
localization of ASAH1 may be critical for its role as a coregulator of SF-1 as it would 
promote local production of the receptor’s ligand SPH. Because SPH has low water 
solubility (568), one can envision the binding of ASAH1 to SF-1 as a way to facilitate 
ligand delivery to the receptor’s ligand binding pocket.     
 Even though all three ceramidase isoforms are expressed in H295R cells (Figure 
5.1), several lines of evidence led me to conclude that ACTH/cAMP signaling specifically 
targets ASAH1 to modulate the steroidogenic metabolic pathway in adrenocortical cells. 
First, because SF-1 is a nuclear protein, I postulated that the nuclear localization of a 
ceramidase isoform was imperative. ACER3 is not localized in the nucleus of H295R 
cells (Figure 5.1A) - and Bt2cAMP stimulation does not promote its nuclear translocation 
(data not shown)- hence excluding this isoform as a potential candidate for nuclear SPH 
production and SF-1 regulation. Second, ASAH1 is the only nuclear ceramidase isoform 
whose activity is upregulated by Bt2cAMP (Figure 5.2). Furthermore, although ASAH2 is 
also localized in the nucleus of these cells (Figure 5.1), coIP studies revealed that, 
opposite to ASAH1, ASAH2 not only does not interact with SF-1 (Figure 5.3C), but also 
is not recruited to the CYP17A1 promoter in respose to Bt2cAMP stimulation (data not 
shown). Third, ASAH1 knockdown resulted in a decrease in the nuclear levels of SPH 
and S1P (Figure 5.2). Consistent with a decrease in nuclear SPH levels, ASAH1 
suppression led to the transcriptional upregulation of various SF-1 target genes (Figure 
4.2).  
 What can be concluded by the experimental evidence in this dissertation is that, 
given that SF-1 is a nuclear protein, the nuclear localization of ASAH1 is important for its 
corepressor role. The nuclear localization of sphingolipid-metabolizing enzymes and the 
presence of a local nuclear sphingolipid flux is a fairly recent concept. Nonetheless, a 
growing body of evidence has linked various sphingolipid species to many nuclear 
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processes (238,444,569). Importantly, some extracellular cues are able to selectively 
promote nuclear lipid metabolism (570-572). Similarly, some nuclear sphingolipid-
metabolizing enzymes have distinct physicochemical properties than their cytosolic 
counterparts (250), suggesting that the nucleus is a self-regulating sphingolipid 
metabolic factory. Consequently, the nuclear localization of ASAH1 in adrenocortical 
cells supports the existence of a local flux of Cer/SPH that may affect diverse nuclear 
functions, including the transcriptional activity of SF-1. As will be discussed in the next 
sub-section of this Chapter, the presence of additional nuclear sphingolipid-metabolizing 
enzymes facilitate a local dynamic flux of many sphingolipid species. 
 
6.6.1.  Implications for the nuclear localization of Cer/SPH-metabolizing enzymes 
 in ASAH1 function 
 
 The activity of a particular enzyme is not only controlled by extracellular and 
intracellular factors but is also limited by the availability of substrate. Therefore, given the 
highly dynamic nature of sphingolipid metabolism, it is plausible to hypothesize that in 
order for ASAH1 to efficiently produce SPH, Cer-generating enzymes (Figure 1.2) must 
ensure that the levels of nuclear Cer are optimally maintained. This is accomplished, at 
least in part, by the nuclear localization of SMase and SM synthase, which together 
control the balance between SM and Cer. SMase has been detected in the nuclear 
matrix (248), NE (249), and chromatin (247) while SM synthase has also been identified 
in the NE and chromatin of various cell types (250). In fact, mass spectrometric analysis 
revealed that the nuclear levels of SM and Cer are altered in response to Bt2cAMP 
stimulation (Figure 5.2), thus supporting the nuclear localization of SM- and Cer-
metabolizing enzymes in the nucleus of adrenocortical cells. In addition, I found that 
CerS5 and CerS6 are also localized in the nucleus of H295R cells (Figure 6.4). Hence, 
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the nuclear localization of multiple SM/Cer-metabolizing enzymes may indirectly 














 The importance of concerted enzymatic action in controlling nuclear sphingolipid 
function is exemplified by the role of SM on DNA stability during the cell cycle (247). 
Concomitant activation of SMase and inhibition of SM synthase at the beginning of S 
phase of the cell cycle leads to a decrease in chromatin-bound SM, which is suggested 
to facilitate DNA unwinding (236). At the end of S phase, increased SM synthase activity 
induces an accummulation of chromatin-associated SM, which facilitates double helix 
restoration after DNA synthesis ends (236). The dynamic balance of nuclear SM gives 
premise to local Cer metabolism in response to different environmental cues. In fact, as 
stated above, ACTH/cAMP signaling promotes SM and Cer turnover with a concomitant 
increase in SPH and S1P levels in the nucleus of H295R cells (Figure 5.2). 
Figure 6.4. Nuclear localization of 
sphingolipid-metabolizing enzymes 
in H295R cells. A. Cytosolic, 
nuclear envelope (NE), and 
nucleoplasmic (NP) fractions of 
H295R cells were isolated. Lysates 
(30 µg of protein) were separated 
by SDS-PAGE followed by western 
blotting analysis using antibodies 
against CerS1-6 (ceramide 
synthase), SPHK1, and SPHK2 
(sphingosine kinase). 
Mitochondrial StAR (steroidogenic 
acute regulatory protein) and 
microsomal P450c17α were used 
as controls. B. Nuclear and 
cytosolic fractions were isolated 
from H295R cells and the protein 
expression of SPTLC1 (serine 
palmitoyltransferase long-chain 
subunit 1) and SPTLC2 was 
















 In addition to localized Cer production, nuclear SPH metabolism is equally 
important in controlling its antagonistic action on SF-1 activity. The amount of 
intracellular SPH is not only regulated by ceramidases but also through its 
phosphorylation into S1P by SPHKs (Figure 1.3). Nuclear ceramidase activity has been 
previously identified in rat hepatocytes (252-253). Likewise, nuclear SPHK activity was 
first described in the NE and nucleoplasm of Swiss 3T3 cells (251). It was subsequenty 
reported by the same group that SPHK2, as discussed previously, is associated with 
histone H3 in chromatin of MCF-7 breast cancer cells (255). SPHK2 promotes S1P 
production and histone acetylation in the nuclei of these cells (255). Of note, SPHK2 is 
also localized in the nucleus of H295R cells (Figure 6.4). Furthermore, we have found 
that Bt2cAMP activates SPHK1 (115), and promotes its phosphorylation and nuclear 
translocation in H295R cells (Li et al., unpublished observations). The nuclear 
localization of SPHKs in H295R cells supports my mass spectrometric data showing 
rapid nuclear S1P accumulation in response to Bt2cAMP treatment (Figure 5.2). 
Interestingly, we have also found that SPHK1 interacts with SF-1 and ASAH1 (Li et al., 
unpublished observation). This suggests that, in response to ACTH/cAMP signaling, a 
complex containing SF-1, ASAH1, and SPHK1 may form on promoter DNA, which may 
be a way to dynamically regulate SF-1 ligand metabolism and HDAC1/2 activity. 
 The functional implications for the nuclear localization of additional sphingolipid-
metabolizing enzymes on the role of SPH as an antagonist of SF-1 are two-fold. First, 
the nuclear localization of SM/Cer-metabolizing enzymes indicates the presence of a 
nuclear SM cycle where a dynamic balance between SM and Cer exist. This suggests 
that, in addition to modulating nuclear ASAH1 activity, ACTH/cAMP signaling may also 
regulate the activity of SM synthase, SMases, and CerS to maintain optimal nuclear Cer 
availability for ASAH1 action. Of note, nuclear SM levels are decreased in response to 
stimulation with Bt2cAMP in WT cells but no change in nuclear SM concentrations were 
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seen in ASAH1KD cells under the same conditions (Figure 5.2). Second, the signaling 
properties of newly generated SPH are controlled by nuclear SPHKs, which would limit 
the antagonistic function of SPH. As discussed above, nuclear SPHK2 and SPHK1 may 
participate in SPH metabolism in H295R cells. Thus, it is evident that dynamic nuclear 
sphingolipid metabolism plays an integral role in facilitating SF-1 ligand exchange.   
  
6.7.  Implications of the current work to the field of sphingolipid research 
 It has become very clear that sphingolipids are essential for physiological 
homeostasis and, as such, intricate networks are involved in their regulation. 
Accordingly, understanding the mechanistic underpinnings of sphingolipid metabolism as 
well as the effects of sphingolipid dysregulation on overall cellular function is imperative. 
To this end, mice knockout models of different sphingolipid enzymes, including CERK 
(573), GM3 synthase (574), SPHKs (575), ASAH2 (576), SPL (577), and CerS2 (578), 
have been generated. However, because disruption of ASAH1 expression is 
embryonically lethal (109), a global knockout model for this enzyme is not feasible. The 
effect of ASAH1 knockout not only exemplifies the essential role of this enzyme in 
development but also indicates that the other ceramidase isoforms cannot compensate 
for loss of ASAH1. It is likely that future studies using tissue-specific or conditional 
knockout mouse models may provide new insights into ASAH1 function. The 
significance of the findings presented in this dissertation to the field of sphingolipid 
research is multifold. First, a novel regulatory role for S1P in adrenocortical steroid 
hormone synthesis was established. Second, I functionally characterized the human 
ASAH1 promoter and established the ACTH/cAMP pathway as an activator of ASAH1 
expression at both transcriptional and post-transcriptional levels. Third, a novel role for 
ASAH1 as a global regulator of gene expression was uncovered. Finally, I identified 
ASAH1 as a nuclear protein in H295R cells and defined its function as an SF-1 
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coregulator. To my knowledge, this is the first demonstration that a sphingolipid-
metabolizing enzyme serves such function. Although the current work focuses on 
adrenocortical steroid hormone production, my findings have global implications as it 
highlights the importance of sphingolipids in the maintenance of hormones that are 
required for varied physiological processes (Section 1.1). Furthermore, characterization 
of the ASAH1KD cell line provides valuable information about the contribution of ASAH1 
to the steady-state levels of sphingolipids.    
 
6.7.1.  Potential role of ASAH1 in the maintenance of sphingolipid homeostasis 
 Mass spectrometric analysis of sphingolipid content in response to ASAH1 
suppression revealed interesting yet unexpected results that implicate ASAH1 as an 
important enzyme not only for the regulation of Cer/SPH/S1P levels but also for the 
maintenance of overall sphingolipid homeostasis. The most stricking consequence of 
ASAH1 silencing was a decrease in the steady-state levels of most sphingolipid species 
quantified (Figure 4.5 and 5.2). A commonality among published studies of knockout (or 
knockdown) models of sphingolipid-metabolizing enzymes is the role of compensatory 
mechanisms to sustain homeostatic conditions. Likewise, these studies highlight the fact 
that suppression of one enzyme can affect cellular sphingolipid composition in 
unpredicted ways. For example, downregulation of CerS2 in neuroblastomal cells 
increased the levels of long-chain Cer and SM, partially due to the upregulation of 
ACER1 and 2 reverse activities (579). Similarly, selective knockdown of different CerS 
isoforms in MCF-7 breast cancer cells revealed complex transcriptional inter-regulation 
among these enzymes, but the changes in sphingolipid content were not readily 
accounted for by the changes in mRNA expression of the different enzyme isoforms 
(553). Accordingly, my findings suggest that ASAH1 silencing have significant effects on 
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the sphingolipid profile of adrenocortical cells. These changes were thoroughly 
discussed in Section 4.4 of Chapter Four. 
 Several recent studies have provided insights into the molecular mechanisms by 
which cells sense and coordinate sphingolipid production. As stated above, the overall 
decrease in sphingolipid content in response to ASAH1 silencing supports a role for 
ASAH1 in maintaining optimal steady-state sphingolipid levels. The outcome of ASAH1 
suppression on cellular sphingolipid content can be partially due to suppression of 
SPTLC2 expression (Figure 4.4 and Section 6.4). In addition, because sphingolipid 
dysregulation is known to cause cellular stress and pathological effects (580-582), it is 
significant that ASAH1 knockdown resulted in reduced cellular proliferation, with no 
change in cell viability (data not shown), than WT cells (Figure 4.3). This effect can be 
partially explained by a decrease in the expression levels of cyclin B2 (Figure 4.3), which 
is expressed during G2/M phase of the cell cycle and regulates mitotic progression 
(583), and PCNA (Figure 4.3), which is essential for DNA replication by serving as a 
sliding clamp for DNA polymerase (584). It is possible that ASAH1 indirectly modulates 
the function of additional proteins that maintain optimal sphingolipid levels and/or control 
cell growth. 
 To date, three groups of proteins have been implicated in the regulation of 
steady-state sphingolipid levels: TORC2 (target of rapamycin complex 2), SMSr (SM 
synthase-related), and ORMs. TORC2 is comprised of TOR (target of rapamycin), 
rapamycin-insensitive companion of TOR, GβL, and stress-activated protein kinase 
interacting protein 1 (585). In mammalian cells, this complex has been implicated in the 
regulation of actin cytoskeleton and cell survival (585). TORC2 kinase complex activity 
was shown to be required for maximal CerS activity (586-587), thus for normal levels of 
sphingoid bases (e.g. SPH and sphinganine, Figure 1.3), sphingoid base phosphates 
(e.g. S1P), and Cer. Similarly, SMRr, a Cer ethanolamine phosphotransferase that 
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synthesizes Cer phosphoethanolamine (588), was shown to act as a Cer sensor and 
modulate sphingolipid production in response to Cer levels (588). Suppression of SMSr 
causes a dramatic increase in Cer and glucosylceramide levels (588), suggesting that 
when this sensor is blocked, unregulated Cer accumulation occurs. Both TORC2 and 
SMSr activity are necessary for normal sphingolipid metabolism, although the intricate 
details of how they act upon the sphingolipid pathway are yet to be detailed. More 
recently, ORM proteins identified in yeast (ORMDL in humans (589)) were implicated in 
a mechanism by which cells can adjust sphingolipid content according to metabolic 
demand (580,590). ORMs are ER-localized transmembrane proteins with no known 
functional domains. However, they are strongly conserved across species (580), 
suggesting that they share a common function. ORM overexpression reduces 
sphingolipid concentrations (591) whereas constitutive loss of ORM gene function 
causes toxic overproduction of sphingolipids (580), which suggest that these proteins 
are negative regulator of sphingolipid synthesis. Although the present work did not 
include an in depth analysis of possible regulatory pathways affected by ASAH1 
silencing, based on these recent discoveries of sphingolipid-regulating proteins, it is 
provocative to speculate that ASAH1 may play a role in controlling the function of these 
proteins.    
 
6.7.2.  Potential implications for altered steady-state sphingolipid levels resulting 
 from ASAH1 suppression    
 
 SM and glycosphingolipids (e.g. HexCer and LacCer) are integral components of 
cell membranes, along with glycerolipids and sterols (592). The complex head-group 
glycans of glycosphingolipids serve as cell surface-exposed membrane elements that 
can be recognized and bound by a series of proteins (592). Therefore, the most obvious 
implication of altered cellular sphingolipid composition in adrenocortical cells is changes 
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in the biophysical properties of lipid bilayers. Because of the physical and functional 
relationships among sphingolipids, glycerolipids, and sterols, perturbations to 
sphingolipid metabolism may affect the amount and location of these other lipid classes. 
Finally, it is now well established that signal transduction initiated at the cell membrane 
is influenced by lipid-microenvironments, known as lipid rafts, which are comprised of 
sphingolipids and cholesterol and serve as organizing centers for the assembly of 
signaling molecules (593-594). Therefore, alterations in intracellular sphingolipid content 
may also affect the formation of these membrane domains, thus impairing cellular 
responses to extracellular cues.         
 Cholesterol is not only important for membrane fluidity but also, as it pertains to 
the present work, is the precursor for steroid hormones (Section 1.1). Extensive 
evidence has established the coregulation between sphingolipids and cholesterol. Their 
extracellular trafficking occurs through the same lipoprotein particles (595) and 
mutations of either sphingolipid- or sterol-metabolizing enzymes cause accumulation of 
both lipid types (577,596). Furthermore, decreases in membrane sphingolipid levels 
promote the redistribution of plasma membrane cholesterol into intracellular membranes 
(e.g. ER), which represses the activity of SREBP2, the major transcriptional regulator of 
cholesterol uptake and biosynthesis (597-599). Conversely, treatment of cells with 
exogenous sphingolipids promotes the accumulation of cholesterol at the plasma 
membrane and a drop in ER-localized cholesterol, which induces the activation of 
SREBP2 and de novo cholesterol synthesis (506,600). Given that suppression of 
ASAH1 expression resulted in decreased levels of HexCer and LacCer (Figure 4.5), one 
can envision a role for ASAH1 in maintaining optimal membrane fluidity and, to a 
broader extent, regulating plasma membrane-associated cholesterol levels.      
 Glycerolipids have many biological functions and perturbations to their 
metabolism lead to a range of pathophysiological conditions, including obesity, type II 
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diabetes, non-alcoholic fatty liver disease, and cancer (reviewed in (601)). Sphingolipids 
and glycerolipids share many direct metabolic connections. As such, it is plausible to 
infer that changes in cellular sphingolipid content may alter glycerolipid metabolism. For 
example, the transfer of a phosphorylcholine group from phosphatidylcholine to Cer 
forms SM, thus generating DAG as a bi-product (Figure 1.3). In addition, 
phosphatidylinositol provides the source of phosphoinositol for the generation of 
inositolphosphorylceramide in yeast (602). Conversely, the degradation of S1P forms 
ethanolamine phosphate, which can be recycled for use in phosphatidylethanolamine 
(PE) synthesis. Interestingly, studies in Drosophila have found that sphingolipids (e.g. 
long-chain sphingoid bases and Cer) are able to regulate the SREBP pathway, which 
senses and regulates PE synthesis (rather than cholesterol) in this organism (603). 
These examples illustrate the ability of sphingolipids to support glycerolipid synthesis 
and the interconnection between the metabolisms of these two lipid groups. Hence, 
ASAH1-dependent dysregulation of steady-state sphingolipid levels may affect 
glycerolipid-regulated cellular functions.    
 The importance of sphingolipids in cellular processes is underscored by the role 
of lipid rafts (i.e. detergent-resistant domains) in membrane fluidity, membrane protein 
trafficking, and intracellular signaling (593,604). These membrane microdomains are 
formed by SM, glycosphingolipids, cholesterol, and lipid-modified proteins (e.g. 
caveolins, Src-family of kinases, flotillins), which together are proposed to spacially 
organize signaling molecules to promote kinetically favorable connections for signaling 
transduction (605). For example, a negative correlation between membrane-associated 
glycosphingolipid concentrations and insulin responsiveness exists in a way that 
excessive glycosphingolipid content hampers insulin receptor signaling (606). Similarly, 
lipid raft-associated LacCer is important for phagocytosis, chemotaxis, and superoxide 
generation in neutrophils (607). Importantly, small changes in the amounts or structure 
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of membrane-embedded lipid molecules are known to greatly influence the behavior of 
lipid rafts (608-609). It was recently reported that combined knockdown of CerS5 and 
CerS6 results in a decrease in long-chain Cer levels and plasma membrane 
permeabilization (554). Therefore, it is possible that decreased HexCer and LacCer 
concentrations in response to ASAH1 knockdown may affect lipid raft formation and thus 
impair cellular signaling. Furthermore, the fact that nuclear SM and Cer levels were 
decreased in ASAH1KD cells (Figure 5.2) suggests that nuclear membrane composition 
and biophysical properties are also affected by changes in ASAH1 expression. 
 
6.8.  Implications of the current work to health and disease 
 
 The studies described in this dissertation characterized the functions of ASAH1 
in ACTH/cAMP-dependent steroid hormone production in adrenocortical cells and 
established this ceramidase as an important factor for steroidogenic homeostasis. 
Because abnormal cortisol and adrenal androgen levels occur in several 
pathophysiological states, including Cushing’s syndrome, polycystic ovary syndrome 
(PCOS), and cancer (reviewed in (610-613)), the present work has several health 
implications. Given the role of S1P as an inducer of cortisol production (Chapter Two) 
and the importance of ASAH1 expression in maintaining optimal adrenocortical 
steroidogenic capacity (Chapter Four), it is plausible to theorize that aberrant ASAH1 
expression may be involved in the etiology of these pathophysiological conditions. 
Concurrently, because ASAH1 is a negative regulator of NR4A nuclear receptor gene 
expression (Figure 4.6) and these receptors are linked to many metabolic disorders (e.g. 
insulin resistance and dyslipidemia), potential implications for ASAH1 in these conditions 




6.9.1.  Glucocorticoids and Cushing’s syndrome    
 Cushing’s syndrome is characterized by the hypersecretion of cortisol (614-615). 
Due to the pleiotropic functions of cortisol (e.g. gluconeogenesis, lipolysis, 
hyperconstriction, and suppression of the innate inflammatory response (616-619)), this 
syndrome has a vast array of systemic effects. The most prevalent causes of 
endogenous Cushing’s syndrome are an ACTH-secreting pituitary adenoma (i.e. 
Cushing’s disease) and adrenocortical hyperplasia, adenoma, or carcinoma, where 
cortisol is hypersecreted from the tumor independently of ACTH stimulation (614). 
Primary Cushing’s syndrome is most often secondary to adrenocortical tumors. 
However, adrenocortical cancer is a rare disease (615) and as such, little is known about 
its etiology. Because ASAH1 is a regulator of cortisol production (Chapter Four), it is 
tempting to speculate that abnormal ASAH1 expression may be characteristic of 
adrenocortical tumors. Although this ceramidase isoform is overexpressed in many 
cancer types (110-113), its expression level in adrenocortical cancer is yet to be 
reported.  
 Due to the opposing roles of Cer and S1P in cell survival (i.e. Cer induces 
apoptosis while S1P is a potent mitogen (45,197)), the intracellular balance between 
these two metabolites, which is controlled by ceramidases, could be an underlying factor 
in adrenocortical tumorigenesis, and subsequently, Cushing’s syndrome. As discussed 
previously, the nuclear localization of ASAH1 in adrenocortical cells infers that this 
ceramidase is important for controlling the intranuclear concentrations of Cer and S1P. 
In cancer, this regulation is important because nuclear Cer and S1P have both been 
implicated in the transcriptional regulation of cancer-related genes through epigenetic 
mechanisms (255,620). SPHK2-generated nuclear S1P can bind to the active site of 
HDAC1/2, inhibit their activity, and consequently induce C-FOS transcription (255). 
Conversely, Cer inhibits the mRNA expression of the pro-metastatic enzyme MMP-2 
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(matrix metalloproteinase 2) by promoting a decrease in histone acetylation at the MMP-
2 promoter (620). Lastly, S1P is a well-known oncogenic agent that promotes tumor 
survival, growth, and metastasis (185,621-622). Hence, this metabolite may be a 
contributing factor for the onset of Cushing’s syndrome not only by activating cancer-
promoting signaling pathways in adrenocortical tumors but also by directly activating 
cholesterol-metabolizing pathways and promoting cortisol production (Chapter Two). 
 Interestingly, many of the deleterious clinical manifestations associated with 
Cushing’s syndrome, such as insulin resistance and hypertension (623), have been 
linked to aberrant sphingolipid metabolism. Cer antagonizes insulin signaling by 
inhibiting the membrane translocation (624) as well as the phosphorylation and 
activation of Akt (625), the obligate intermediate in the insulin signaling pathway. Cer 
has also been proposed to impair insulin action by inducing the formation of reactive 
oxygen species (626-627), which promote insulin resistance, and mediates TNF-α-
induced downregulation of the insulin-responsive glucose transporter (GLUT4) in 
adipocytes (628). Glucocorticoids, which are known to induce insulin resistance (629), 
can influence insulin action by modulating the sphingolipid pathway. Cer has been 
described as an intermediate linking glucocorticoids to the induction of insulin resistance. 
Dexamethasone promotes Cer accumulation by inducing the expression of various 
sphingolipid-metabolizing enzymes including SPTLC2 and CerS (527). Furthermore, 
dexamethasone antagonizes insulin-stimulated glucose uptake by promoting an 
increase in membrane SM levels (630) whereas adrenalectomy not only increases 
insulin sensitivity but also significantly decreases adipocyte SM levels (631). Similarly, 
sphingolipids may contribute to hypertension by altering membrane fluidity (609) as well 
as inhibiting nitric oxide accumulation, which has strong vasodilatory functions (632). 
Collectively, these findings give premise to a mutual inter-regulation between 
glucocorticoids and sphingolipids where sphingolipids control glucocorticoid synthesis in 
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the adrenal cortex while glucocorticoids influence sphingolipid metabolism at numerous 
target tissues. As it relates to the present work, this suggests that aberrant ASAH1 
espression and/or S1P levels that lead to excessive cortisol production have systemic 
pleiotropic effects that may be related to the pathogenesis of Cushing’s syndrome. 
Future studies using mouse models with conditional deletion of ASAH1 in the adrenal 
gland may provide insight into the role of this ceramidase in modulating glucocorticoid-
dependent physiological responses.   
 
6.9.2.  Adrenal androgens and polycystic ovary syndrome  
 PCOS is a heterogeneous disorder characterized by chronic anovulation and 
aberrant androgen production (633). Although the ovaries are the main source of 
increased androgens in this condition, elevated levels of adrenal androgens, mainly 
DHEA-sulfate (DHEAS), is observed in about 40% of patients (634). DHEAS, produced 
in the zona reticularis of the adrenal cortex (Section 1.1), is the second most abundant 
steroid, after cortisol, and is converted into testosterone and estrogens (e.g. estrone, 
estradiol, and estriol) in peripheral tissues (635). Therefore, plasma DHEAS is a marker 
for adrenal androgen secretion and a diagnostic factor for PCOS. Adrenal androgen 
excess correlates with an exaggerated secretion of DHEAS from the adrenal cortex 
rather than altered pituitary responsiveness to chorticotropin-releasing hormone or 
increased adrenocortical ACTH responsiveness (636-637). Given that ASAH1 is a 
negative regulator of DHEA secretion (Chapter Four) and steroidogenic gene 
transcription (Chapters Four and Five) in adrenocortical cells, aberrant ASAH1 
expression may be a contributing factor for the manifestation of PCOS.   
  The causes for adrenal hyperandrogenism are not fully understood, but 
researchers have shown that the activities of P450c17α and 3β-HSDII enzymes, both of 
which are essential for androgen synthesis (Section 1.1), are upregulated in PCOS 
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samples (638-639). In addition, increased steroid hormone secretion in PCOS ovarian 
theca cells is associated with the transcriptional upregulation of various steroidogenic 
genes including CYP17A1 (640-641), CYP11A1 (640), 3β-HSDII (638), and StAR (640). 
Although it is logical that not one single mechanism is responsible for the complex 
changes in gene expression associated with the PCOS phenotype, based on the global 
changes in gene transcription resulting from ASAH1 knockdown (Chapter Four), it is 
provocative to speculate that aberrant sphingolipid metabolism, and more precisely, 
ASAH1 expression, may be a causal factor for disregulated steroidogenic gene 
transcription in this syndrome.  
 Similar to Cushing’s syndrome, PCOS is also associated with the development of 
insulin resistance (642). Although the mechanism of impared glucose utilization in PCOS 
is largely unknown, a link between androgens and insulin resistance has been proposed. 
Increased insulin sensitivity was observed during androgen suppression (643) or with 
anti-androgen treatment (644). Conversely, studies have suggested that 
hyperandrogenism results from hyperinsulinemia as insulin and IGF-I stimulate 
steroidogenesis from ovarian (645-647) and adrenal (648-650) tissues. Of note, PCOS is 
also associated with dyslipidemia (546), a condition where, as discussed previously, the 
nuclear receptor SHP plays a prominent role. SHP is involved in multiple aspects of 
lipogenesis (543) including the transcriptional regulation of genes associated with lipid 
metabolism, such as PPARγ (651), SREBP-1c (652), and microsomal triglyceride 
transfer protein (653). Furthermore, SHP knockout mice are protected against 
dyslipidemia (546) and have increased adipocyte energy utilization (654). Therefore, 
even though a direct link between PCOS and sphingolipids is yet to be established, 
based on the role of ASAH1 as a global regulator of gene expression, including SHP 
(Figure 4.6), and adrenocortical steroidogenic capacity (Figure 4.3), it is logical to think 
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that ASAH1 is probably involved in the onset of secondary pathophysiological states 
associated with PCOS.   
 
6.9.3.  NR4A nuclear receptors and energy metabolism 
   The prominent effect of ASAH1 suppression on the mRNA and protein 
expression of members of the NR4A subfamily of nuclear receptors (i.e. Nur77, Nurr1, 
and Nor-1) (Figure 4.6), implicate ASAH1 to various NR4A-regulated cellular processes. 
Emerging evidence has established members of the NR4A subgroup as key 
transcriptional regulators of lipid, carbohydrate, and energy homeostasis (reviewed in 
(655)). Hence, these receptors play roles in the development of various 
pathophysiological conditions including cardiovascular disease (656), inflammation 
(657), and metabolic diseases (658). Of note, because endogenous ligands for these 
receptors have not yet been identified, their activity may be regulated by expression, or 
perhaps by a yet to be identified lipid. 
 NR4A receptors are linked to multiple metabolic functions. In skeletal muscle, 
NR4A expression is regulated by β-adrenergic signaling, an integral regulator of 
metabolic homeostasis (659). Nur77 regulates the transcription of genes involved in 
glucose transport, insulin signaling, and glycolysis (655) while Nor-1 control genes 
involved in oxidative metabolism (660). Accordingly, Nor-1 knockdown results in 
decreased fatty acid oxidation and greater lactate production (660) while loss of Nur77 
leads to impaired insuling signaling (661). In the liver, NR4A genes are induced by 
glucagon and fasting (662), and all three receptor subtypes induce hepatocyte glucose 
production (662). In adipose tissue, Nur77 overexpression inhibits adipogenesis (663-
664) whereas Nur77 knockout prevents β-adrenoreceptor-mediated thermogenesis 
(665).  
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 Interestingly, NR4A receptors have also been implicated in dyslipidemia and 
insulin resistance, both of which, as stated above, are linked to Cushing’s syndrome and 
PCOS. NR4A receptors control the expression of numerous genes involved in lipid 
metabolism and insulin signaling. Nur77 regulates lipid metabolism by acting as a 
negative regulator of SREBP-1c (666) and glucose-6-phosphatase (662) expression 
while being an inducer of fatty acid translocase (Cd36) transcription (667). Similarly, Nor-
1 controls the expression of PGC-1α and lipin1 (660,668). As it relates to insulin 
function, Nur77 modulates insuling signaling by controlling GLUT4 and AMP-activated 
protein kinase gene transcription (667). In adipocytes, insulin induces Nor-1 and Nur77 
expression (658) and Nor-1 overexpression increases insulin-stimulated Akt 
phosphorylation, GLUT4 plasma membrane translocation, and glucose uptake (658). 
These findings not only suggest that NR4A receptors play a role in some of the 
etiologies of Cushing’s syndrome and PCOS but also lend support to the potential role of 
ASAH1 in the regulation of energy homeostasis and associated pathophysiological 
conditions. 
 
6.10.  Concluding remarks  
 Adrenocortical steroid hormones are essential for physiological homeostasis. As 
such, intricate molecular mechanisms control their biosynthesis. This dissertation was 
aimed at elucidating the role of sphingolipids in ACTH-dependent steroidogenesis by 
defining the role of S1P in acute cortisol biosynthesis as well as defining the functions of 
ASAH1 in multiple aspects of steroidogenic regulation in the human adrenal cortex. 
Completion of these studies led to the following conclusions: (1) S1P is an inducer of 
acute cortisol production in adrenocortical cells, (2) CREB is an essential transcriptional 
activator of the ASAH1 gene, (3) ASAH1 is a global regulator of steroidogenic gene 
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transcription and steroidogenic capacity in the adrenal gland, and (4) ASAH1 is a novel 
SF-1 coregulator.     
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APPENDIX 1: 
Genistein induces MCF-7 breast cancer cell growth by inducing acid ceramidase gene 
expression 
 
A1.1.  Introduction 
 
 Genistein (4,5,7-trihydroxyisoflavone) is an isoflavone that is abundantly present 
in soybeans, vegetables, and fruits (669). It is classified as a phytoestrogen because it 
has estrogenic effects in animals. In a broad sense, phytoestrogens are capable of 
binding to ERs, thereby modulating ER signaling pathways (670). Due to their estrogenic 
properties, these plant-based compounds have attracted significant research interest 
and are considered, for the most part, natural chemopreventive agents (671-672). 
Genistein is the predominant isoflavone in soy products (673), and therefore, has been 
the subject of much research, mainly focused on its effects on the growth of E2-
dependent mammary tumors both in vitro and in vivo (reviewed in (674)). Functional 
studies determined that genistein has properties of a selective ER modulator. In this 
manner, genistein activates numerous E2-dependent signaling cascades and induce 
gene transcription by modulating the activity of ERs (675-676). Binding studies revealed 
that, even though genistein competes with E2 for binding to ERα and ERβ, it does so 
with different affinities. The binding affinity of genistein for ERα  and ERβ is 4% and 
87%, respectively, compared to E2 (677-679). Furthermore, genistein also activates 
GPR30 (680-682), a GPCR that binds most ER ligands and mediates rapid estrogenic 
signaling (683-684). 
 Genistein exerts many cellular effects including activating apoptosis, inhibiting 
protein tyrosine kinase activity, and suppressing angiogenesis (685-686). Genistein also 
acts in a dose-dependent manner to both positively (687-691) and negatively (678,692-
697) regulate tumorigenesis. In ER-positive cells, high doses of genistein (> 10 µM) are 
associated with tumor suppression while low doses (0.01 - 1 µM) have a mitogenic effect 
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(693,698-699). Genistein promotes proliferation of E2-dependent breast and thyroid 
cancer cells (680,694,700), and induces the expression of vascular endothelial growth 
factor (701), C-FOS (681), PPARγ (702), and proteinase inhibitor 9 (703). The 
proliferative properties of genistein are mostly due to its ability to activate genomic and 
non-genomic estrogenic pathways by binding to ERα, ERβ, and GPR30 (695). The 
binding of E2 to GPR30 stimulates the cAMP pathway (704), increases intracellular Ca2+ 
(683-684), and induces epidermal growth factor receptor transactivation in ER-negative 
breast cancer cells (705-706). Signaling through GPR30 promotes the proliferation of 
multiple carcinomas (707-708), stimulates cell migration through induction of the 
connective tissue growth factor gene (709), and promotes C-FOS (681), Bcl-2 (710-711), 
cyclin D2 (712), and estrogen-related receptor α (713) gene expression.  
 Sphingolipids are involved in many aspects of cell regulation (reviewed in 
(89,440,443)). Cer and S1P have been extensively studied for their opposing roles in the 
regulation of various aspects of cancer pathogenesis and therapy (714). Cer inhibits cell 
growth and promotes apoptosis and senescence, while S1P induces cell proliferation 
and migration by signaling through five S1PRs (44,82,106) (Figure 1.8). In this manner, 
the relative concentrations of these two molecules determine if the cell undergoes 
apoptosis or proliferates (714). Consequently, targeting pathways that elevate Cer or 
decrease S1P accumulation has been a promising therapeutic approach in cancer 
treatment (56).  
 ASAH1 regulates Cer metabolism by catalyzing its degradation to SPH and a 
free fatty acid (423). SPH is phosphorylated by SPHKs to form S1P. Because Cer 
hydrolysis is the major pathway for SPH generation (715), ASAH1 plays a key role in 
regulating cellular homeostasis by controlling the Cer/SPH/S1P balance within the cell. 
In addition, the aberrant expression of ASAH1 in various human cancers (110-113), 
including breast cancer (716), prompted the emergence of this enzyme as a potential 
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target for chemotherapy (112,717-718). Inhibitors of ASAH1 such as B13 [(1R,2R)-2-(N-
tetradecanoylamino)-1-(4-nitrophenyl-1,3-propanediol)] and LCL464 (an analog of B13) 
were shown to cause Cer accumulation and prevent tumor growth (717,719). At the 
transcriptional level, functional characterization of ASAH1 has been previously reported 
(423-424), and I (Chapter Three) and others (425) have established that CREB and 
KLF6 are important transcriptional regulators of this gene.  
 Despite the prominent roles of sphingolipids in cancer development and the 
proliferative actions of low-doses of genistein, little is known about the relationship 
between these two factors in cancer progression. Therefore, based on the importance of 
ASAH1 in sphingolipid metabolism, the role of Cer/S1P balance in carcinogenesis, and 
the numerous biological effects of genistein in cancer cells, I sought to determine the 
role of genistein in ASAH1 gene transcription in MCF-7 breast cancer cells. In this 
Chapter I show that genistein induces ASAH1 gene expression through an ERK1/2-
dependent mechanism involving both GPR30 and ERα. Furthermore, I demonstrate that 




A1.2. Materials and Methods 
A1.2.1. Cell Culture 
  MCF-7 human breast cancer cells were obtained from American Type Culture 
Collection (ATCC) (Manassas, VA) and cultured in phenol red-free Eagle's minimum 
essential medium (MEM) (Mediatech, Inc., Manassas, VA) supplemented with 10% fetal 
bovine serum (Mediatech, Inc.), 11 mM sodium pyruvate (Sigma), 0.01 mg/ml bovine 
insulin (Sigma), antibiotics, and antimycotics. MDA-MB-231 human breast cancer cells 
were obtained from ATCC (Manassas, VA) and cultured in Dulbecco’s Modified Eagle 
Medium (DMEM) (Mediatech, Inc.) supplemented with 10% bovine calf serum 
(Mediatech, Inc.), antibiotics, and antimycotics. 
  
A1.2.2. Real Time RT-PCR (qRT-PCR) 
  MCF-7 cells were sub-cultured into 12-well plates and 48 h later treated with 20 
nM genistein or 10 nM G-1 for 1 - 24 h. In some experiments, cells were pre-incubated 
with 100 - 200 nM G-15 for 1 h prior to treatment with genistein or G-1. Total RNA was 
isolated and quantified by qRT-PCR as previously described (461). ASAH expression 
was normalized to β-actin mRNA levels and calculated using the delta-delta cycle 
threshold (∆∆CT) method. 
  
A1.2.3. RNA interference (RNAi) and real time RT-PCR 
  MCF-7 cells were sub-cultured into 12-well plates and 24 h later transfected with 
75 nM non-specific, 100 nM GPR30 (L-005563-00-0005, Dharmacon/Thermo Scientific), 
or 75 nM ERα (L-003401-00-0005, Dharmacon/Thermo Scientific) small interfering RNA 
(siRNA) oligonucleotides using HiPerfect Transfection Reagent (Qiagen, Valencia, CA). 
Twenty-four h later, cells were transfected again, incubated for an additional 24 h, and 
then treated with 20 nM genistein or 10 nM G-1 for 24 h. Total RNA was isolated and 
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quantified by qRT-PCR as described above. Reduction of GPR30 and ERα protein 
expression at the time of RNA isolation was confirmed by western blotting. 
  
A1.2.4. ERα transient transfection 
  MDA-MB-231 cells were sub-cultured into 12-well plates and transfected with 1 
µg pCMV-hERα (kindly provided by Dr. Ann Nardulli, University of Illinois, Urbana, IL) 
using GeneJuice (EMD Biosciences). Twenty-four h after transfection, cells were treated 
with 20 nM genistein or 5 nM E2 for 24 h. Total RNA was isolated and ASAH1, pS2, and 
β-actin mRNA levels were quantified by qRT-PCR as described above. Expression of 
ERα was confirmed by western blotting 48 h after transfection.  
  
A1.2.5. Western blotting  
 For quantification of ASAH1 protein expression, MCF-7 cells were treated with 20 
nM genistein for 24, 48, or 72 h and harvested into RIPA buffer. Cell lysates were 
isolated and separated by SDS-PAGE as previously described (461). Western blots 
were incubated with anti-ASAH1 (HPA005468, Sigma) and anti-GAPDH (sc-25778, 
Santa Cruz Biotechnology, Santa Cruz, CA) antibodies. For quantification of ERK1/2 
activation, MCF-7 cells were serum-starved for 40 h, then treated with 20 nM genistein 
for 0 to 30 min. ERK1/2 phosphorylation was determined by western blotting using an 
anti-phospho-ERK1/2 antibody (sc-7383, Santa Cruz) and normalized to total ERK2 
expression (sc-154, Santa Cruz). For quantification of phosphorylated ERα, MCF-7 cells 
were serum-starved for 40 h, then treated with 20 nM genistein for 10, 30, or 60 min. 
ERα phosphorylation at serine-118 was determined by western blotting using an anti-
phospho-Ser118-ERα antibody (clone NL-44, Millipore) and normalized to total ERα 
expression (H-184, Santa Cruz). For quantification of cyclin B2 protein expression, MCF-
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7 cells were serum-starved for 48 h and then pre-treated with 200 ng/mL nocodazole 
(Calbiochem Inc.) for 10 h. Cells were rinsed 3 times with PBS, serum-free MEM 
medium was added to each well, and cells were treated with 20 nM genistein for 6 or 12 
h. In some experiments, cells were transfected with 75 nM ASAH1 siRNA 
oligonucleotides (M-005228-01-0005, Dharmacon/Thermo Scientific) using HiPerfect 
Transfection Reagent (Qiagen) for 24 h prior to pre-treatment with nocodazole. Cell 
lysates were isolated and separated by SDS-PAGE. Western blots were incubated with 
anti-cyclin B2 (K0189-3, Cell Signaling), anti-ASAH1 (Sigma), and anti-GAPDH (Santa 
Cruz) antibodies. Protein expression was detected using an ECF western blotting kit (GE 
Healthcare, Piscataway, NJ) and visualized using a VersaDoc 4000 Imager (Bio-Rad 
Laboratories, Hercules, CA). 
  
A1.2.6. Transient transfection and reporter gene analysis 
 Cloning of the human ASAH1 promoter and generation of deletion constructs 
were previously described (461). MCF-7 cells were sub-cultured into 24-well plates and 
transfected with 100 ng of pGL3-ASAH1 or pGL3-ASAH1(EREmutant) and 1.5 ng pRL-
TK (Promega) using GeneJuice (EMD Biosciences). Some cells were co-transfected 
with 50 ng pCMV-hERα. Twenty-four h after transfection, cells were treated with 20 nM 
genistein for 16 h and the transcriptional activity of the ASAH1 reporter gene determined 
using a dual luciferase assay kit (Promega).  Firefly (pGL3-ASAH1) luciferase activity 
was normalized to Renilla luciferase activity (pRL-TK) and expressed as fold change 
over the mean of the untreated control group. 
  
A1.2.7. Site-directed mutagenesis 
  Mutagenesis of the putative ER response element (ERE) at position  
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-475/-457 of the ASAH1 promoter was carried out using a QuikChange site-directed 
mutagenesis kit (Agilent, Santa Clara, CA) and confirmed by sequencing. ERE was 
disrupted by mutating 4 consecutive residues to alanine (italized) using the following 
primer set: forward 5’- GGG CAA AGA TGG AAA AGG GTG GGA TGT TAC-3’, reverse 
5’- ACA TCC CAC CCT TTT CCA TCT TTG CCC TCT-3’. 
  
A1.2.8. Chromatin immunoprecipitation (ChIP) 
  MCF-7 cells were sub-cultured into 150-mm dishes and treated for 1 h with 20 
nM genistein and ChIP assays were performed as described previously (158). The 
purified chromatin solutions were pre-cleared and immunoprecipitated using 5 µg of 
primary antibody [anti-acetyl-histone H3, anti-RNA polymerase II, anti-phospho-Ser118-
ERα (clone NL-44), anti-SRC-1, or anti-Sp1] and 30 µL protein A/G Plus agarose (Santa 
Cruz). Quantitative PCR was carried out using 20% of output, 5% input (diluted 1:4) and 
the ABsolute qPCR SYBR Green Fluorescein Mix (Thermo Scientific).  
  
A1.2.9. Cell proliferation 
  For quantitative proliferative assays, MCF-7 cells were seeded into 96-well 
plates (5 x 103 cells/well) and 24 h later transfected with 75 nM non-specific siRNA 
oligonucleotides or siRNA against ASAH1 or siRNA against ASAH2 (M-005229-00-0005, 
Dharmacon/Thermo Scientific) for 24 h. In some experiments, cells were seeded in 96-
well plates (5 x 103 cells/well) and 24 h later transfected with an ASAH1 expression 
plasmid (0.4 µg/well) for 24 h. Cells were then treated with 20 nM genistein, 10 nM G-1, 
or vehicle (DMSO) for 24 h. After treatment, the cultures were incubated for an additional 
6 h in the presence of 5-bromo-2-deoxyuridine (BrdU; 10 µM). Cell proliferation was 
assayed by BrdU incorporation measurements with an ELISA kit (Roche Applied 
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Science, Indianapolis, IN). Western blotting was used to confirm reduction of ASAH1 
and ASAH2 protein levels 48 h after siRNA transfection. Similarly, ASAH1 
overexpression was confirmed by western blotting 48 h after transfection. 
  
A1.2.10. Cell viability 
  MCF-7 cells were plated into 96-well plates (5 x 103 cells/well) and 24 h later 
transfected with 75 nM non-specific siRNA oligonucleotides or siRNA against ASAH1 
(M-005228-01-0005, Dharmacon/Thermo Scientific). Twenty-four h later, cells were 
treated for 12, 24, or 48 h with 20 nM genistein or DMSO. Cell viability was assessed 
using the CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega) following 
the manufacturer’s instructions. Reduction of ASAH1 protein levels was confirmed by 
western blotting 48 h after transfection.     
  
A1.2.11. Acid ceramidase activity 
  MCF-7 cells were sub-cultured into 100-mm dishes and treated for 48 or 72 h 
with 20 nM genistein and in vitro ASAH1 activity assay was performed as previously 
described (461). TLC plates were visualized by fluorescence scanning on a VersaDoc 
4000 imager (Bio-Rad). NBD-dodecanoic acid formation was quantified and normalized 
to the protein content of each sample. 
  
A1.2.12. Statistical analysis 
  One-way ANOVA, Tukey-Kramer multiple comparison, and unpaired student t-
tests were performed using GraphPad InStat software (GraphPad Software Inc., San 
Diego, CA). Statistically significant differences from a compared value were defined as p 
< 0.05 denoted by asterisks (*) or carats (^). 
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A1.3.  Results 
A1.3.1. Genistein induces ASAH1 mRNA expression 
   To evaluate the effect of genistein on the transcription of ceramidase genes 
(ASAH), MCF-7 cells were treated with 20 nM genistein for 24 h. ASAH1 mRNA 
expression was significantly increased by 2.5-fold in response to low-dose genistein 
treatment (Figure A1.1A). Interestingly, ASAH2 mRNA expression was also induced by 
2.6-fold in response to treatment, while the expression of ACER3 was unchanged 
(Figure A1.1A). Because aberrant ASAH1 expression has been reported in cancer cells 
(110,113,716), I focused on the effect of genistein on the transcription of this ceramidase 
isoform. Experiments to assess the kinetics of the ASAH1 transcriptional response to 
genistein were carried out by treating cells for 6, 12, and 24 h. As shown in Figure 
A1.1B, ASAH1 mRNA levels begin to increase after 6 h of genistein stimulation with 
maximal induction at the 24 h time point. 
Figure A1.1. Genistein induces ASAH1 transcription. A. MCF-7 cells were treated for 24 h 
with 20 nM genistein. Total RNA was isolated for analysis of acid (ASAH1), neutral 
(ASAH2), and alkaline (ACER3) ceramidase mRNA expression by qRT-PCR. B. MCF-7 
cells were treated for 6, 12, or 24 h with 20 nM genistein and ASAH1 and β-actin mRNA 
expression were quantified by qRT-PCR. Data graphed are expressed as fold change in 
ASAH mRNA expression normalized to the mRNA expression of β-actin and represent 
mean ± SEM of three separate experiments, each done in triplicate. *Statistically different 
from untreated control group (p < 0.05).  
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A1.3.2. GPR30 and ERα mediate genistein-induced ASAH1 transcription 
  Genistein activates GPR30-mediated non-genomic signaling in thyroid and 
breast cancer cells (680-681). Therefore, to investigate the involvement of GPR30 in the 
up-regulation of ASAH1 expression in response to genistein stimulation, ASAH1 mRNA 
levels were quantified in MCF-7 cells treated with 10 nM of the high-affinity GPR30 
agonist G-1 (720). As shown in Figure A1.2A, G-1 significantly increased ASAH1 
transcription by 2.6-fold, which paralleled the fold-increase elicited by genistein. Further, 
neither genistein nor G-1 was able to induce ASAH1 expression in the presence of the 
high-affinity GPR30 antagonist G-15 (721) (Figure A1.2A). Significantly, the 
transcriptional response was not enhanced by G-1 in combination with genistein (Figure 
A1.2A). Because G-1 and G-15 are not ligands for ER α or β (720-721), these data 
suggest that GPR30 plays a key role in genistein-stimulated ASAH1 transcription. The 
selectivity of genistein for GPR30 is further supported by the inability of ICI-182780, an 
ER antagonist (722), to repress genistein-induced ASAH1 mRNA expression (Figure 
A1.3). ICI-182780 is also a high-affinity GPR30 agonist (684), which is consistent with an 
increase in ASAH1 mRNA transcript levels observed in ICI-182780 only-treated cells 
(Figure A1.3). 
 To determine if GPR30 is required for ASAH1 transcription, GPR30 translation 
was suppressed (Figure A1.2B, inset) and the effect of reduced GPR30 expression on 
genistein- and G-1-stimulated ASAH1 mRNA expression was assessed. As shown in 
Figure A1.2B, neither genistein nor G-1 was able to induce ASAH1 transcription in cells 
transfected with GPR30 siRNA oligonucleotides. Because genistein can also signal 
through ERα (698) and GPR30 can work together with ERα in certain E2-mediated  
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Figure A1.2. GPR30 and ERα mediate genistein-dependent ASAH1 transcription. A. 
MCF-7 cells were pre-treated for 1 h with 100 or 200 nM G-15 followed by treatment with 
10 nM G-1 or 20 nM genistein (gen) for 24 h. Some cells were treated with both G-1 and 
genistein in the presence or absence of 200 nM G-15. Total RNA was isolated for analysis 
of ASAH1 mRNA expression by qRT-PCR. B. MCF-7 cells were transfected twice with 
100 nM GPR30, 75 nM ERα, or 75 nM non-specific siRNA for 48 h (GPR30) or 24 h 
(ERα) followed by treatment with 20 nM genistein or 10 nM G-1 for 24 h. Total RNA was 
isolated and ASAH1 mRNA expression was quantified by qRT-PCR and normalized to β-
actin. Inset: Western blot of GPR30 and ERα protein expression at the time of RNA 
isolation. C. ERα, ERβ, and GPR30 protein quantification in MCF-7 and MDA-MB-231 
cells. D. ERα was expressed in MDA-MB-231 cells followed by treatment with 20 nM 
genistein (Gen) or 5 nM E2 for 24 h. ASAH1 and pS2 mRNA levels were quantified by 
qRT-PCR and normalized to β-actin. Inset: Ectopic expression of ERα; (-) control, (+) 
ERα-transfected cells. Data are graphed as fold change in ASAH1 mRNA expression 
normalized to the mRNA expression of β-actin and represent mean ± SEM of three 
separate experiments, each done in triplicate. 
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activities (707,723-724), I also determined the effect of ERα suppression on ASAH1 
transcription. Surprisingly, similar to GPR30, ERα suppression by siRNA (Figure  
A1.2B, inset) significantly reduced both genistein- and G-1-stimulated ASAH1 
transcription (Figure A1.2B). Collectively, these data suggest that both GPR30 and ERα 
are required for the induction of ASAH1 mRNA expression by genistein.  
 Consistent with other reports (683,723), MCF-7 cells express ERα, ERβ, and 
GPR30 protein while MDA-MB-231 cells only express ERβ (Figure A1.2C). Therefore, to 
further investigate the role of ERα in genistein-mediated ASAH1 transcription, ASAH1 
mRNA expression was quantified in genistein-treated MDA-MB-231 cells transfected 
with an ERα expression plasmid (Figure A1.2D, inset). Significantly, although ectopic 
expression of ERα was capable of inducing pS2 transcription, a well-known ERα-target 
gene (also known as TFF1), expression of the receptor was not sufficient to promote 




Figure A1.3. ER antagonist effect on 
genistein-dependent ASAH1 
transcription. A. MCF-7 cells were 
pre-treated for 1 h with 1 µM ICI-
182780 followed by treatment with 
20 nM genistein for 24 h. Total RNA 
was isolated for analysis of ASAH1 
mRNA expression by qRT-PCR. 
Data are graphed as fold change in 
ASAH1 mRNA expression and 
normalized to the mRNA expression 
of β-actin. Data graphed represent 
mean ± SEM of two separate 
experiments, each done in triplicate. 
*Statistically different from untreated 
control group (p<0.05). 
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A1.3.3. Genistein-induced ASAH1 transcription occurs via a pertussis toxin-
 sensitive pathway that requires c-Src and ERK1/2 activation  
 
  GPR30 signaling activates various downstream signaling cascades including 
ERK and phosphoinositol-3-kinase (PI3K)/Akt pathways (705). Therefore, to determine 
which kinases are activated by genistein stimulation, the ability of genistein to increase 
ERK1/2 phosphorylation was tested. As shown in Figure A1.4A, genistein rapidly 
increased the phosphorylation of ERK1/2 in MCF-7 cells, but genistein did not activate 
Akt (data not shown). In addition, the effect of genistein on ERK1/2 activation was 
mimicked by G-1 (Figure A1.4B, top panel) and G-15 prevented ERK1/2 phosphorylation 
induced by both G-1 (top panel) and genistein (bottom panel) (Figure A1.4B). Additional 
experiments geared towards identifying effector kinases in the ERK pathway revealed 
that genistein also activated Raf-1 and c-Src (Figure A1.5A), and that activation of these 
kinases was required for ERK phosphorylation (Figure A1.5B). Consistent with these 
western blot data, inhibition of ERK, c-Src, and Gαi activation attenuated genistein-
stimulated ASAH1 mRNA expression (Figure A1.4C). Furthermore, in agreement with 
the modulation of nuclear ERs by membrane-initiated signaling (reviewed in (725)) and 
ligand-independent activation of ER by ERK signaling (726), both genistein (top panel) 
and G-1 (bottom panel) rapidly increased the levels of phospho-Ser118-ERα by 1.6- and 
1.5-fold after 30 min, respectively (Figure A1.4D). 
 
A1.3.4. Genistein promotes the recruitment of ERα and Sp1 to the ASAH1 
 promoter 
 
   To further define the mechanism by which genistein modulates ASAH1 mRNA 
expression, MCF-7 cells were transfected with a luciferase reporter construct that 
contains 2.7 kb of the ASAH1 promoter and treated with 20 nM genistein for 16 h.  As 
shown in Figure A1.6A, genistein treatment significantly increased the transcriptional 
activity of the 2.7 kb reporter gene by 1.8-fold. To identify the genistein-responsive  
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Figure A1.4. Genistein-induced ASAH1 mRNA expression requires Gαi, c-Src, and ERK1/2. 
A. MCF-7 cells were serum-starved for 40 h followed by treatment with 20 nM genistein for 0-
30 min or 25 ng/mL EGF for 10 min. Cell lysates were harvested and separated by SDS-
PAGE followed by western blotting using anti-phospho-ERK1/2 and ERK2 antibodies. B. 
MCF-7 cells were serum-starved for 40 h, pre-treated with G-15 for 1 h, and then treated with 
10 nM G-1 (top panel) or 20 nM genistein (lower panel) for 5 or 15 min. Cell lysates were 
harvested and separated by SDS-PAGE followed by western blotting using anti-phospho-
ERK1/2 and ERK2 antibodies. C. MCF-7 cells pre-treated for 1 h with 1 µM U0126, 10 µM 
PP2, 1 pg/mL PTX, or 10 µM LY294002 followed by treatment with 20 nM genistein for 24 h. 
Total RNA was isolated for analysis of ASAH1 mRNA expression by qRT-PCR. Data are 
graphed as fold change in ASAH1 mRNA expression normalized to the mRNA expression of 
β-actin and represent mean ± SEM of three separate experiments, each done in triplicate. 
*Statistically different from untreated control group (p < 0.05). D. MCF-7 cells were serum-
starved for 40 h followed by treatment with 20 nM genistein (top panel) or 10 nM G-1 (lower 
panel) for 0 - 60 min. Lysates were isolated and separated by SDS-PAGE followed by western 
blotting using antibodies against phospho-Ser118-ERα or ERα. 
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region(s) on the ASAH1 promoter, different lengths of the ASAH1 promoter (461) were 
tested for their ability to activate a luciferase reporter construct. While deletion of the 
region between -2740 bp to -496 bp had no significant effect on the ability of genistein to 
stimulate reporter gene activity, removal of 250 bp (from the -496 bp construct) 
completely abolished the genistein response (Figure A1.6A). 
 Next, I performed in silico promoter analysis and identified putative binding sites 
for Sp1 and ER (ER response element, ERE) within the first 500 bp upstream of the 
transcription initiation site of the ASAH1 gene (Figure A1.6B). To define key ER 
transcriptional elements within the genistein-responsive region, a putative ERE at 
position -475/-457 bp of the ASAH1 promoter (Figure A1.6B) was mutated and 
genistein-dependent ASAH1 reporter gene activity determined in luciferase assays. As 
Figure A1.5. Kinase-dependent 
genistein signaling. A. MCF-7 cells 
were serum-starved for 40 h and 
treated with 20 nM genistein for 5 - 
15 min or 25 ng/mL EGF for 10 
min. Cell lysates were harvested 
and separated by SDS-PAGE 
followed by western blotting 
analysis using anti-phospho-Src 
and anti-Src (top panel) or anti-
phospho-Raf-1 and anti-Raf-1 
(bottom panel) antibodies. B. MCF-
7 cells were serum-starved for 40 
h, pre-treated for 1 h with 10 µM 
PP2 (top panel), 1 µM U0126 
(middle panel), or 1 pg/mL PTX 
(bottom panel), and then treated 
with 20 nM genistein for 5 - 15 min 
or 25 ng/mL EGF for 10 min. Cell 
lysates were harvested and 
separated by SDS-PAGE followed 
by western blotting using anti-





shown in Figure A1.6C, ERα significantly increased the transcriptional activity of the wild 
type ASAH1 promoter, but failed to increase the reporter gene activity in cells 
transfected with an ASAH1 reporter plasmid harboring a mutation in the ERE. 
Interestingly, mutation of this ERE not only abolished the ability of genistein to stimulate 
promoter activity but also significantly decreased reporter gene activity in untreated cells, 
suggesting that this ERE may play a role in maintaining basal transcription (Figure 
A1.6C). I next performed ChIP analysis on chromatin isolated from MCF-7 cells treated 
for 1 h with 20 nM genistein. Phospho-Ser118-ERα was enriched by 2.8-fold at region A (-
500/-278) and 2.5-fold at region B (-325/-214) of the ASAH1 promoter in response to 
genistein (Figure A1.6D and A1.6E). Sp1 and the coactivator SRC-1 were also recruited 
to regions A and B in response to genistein stimulation (Figure A1.6E). Furthermore, 
genistein increased acetylation of histone H3 in all regions, indicating that genistein-
stimulated phospho-Ser118-ERα and Sp1 binding occurs concomitant with histone H3 
modification (Figure A1.6E).  
  
A1.3.5. Genistein increases ASAH1 protein expression and enzymatic activity 
   Next, I determined if genistein also increased protein expression by carrying out 
western blot analysis of lysates isolated from MCF-7 cells that were treated for 24, 48, or 
72 h with 20 nM genistein. As shown in Figures A1.7A and A1.7B, genistein significantly 
increased ASAH1 protein levels by 1.8- and 2.3-fold after 48 or 72 h treatment, 
respectively. This increase in ASAH1 protein content resulted in increased ceramidase 




Figure A1.6. Genistein stimulation promotes the recruitment of ERα and Sp1 to the ASAH1 
promoter. A. MCF-7 cells were transfected with reporter gene plasmids (pGL3-ASAH1) containing 
varying regions of the ASAH1 promoter and a Renilla luciferase plasmid (pRL-TK). Twenty-four h 
after transfection, cells were treated with 20 nM genistein for 16 h and luciferase activity 
quantified by luminometry. Data are graphed as fold change ± SEM of three separate 
experiments, each done in triplicate, and normalized to -120 bp construct. Asterisks (*) and carats 
(^) denote statistically significant differences from untreated control within each transfection group 
or from untreated -120 bp construct, respectively (p < 0.05). B. Diagram of putative binding sites 
for Sp1 and ER within the genistein-responsive region of the ASAH1 promoter. Letters A, B, and 
C denote regions amplified by each primer set used for ChIP assay. The ERE at position -475/-
457 bp that was mutated for further analysis in ‘C’ is denoted by a grey-shaded square. C. MCF-7 
cells were transfected with pGL3-ASAH1-496 (WT) or pGL3-ASAH1-496-EREmutant (EREmut) 
reporter gene plasmid, pCMV-hERα, and a Renilla luciferase plasmid (pRL-TK). Twenty-four h 
after transfection, cells were treated with 20 nM genistein for 16 h and luciferase activity 
qu0antified by luminometry. Data are graphed as fold change ± SEM of three separate 
experiments, each done in triplicate and normalized to untreated WT-transfected controls. 
Asterisks (*) and carats (^) denote statistically significant differences from untreated control within 
each transfection group or from untreated WT controls, respectively (p < 0.05). D. Representative 
agarose gels of the PCR products from ChIP assays obtained for region B (-325/-214). (-) and (+) 
denote untreated or genistein-treated, respectively. E. MCF-7 cells were treated for 1 h with 20 
nM genistein, cross-linked with 1% formaldehyde, and the sheared chromatin immunoprecipitated 
with antibodies against phospho-Ser118-ERα, Sp1, RNA Pol II, acetyl-histone H3, or SRC-1 and 
recruitment to regions A (-500/-278), B (-325/-214), or C (-123/+34) of the ASAH1 promoter 
assessed by qPCR. DNA purified was quantified by real time PCR and normalized to the ΔCt 
values of input DNA. Data are graphed as fold enrichment over untreated control ± STD. 
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A1.3.6. Genistein induces MCF-7 cell proliferation and viability in an ASAH1-
 dependent manner 
 
  Given that genistein-induced cell growth is mediated by GPR30 signaling (680), I 
examined the role of ASAH1 in cell proliferation in cells transfected with non-specific, 
ASAH1, or ASAH2 siRNAs (Figure A1.8A, inset). The increase in BrdU incorporation 
elicited by both genistein and G-1 was dependent on ASAH1 expression (Figure A1.8A). 
Although G-1 was able to induce cell proliferation by 1.3-fold in ASAH1-depleted cells, 
this increase was significantly lower than the 3.4-fold increase observed in untransfected 
cells (Figure A1.8A). Importantly, suppression of ASAH2 had no effect on genistein- or 
G-1-induced cell proliferation (Figure A1.8A). Moreover, ASAH1 overexpression 
potentiated cell proliferation is response to genistein and G-1 stimulation by 1.4- and 2.1-
fold, respectively (Figure A1.8B). The role of ASAH1 in genistein-dependent cell 
proliferation was further supported by MTT assays (Figure A1.8C). Finally, to define the 
functional significance of ASAH1 on the cell cycle, the effect of ASAH1 silencing on the 
phosphorylation state of cyclin-dependent kinase 7 (CDK7) and CDK2, and cyclin B2 
protein levels in genistein-treated MCF-7 cells was determined. As shown in Figure 
A1.8D, whereas cyclin B2 expression was increased by 2.3- and 2.5-fold in response to 
6 or 12 h genistein treatment, respectively, this increase was attenuated in cells 
transfected with ASAH1 siRNA oligonucleotides. Although genistein induced the 
phosphorylation of both CDK7 and CDK2, these events were independent of ASAH1 
expression (data not shown).  
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Figure A1.7. Genistein increases ASAH1 protein expression and enzymatic activity. A. 
MCF-7 cells were treated for 24, 48, or 72 h with 20 nM genistein. Total cell lysates 
were harvested and separated by SDS-PAGE followed by western blotting analysis 
using anti-ASAH1 and anti-GAPDH antibodies. B. Graphical analysis of data obtained 
from densitometric analysis of western blots. Data graphed represent mean ± STD of 
two separate experiments, each done in duplicate. *Statistically different from untreated 
control group (p < 0.05). C. MCF-7 cells were treated for 48 or 72 h with 20 nM 
genistein and cell lysates were isolated for in vitro ASAH1 activity assays as described 
in Section A1.2. TLC plates were visualized by fluorescence scanning. NBD-
dodecanoic acid formation was quantified and normalized to the protein content of each 
sample. Data graphed represents mean ± STD of three separate experiments, each 
done in duplicate. *Statistically different from untreated control group (p < 0.05).  
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Figure A1.8. Genistein increases cell proliferation, cell viability, and cyclin B2 expression in an 
ASAH1-dependent manner. A. MCF-7 cells were seeded in 96-well plates at 5 x 103 cells/well 
and 24 h later transfected with 75 nM ASAH1, ASAH2, or non-specific siRNA for 24 h. Cells were 
then treated with 20 nM genistein or 10 nM G-1 and 24 h later, cell proliferation was measured 
with a BrdU incorporation ELISA kit. Data are expressed as mean % of control ± SEM of four 
separate experiments, each done in quadruplicate. Inset: Western blot of ASAH1 and ASAH2 
protein expression in siRNA-transfected cells 48 h after transfection. B. MCF-7 cells were seeded 
in 96-well plates at 5 x 103 cells/well and 24 h later transfected with 0.4 µg of an ASAH1 
expression plasmid for 24 h. Cells were then treated with 20 nM genistein or 10 nM G-1 and 24 h 
later, cell proliferation was measured with a BrdU incorporation ELISA kit. Data are expressed as 
mean % of control ± SEM of three separate experiments, each done in quadruplicate. Inset: 
Western blot of ASAH1 protein expression in control (-) and transfected (+) cells 48 h after 
transfection. C. MCF-7 cells were seeded in 96-well plates and transfected with 75 nM ASAH1 or 
non-specific siRNA for 24 h. Cells were then treated with 20 nM genistein for 12, 24, or 48 h and 
cell viability was measured with an MTT assay kit. Data graphed represent mean ± SEM of three 
separate experiments, each performed in triplicate. Asterisks (*) indicate statistically significant 
differences from untreated/untransfected or untreated/siRNA-transfected control groups, 
respectively (p < 0.05). D. MCF-7 cells were transfected with 75 nM ASAH1 siRNA for 24 h, pre-
treated with 200 ng/mL nocodazole for 10 h, and then treated with 20 nM genistein for 6 or 12 h. 
Total lysates were harvested and separated by SDS-PAGE followed by western blotting analysis 
using anti-ASAH1, anti-cyclin B2, or anti-GAPDH antibodies. (-) and (+) denotes untreated or 
genistein-treated groups, respectively. ‘Unsynchronized controls’ denote cells grown in regular 
MEM media neither treated with nocodazole nor genistein. 
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A1.4.  Discussion 
  Genistein mediates many E2-dependent pathways by binding to ERs (694,700) 
and it has been reported that this phytoestrogen can promote breast cancer cell growth 
in a dose-dependent manner (693,698-699,727-728). Although E2-activated non-
genomic signaling is well documented (reviewed in (725)), the mechanisms by which 
phytoestrogens evoke changes in cell growth are less defined. Therefore, I investigated 
the role of genistein in ASAH1 expression in MCF-7 breast cancer cells. 
 GPR30 is increasingly recognized as an important mediator of rapid non-
genomic estrogenic action (705-706,709,713). I show that 20 nM genistein and the high-
affinity GPR30 agonist G-1 induce ASAH1 transcription (Figure A1.1) through a GPR30-
dependent (Figure A1.2) ERK1/2 signaling pathway (Figure A1.4). Consistent with my 
findings, genistein has been shown to activate ERK1/2 through GPR30 in MCF-7 and 
thyroid cancer cells (680-681). In addition, Maggiolini et al. (681) has shown that 
genistein induces C-FOS gene expression through a GPR30-dependent ERK1/2 
cascade that requires c-Src kinase activity. 
 Importantly, I show that the transcriptional response elicited by genistein requires 
both GPR30 and ERα (Figure A1.2). Studies have demonstrated that these two 
receptors act cooperatively to mediate cell proliferation in ER-positive cancer cells 
(707,724). Although it is possible that GPR30 and ERα are acting in mutually exclusive 
signaling pathways, three lines of evidence suggest that these two receptors are part of 
the same signaling cascade: (a) Genistein and G-1 do not have a synergistic effect on 
ASAH1 transcription (Figure A1.2A), (b) abrogation of either GPR30 or ERα expression 
by siRNA prevents genistein-dependent ASAH1 gene expression (Figure A1.2B), and (c) 
ERα suppression inhibits G-1-stimulated ASAH1 gene expression (Figure A1.2B). 
Reconstitution of this pathway in ERα/GPR30-deficient MDA-MB-231 cells (Figure 
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A1.2D) revealed that ERα alone is not sufficient to promote ASAH1 transcription in 
response to genistein, although E2-induced pS2 expression is restored in the presence 
of the receptor (Figure A1.2D). ER-mediated transcription can be stimulated by ligand-
independent mechanisms involving second messenger signaling systems (726). I show 
that stimulation with genistein and G-1 leads to phosphorylation of ERα at Ser118 (Figure 
A1.4D), a major target of MAPK signaling (726,729). Furthermore, promoter analysis 
revealed that an ERE at position -475 bp of the ASAH1 promoter is required for ERα-
dependent ASAH1 reporter gene activity (Figure A1.6C), suggesting that ERα is 
recruited to this site following genistein stimulation. Indeed, ChIP studies demonstrated 
that phospho-Ser118-ERα is recruited to the ASAH1 promoter in response to genistein 
stimulation (Figure A1.6D). Sp1, which has been shown to interact with ERα to 
transactivate target genes by binding to Sp1xERE motifs (730), is also recruited to the 
same promoter region (Figure A1.6D). In agreement with these findings, ASAH1 
expression was shown to positively correlate with ER status in breast cancer tumors 
(716) and ER-positive tumors display higher ASAH1 expression (731), supporting a role 
for ER in the transcriptional regulation of the ASAH1 gene.  
 Significantly, I show that ASAH1 expression is required for the increase in cell 
proliferation by genistein (Figure A1.8A) and ASAH1 overexpression potentiates this 
proliferative response (Figure A1.8B). These data suggest that ASAH1 mediates 
genistein-stimulated cell proliferation. Moreover, I demonstrate that genistein increases 
cyclin B2 protein expression in an ASAH1-dependent manner (Figure A1.8D). Cyclin B2 
expression during G2/M phase of the cell cycle facilitates the activation of CDK1, 
regulates mitotic progression (583), and prevents DNA re-replication (732). Thus, the 
data presented in this Chapter suggests that endogenous ASAH1 mediates progression 
through the cell cycle in response to low doses of genistein, at least in part, by triggering 
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cyclin B2 expression. Of note, ACER3 and ASAH2 were both reported to modulate cell 
proliferation either by upregulating CDK inhibitor p21CIP1/WAF1 expression (100) or 
inducing cell cycle arrest at G0/G1 and Rb protein dephosphorylation (472), respectively. 
Genistein has been shown to promote cell proliferation of pancreatic β-cells (733), and 
breast (681,686,700), thyroid (680), and prostate (734) cancer cells through multiple 
signaling pathways. Because genistein has a dose-dependent effect on the growth of 
breast cancer cells (693,698-699), it is noteworthy that the effect of genistein on ASAH1 
transcription was only observed at nanomolar concentrations (micromolar concentrations 
had no effect on ASAH1 transcription, data not shown), the same dosage at which it 
promotes tumor growth in vivo and in vitro (686,693-694,703,727-728). Because 
genistein also induced the transcription of ASAH2 (Figure A1.1A) and SPHK1 (data not 
shown), it is likely that this phytoestrogen may promote sphingolipid metabolic changes 
by regulating the expression of multiple sphingolipid genes. Indeed, mass spectrometric 
analysis revealed that genistein evoked a 1.3-fold increase in the cellular concentration 
of S1P (Lucki and Sewer, unpublished observations). Total Cer levels were not 
significantly altered by genistein stimulation while SM levels modestly increased by 1.2-
fold in genistein-treated cells (Lucki and Sewer, unpublished observations). Given the 
complexity of the sphingolipid metabolic pathway and its many metabolites, temporal 
genomic transcriptional and lipidomic analysis is required to pinpoint the mechanisms by 
which genistein alters sphingolipid concentrations. Gupta et al. (246) recently reported a 
quantitative model of the sphingolipid pathway that illustrates the complexity of 
sphingolipid flux alterations in response to pharmacological perturbations. Nonetheless, 
because S1P activates cell growth-related pathways in a paracrine/autocrine manner by 
binding to S1PRs (621,735) (Figure 1.8), it is possible that genistein also promotes S1P 
secretion. Given that SPHK1 is overexpressed in breast cancer cells (736), it is likely 
that an increase in ASAH1 activity could lead to increased S1P production. Of note, E2 
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was shown to promote breast cancer cell proliferation by activating SPHK1 (737) and 
Takabe et al. (192) recently demonstrated that E2 induces ERK1/2 activation in MCF-7 
cells by stimulating SPHK1 activity and promoting a rapid secretion of S1P in an ERα-
dependent manner. Further studies are required to establish that genistein evokes the 
export of S1P via a similar mechanism. Nonetheless, because E2 treatment mirrored the 
stimulatory effects of genistein on ASAH1 transcription and protein expression (data not 
shown), the regulation of ASAH1 expression by this phytoestrogen adds to the current 
understanding of the molecular mechanisms underlying E2-dependent mammary cell 
proliferation. Because Cer degradation is the only source of cellular SPH (42,104), 
ASAH1 directly regulates SPHK1 substrate availability. Thus, the effect of E2 on SPHK1 
activity would benefit from increased ASAH1 expression. Further, long-term exposure to 
genistein was recently shown to enhance E2 responsiveness in rat uterus (738) and 
reverse the inhibitory effects of tamoxifen (739-740). Therefore, I hypothesize that low 
doses of genistein may have a detrimental additive effect to E2 in vivo by promoting 
sphingolipid-mediated breast cell growth.  
 In conclusion, I propose a model whereby genistein induces ASAH1 gene 
expression by activating a GPR30-dependent pathway that culminates in ERK1/2 
phosphorylation (Figure A1.9). ERK1/2 activation induces the phosphorylation of ERα 
and the binding of a complex containing the receptor, Sp1, and SRC-1 to the ASAH1 
promoter. ASAH1 transcription is followed by increased protein expression and 
enzymatic activity, which results in increased S1P production. S1P can then be exported 
(621) and activate proliferative pathways by binding to cell surface S1PRs (735) (Figure 
A1.9). Concomitantly, ASAH1 mediates cyclin B2 expression, which drives mitotic 
progression and, consequently, cell growth. Further studies are needed to determine if 
S1P is involved in genistein-dependent cyclin B2 expression. In light of the growing 
interest in the role of phytoestrogens in cancer progression and treatment, and the 
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development of chemotherapeutic strategies to modulate sphingolipid metabolism, my 
results provide evidence for the integral role of ASAH1 in maintaining cellular 
proliferative capacity of ER-positive breast cancer cells. 
  
Figure A1.9. Model pathway for genistein-induced ASAH1 transcription in MCF-7 cells. 
Genistein (GEN) activates GPR30, which signals through Gαi to activate c-Src and 
subsequently the MAPK pathway. ERK1/2 activation promotes the phosphorylation of 
ERα and its recruitment to the ASAH1 promoter. Induction of ASAH1 gene transcription 
leads to an increase in protein expression and subsequent upregulation of enzymatic 
activity, which results in the degradation of ceramide (CER) into sphingosine (SPH) and 
its phosphorylation into sphingosine-1-phosphate (S1P). S1P is exported from cells via 
the ABC transporters ABCC1 and ABCG2 and acts in a paracrine/autocrine matter to 
activate proliferative signaling cascades by binding to cell-surface S1P receptors 
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